

Organizers:



INSTITUTE OF INTERNAL MEDICINE & HEPATOLOGY, LARISSA, GREECE



DEPARTMENT OF MEDICINE & RESEARCH LABORATORY OF INTERNAL MEDICINE  
UNIVERSITY OF THESSALY MEDICAL SCHOOL, LARISSA, GREECE

Director: Professor G.N. Dalekos

In cooperation with:



HELLENIC ASSOCIATION FOR THE STUDY OF THE LIVER



HELLENIC STROKE ORGANIZATION

Under the auspices of the:



UNIVERSITY OF THESSALY MEDICAL SCHOOL, LARISSA, GREECE

# 8<sup>th</sup> Larissa

# International Congress of Internal Medicine

**March 17-19, 2016**

Larissa Imperial Hotel

**LARISSA, GREECE**

<http://www.internalmedicine-uth.gr>

The Congress has been accredited with **16 Continuing Medical Education (C.M.E.) Credits**  
by the Panhellenic Medical Association

## Final Programme



**HARVONI**<sup>®</sup>  
ledipasvir/sofosbuvir



*Albert Einstein*

Η φωτογραφία του Albert Einstein χρησιμοποιείται με την άδεια του HUJ/GreenLight.

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και  
Αναφέρετε  
ΟΛΕΣ τις ανεπιθύμητες ενέργειες για ΟΛΑ τα φάρμακα  
Συμπληρώνοντας στην “ΚΙΤΡΙΝΗ ΚΑΡΤΑ”

Τιμή (Ex-factory): 15.306,72 €

Τρόπος διάθεσης: Περιορισμένη ιατρική συνταγή από ειδικό  
ιατρό και παρακολούθηση κατά τη διάρκεια της αγωγής.

HAR/GR/15-01/1027(2)



**GILEAD**

Advancing Therapeutics.  
Improving Lives.

Για την πλήρη εγκεκριμένη Π.Χ.Π. απευθυνθείτε στην εταιρεία  
Gilead Sciences Ελλάς Μ. ΕΠΕ, Ριζούντος 2 & Θράκης,  
167 77 Ελληνικό. Τηλ.: 210 89 30 100, Fax: 210 96 18 260



ΜΕ ΤΟ DAKLINZA® (Daclatasvir) ΩΣ ΣΥΜΜΑΧΟ ΣΑΣ, ΜΠΟΡΕΙΤΕ ΝΑ ΕΠΙΤΥΧΕΤΕ...

ΕΓΚΡΙΘΗΚΕ



# ΤΗΝ ΠΟΛΥΑΝΑΜΕΝΟΜΕΝΗ ΑΝΤΑΠΟΚΡΙΣΗ

Σας παρουσιάζουμε το Daklinza, έναν ισχυρό, παν-γονοτυπικό (*in vitro*) αναστολέα της NS5A με κλινική αποτελεσματικότητα σε πολλαπλούς γονότυπους.<sup>1,2</sup>

Το Daklinza μαζί με sofosbuvir είναι ένα από στόματος χορηγούμενο σχήμα χωρίς ιντερφερόνη, το οποίο θεραπεύει\* τη χρόνια ηπατίτιδα C στην πλειοψηφία των ασθενών σας, συμπεριλαμβανομένων των ασθενών με ανεκπλήρωτες ιατρικές ανάγκες, όπως προχωρημένη κίρρωση, αποτυχία της θεραπείας με αναστολέα της πρωτεάσης (PI) ή γονότυπο 3.<sup>1,2</sup>

\*Σε μακροχρόνιες μελέτες παρακολούθησης έχει καταδειχθεί ότι η SVR<sub>12</sub> αντιστοιχεί σε οριστική ίαση της λοίμωξης από ΗCV τουλάχιστον στο 99% των περιπτώσεων<sup>3,4</sup>

#### Βιβλιογραφικές παραπομπές

1. Sukkowki MS, Gardiner DF, Rodriguez-Torres M et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. *N Engl J Med.* 2014;370:211-221.
2. DAKLINZA™ (daclatasvir) Summary of Product Characteristics. Bristol-Myers Squibb Company, March 2014.
3. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. *J Hepatol.* 2014;60:392-420.
4. Swain MG, Lai MY, Shiffman ML, et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alpha-2a and ribavirin. *Gastroenterology.* 2010;139:1593-1601

 **NEO**  
**Daklinza**®  
(daclatasvir)

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και  
Αναφέρετε  
ΟΛΕΣ τις ανεπιθύμητες ενέργειες για  
ΟΛΑ τα φάρμακα  
Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»

## Θεραπεύοντας τη λοίμωξη από *Clostridium difficile*...



## ... απελευθερώνετε τους ασθενείς σας από τον κίνδυνο της υποτροπής

1. Louie T.J et al. *N Engl J Med* 2011; 364(6): 422-431.  
2. Coombs OA et al. *Lancet Infect Dis* 2012; 12: 281-289.

ADV/DFIF/01.2015

### ΠΕΡΙΛΗΨΗ ΤΩΝ ΧΑΡΑΚΤΗΡΙΣΤΙΚΩΝ ΤΟΥ ΠΡΟΪΟΝΤΟΣ (SPC)

▽ Το φάρμακο αυτό τελεί υπό συμπληρωματική παρακολούθηση. Αυτό θα επιτρέψει τον ταχύ προσδιορισμό νέων πληροφοριών ασφαλείας. Ζητείται από τους επαγγελματίες του τομέα της υγειονομικής περίθαλψης να αναφέρουν οποιοδήποτε πιθανολογούμενο ανεπιθύμητο ενέργεια. Βλ. παράγραφο 4.8 για τον τρόπο αναφοράς ανεπιθύμητων ενεργειών.

#### 1. ΟΝΟΜΑΣΙΑ ΤΟΥ ΦΑΡΜΑΚΕΥΤΙΚΟΥ ΠΡΟΪΟΝΤΟΣ

DIFICLIR 200 mg επικαλυμμένα με λεπτό υμένιο δισκία

#### 2. ΠΟΙΟΤΙΚΗ ΚΑΙ ΠΟΣΟΤΙΚΗ ΣΥΝΘΕΣΗ

Κάθε δισκίο περιέχει 200 mg fidaxomicin. Για τον πλήρη κατάλογο των εκδόσων, βλ. παράγραφο 6.1.

#### 3. ΦΑΡΜΑΚΟΤΕΧΝΙΚΗ ΜΟΡΦΗ

Επικαλυμμένο με λεπτό υμένιο δισκίο. Δισκία σχήματος καρδιακού, χρώματος λευκού έως υπόλευκου, με τυπωμένο το «FD» στη μία πλευρά και «200» στην άλλη πλευρά.

#### 4. ΚΛΙΝΙΚΕΣ ΠΛΗΡΟΦΟΡΙΕΣ

**4.1 Θεραπευτικές ενδείξεις:** Το DIFICLIR ενδείκνυται σε ενήλικες για τη θεραπεία των λοιμώξεων του *Clostridium difficile* (CD), επίσης γνωστή ως διάρροια συσχετιζόμενη με το «FD» στη μία πλευρά (CDAD) (βλέπε παράγραφο 5.1). Θα πρέπει να λαμβάνονται υπόψη οι επίσημες οδηγίες για την κατάλληλη χρήση των αντιβιοτικών παραγόντων.

#### Δοσολογία: Βλέπετε την Παράγραφο 5.2

Η συνιστώμενη δόση είναι 200 mg (ένα δισκίο) δύο φορές ημερησίως (μία φορά κάθε 12 ώρες) για 10 ημέρες. **Παιδιατρικές πληροφορίες:** Η ασφάλεια και η αποτελεσματικότητα της fidaxomicin σε παιδιά ηλικίας κάτω των 18 ετών δεν έχει ακόμη εδραιωθεί. Δεν υπάρχουν διαθέσιμα δεδομένα.

**Παιρική δυσλελυτογυα:** Δεν θεωρείται απαραίτητη η προσαρμογή της δόσης. Λόγω των περιορισμένων κλινικών δεδομένων σε αυτόν τον πληθυσμό, το DIFICLIR πρέπει να χρησιμοποιείται με προσοχή σε ασθενείς με σοβαρή δυσλελυτογυα (βλέπε παραγράφους 4.4 και 5.2).

**Ηπατική δυσλελυτογυα:** Δεν θεωρείται απαραίτητη η προσαρμογή της δόσης. Λόγω των περιορισμένων κλινικών δεδομένων σε αυτόν τον πληθυσμό, το DIFICLIR πρέπει να χρη-

σιμοποιείται με προσοχή σε ασθενείς με μέτρια έως σοβαρή ηπατική δυσλελυτογυα (βλέπε παραγράφους 4.4 και 5.2).

**Τρόπος χορήγησης:** Το DIFICLIR προορίζεται για χορήγηση από το στόμα. Το DIFICLIR μπορεί να ληφθεί με ή χωρίς τροφή. **4.3 Αντενδείξεις:** Υπερευαίσθησία στη δραστική ουσία ή σε κάποιο από τα έκδοχα που αναφέρονται στην παράγραφο 6.1. **4.4 Ειδικές προειδοποιήσεις και προφυλάξεις κατά τη χρήση:** Έχουν αναφερθεί αντιδράσεις υπερευαίσθησίας συμπεριλαμβανομένου του σοβαρού αγγειοοίδηματος. Εάν παρατηρηθεί μια σοβαρή αλλεργική αντίδραση κατά τη διάρκεια της θεραπείας με το DIFICLIR, το φαρμακευτικό προϊόν πρέπει να διακοπεί και να λαμβάνονται τα κατάλληλα μέτρα. Μερικοί ασθενείς με αντιδράσεις υπερευαίσθησίας ανέφεραν ιστορικό αλλεργίας σε μακρολίδες. Η fidaxomicin πρέπει να χρησιμοποιείται με προσοχή σε ασθενείς με γνωστή αλλεργία στις μακρολίδες. Λόγω των περιορισμένων κλινικών δεδομένων, η fidaxomicin πρέπει να χρησιμοποιείται με προσοχή σε ασθενείς με σοβαρή νεφρική δυσλελυτογυα ή μέτρια έως σοβαρή ηπατική δυσλελυτογυα (βλέπε παράγραφο 5.2). Λόγω των περιορισμένων κλινικών δεδομένων, η fidaxomicin πρέπει να χρησιμοποιείται με προσοχή σε ασθενείς με ψευδομεμβρανώδη κολίτιδα, κεραυνοβόλο ή απεπτική για τη ζωή CD. Δεν υπάρχουν στοιχεία σε ασθενείς με συνοδό φλεγμονώδη νόσο του ατέρους. Η fidaxomicin πρέπει να χρησιμοποιείται με προσοχή σε αυτούς τους ασθενείς λόγω του κινδύνου της αυξημένης απορρόφησης και του πιθανού κίνδυνου συμπτωμάτων ανεπιθύμητων αντιδράσεων. Η συγχρησιμοποίηση ορισμένων αναστολέων της P-πυκνωτικής όπως κλοζιμολίνη, κετοκοναζόλη, ερυθρομυκίνη, κλαριθρομυκίνη, βεραπρίλη, ερομεβρόνη και εμιδορόνη δεν συνιστάται (βλέπε παραγράφους 4.5 και 5.2).

Προσοχή στη πληθυσμιακή ασθένεια σε κλινικές δοκιμές. Στις δύο κλινικές δοκιμές ασθενών με CD, το 47,9% (479/999) των ασθενών (συμπεριλαμβανομένου του πληθυσμού του προποικισμού) ήταν ηλικίας ≥ 65 ετών και το 27,5% (275/999) των ασθενών υποβλήθηκε σε τουλάχιστον μία θεραπεία με αντιβιοτικά κατά τη διάρκεια της περιόδου της μελέτης. Το αντίστοιχο ποσοστό εκεί των ασθενών εκπλήρωσε τουλάχιστον ένα από τα ακόλουθα τρία κριτήρια στη τιμή αναφοράς σε ότι αφορούσε τη σοβαρότητα της

διαβόλησης: θερμοκρασία σώματος > 38,5°C, αριθμός λευκοκυττάρων > 15.000 ή τιμή κρεατινίνης ≥ 1,5 mg/dl. Οι ασθενείς με κεραυνοβόλο κολίτιδα και οι ασθενείς με πολλαπλά επεισόδια (ορίζονται ως περισσότερα του ενός προηγούμενα επεισόδια εντός των προηγούμενων 3 μηνών) CDI αποκλείστηκαν από τις μελέτες. **4.8 Ανεπιθύμητες ενέργειες:** Περίληψη του προφίλ ασφαλείας Το προφίλ ασφαλείας του DIFICLIR βασίζεται σε δεδομένα από 564 ασθενείς με CD στους οποίους χορηγήθηκε θεραπεία με fidaxomicin σε μελέτες Φάσης 3. Οι πιο συχνές σχετιζόμενες με τη θεραπεία ανεπιθύμητες ενέργειες ήταν έμετος (1,2%), ναυτία (2,7%) και δυσκοιλιότητα (1,2%). Παρακάτω αναφέρονται οι ανεπιθύμητες ενέργειες που σχετίζονται με τη δισ ημερήσια χορήγηση της fidaxomicin στη θεραπεία της λοίμωξης από *C. difficile* που αναφέρθηκαν σε τουλάχιστον δύο ασθενείς, παρουσιάζονται ανά κατηγορία οργανικού συστήματος. Η συχνότητα των ανεπιθύμητων ενεργειών ορίστηκε ως εξής: πολύ συχνές (≥1/10), συχνές (≥1/100 έως <1/10), όχι συχνές (≥1/1.000 έως <1/100), σπάνιες (≥1/10.000 έως <1/1.000), πολύ σπάνιες (<1/10.000), μη γνωστές (δεν υπάρχουν να εκτιμηθούν με βάση τα διαθέσιμα δεδομένα). Εντός κάθε κατηγορίας συστήματος εμάνθη, οι ανεπιθύμητες ενέργειες παρατηρήθηκαν κατά φθίνουσα σειρά σοβαρότητας. **Κατηγορία/Οργανικό Σύστημα κατά MedDRA**

**Διαταραχές του ανοσοποιητικού συστήματος:** - Όχι συχνές: εξάνθημα, κνησμός - Συχνότητα μη γνωστή: αντιδράσεις υπερευαίσθησίας (αγγειοοίδημα, δύσπνοια), διαταραχές του μεταβολισμού και θρέψης - Όχι συχνές: μειωμένη όρεξη. **Διαταραχές του νευρικού συστήματος:** - Όχι συχνές (όχι κεφαλαλγία, δύσπνοια): Διαταραχές του γαστροεντερικού - Συχνές έμετος, ναυτία, δυσκοιλιότητα - Όχι συχνές: κόπωση, δίψαση, μετανευρικός ερεθισμός, διαταραχές του ήπατος - Όχι συχνές: αυξημένη εμπατισσαρόφηση της αλανίνης. **Ανεπιθύμητες ενέργειες που σχετίζονται με ανεπιθύμητες ενέργειες:** Η αναφορά πιθανολογούμενων ανεπιθύμητων ενεργειών μετά από τη χορήγηση άδεια κυκλοφορίας του φαρμακευτικού προϊόντος είναι σημαντική. Επιτρέπει τη συνεχή παρακολούθηση της σχέσης οφέλους-κινδύνου του φαρμακευτικού προϊόντος. Ζητείται από τους επαγγελματίες του τομέα της υγειονομικής περίθαλψης να αναφέρουν

οποιοδήποτε πιθανολογούμενο ανεπιθύμητο ενέργεια μέσω: **Ελλάδα:** Εθνικός Οργανισμός Φαρμάκων, Μεσογείων 284, GR-15562 Χολαργός Αθήνα, Τηλ: +30 21 32040380/337, Φαξ: +30 21 06549585, Ιστοτόπος: <http://www.eof.gr> **Κύπρος:** Φαρμακευτικές Υπηρεσίες Υπουργείο Υγείας, CY-1475 Λευκωσία, Φαξ: +357 22608649, Ιστοτόπος: [www.moh.gov.cy/phs](http://www.moh.gov.cy/phs)

**ΚΑΤΟΧΟΣ ΤΗΣ ΑΔΕΙΑΣ ΚΥΚΛΟΦΟΡΙΑΣ:** Astellas Pharma Europe

B.V., Sylviusweg 62, 2333 BE Leiden, Ολλανδία

**ΑΡΙΘΜΟΣ(ΟΙ) ΑΔΕΙΑΣ ΚΥΚΛΟΦΟΡΙΑΣ:** EU/11/1733/001-004

**ΗΜΕΡΟΜΗΝΙΑ ΠΡΩΤΗΣ ΕΓΚΡΙΣΗΣ/ΑΝΑΝΕΩΣΗΣ ΤΗΣ ΑΔΕΙΑΣ:**

05/12/2011

**ΗΜΕΡΟΜΗΝΙΑ ΑΝΑΒΕΒΛΗΣΗΣ ΤΟΥ ΚΕΙΜΕΝΟΥ:** 26 Ιουνίου 2014

Λεπτομερή πληροφοριακά στοιχεία για το παρόν φαρμακευτικό προϊόν είναι διαθέσιμα στον δικτυακό τόπο του Ευρωπαϊκού Οργανισμού Φαρμάκων: <http://www.ema.europa.eu>

Φαρμακευτικό προϊόν για το οποίο απαιτείται ιατρική συνταγή.

Νοσοκομειακή τιμή: 1325,85 €

Βοήθησα να γίνω το φάρμακο που ασφαλίσει και Αναμένω: **ΟΝΕΣ** τις ανεπιθύμητες ενέργειες για **ΟΑΕ** τα φάρμακα Συμπεριλαμβανομένης της «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»

Παραπομπή πληροφοριών διαθέσιμη από τον κάτοχο της άδειας κυκλοφορίας κατόπιν αιτήσεως.



Astellas Pharmaceutical A.E.B.E.  
Θουκυδίδου 1, 14565 Αγ. Σπυρίδων Αττικής  
Τηλ.: 210 8189 900, Fax: 210 8189 960

# TABLE OF CONTENTS

<b>Welcome Message .....</b>	<b>7</b>
<b>Organization .....</b>	<b>8</b>
<b>General Information .....</b>	<b>10-12</b>
- Venue/Dates & Hours/ Official Language/ Webcasting/ Accreditation/ e-Abstract Book .....	10
- Social Events/ Registration/ Receipts .....	11
- Name Badge /Certificate of Attendance/ Exhibition/ Mobile Phones/ Liability and Insurance/ Contact .....	12
<b>Scientific Information .....</b>	<b>13-17</b>
- Guidelines for Invited Faculty & Presenting Authors .....	13-14
- Oral Presentations .....	15
- e-Poster Presentations .....	16
- e-Poster Timetable .....	17
<b>Scientific Programme .....</b>	<b>19-65</b>
- Thursday, March 17, 2016 .....	19-24
- Friday, March 18, 2016 .....	25-48
- Saturday, March 19, 2016 .....	49-65
<b>Index of Invited Faculty .....</b>	<b>67-72</b>
<b>Index of Oral &amp; e-Poster Presentations .....</b>	<b>73-82</b>
<b>Sponsors/Acknowledgements .....</b>	<b>83</b>
<b>Floor plan (Halls) .....</b>	<b>84</b>



# PCSK9: μια πρωτεΐνη- κλειδί στην κατανόηση του μεταβολισμού της LDL-C

Η ανακάλυψη της PCSK9, μιας πρωτεΐνης η οποία παίζει σημαντικό ρόλο στην ικανότητα του οργανισμού να ρυθμίζει τα επίπεδα της LDL-C, ανοίγει το δρόμο για μια εντελώς καινούργια στρατηγική αντιμετώπισης της υψηλής χοληστερόλης.

PCSK9

PCSK9

GR:ALI.15.03.01

LDL-C

PCSK9

LDLR

Lagace TA et al. J Clin Invest. 2006;116:2995-3005.

*Η Sanofi και η Regeneron συνεργάζονται με στόχο τη βελτιστοποίηση της διαχείρισης της υπερχοληστερολαιμίας, διερευνώντας τις ανάγκες των ασθενών με μη ικανοποιητικά ρυθμισμένη LDL-C.*

**Sanofi-aventis A.E.B.E.** Λεωφ. Συγγρού 348, Κτήριο Α'  
17674 Καλλιθέα. Τηλ.: 210 90 01 600, Fax: 210 92 49 088  
[www.sanofi.gr](http://www.sanofi.gr)

**SANOFI** 

## WELCOME MESSAGE

Dear colleagues,

On behalf of the Organizing Committee, it is a great pleasure to welcome you to the **8<sup>th</sup> Larissa International Congress of Internal Medicine** taking place on **17-19 March, 2016** at Larissa Imperial Hotel, in **Larissa, Greece**.

The Congress is organized with the joint effort of the **Institute of Internal Medicine and Hepatology** and the **Department of Medicine and Research Laboratory of Internal Medicine of the University of Thessaly Medical School, Larissa, Greece**. We are also glad that the Congress is organized in cooperation with the **Hellenic Association for the Study of the Liver** and the **Hellenic Stroke Organization**, under the auspices of the **University of Thessaly Medical School**.

The Organizing and Scientific Committees, aiming to keep up with the educational nature of the previous successful Congresses, have prepared a stimulating scientific programme that will bring topics with broad, interdisciplinary interest to open dialogue and highlight the latest scientific achievements in a variety of diseases encountered in everyday clinical practice of Internal Medicine.

The multi topic scientific programme, given the importance of the international character of the Congress, is designed to feature rather interesting plenary state-of-the-art lectures, delivered by leading foreign and Greek experts, round tables designed in collaboration with different Scientific Societies covering hot topics and current issues in the field of Internal Medicine, up-to-date symposia along with satellite lectures and symposia.

Furthermore, the Congress will provide young-and not only-colleagues with a great opportunity to present their work, research and clinical experience through a very important number of oral and poster presentations.

We trust that the three days experience in the Congress will become a great opportunity for younger to learn from the older, for experts to share their valuable knowledge and for all to gain from rewarding presentations and discussions.

Best regards,

The President of the Organizing Committee

**George N. Dalekos**

*Professor of Medicine,*

*President, Institute of Internal Medicine and Hepatology,*

*President, Hellenic Association for the Study of the Liver,*

*Vice President, Internal Medicine Society of Northern Greece,*

*Head, Department of Medicine and Research Laboratory of Internal Medicine,*

*Medical School, University of Thessaly, Larissa, Greece*







**Lucidel®**

Irbesartan

75mg, 150mg, 300mg

**Lucidelplus®**

Irbesartan+HCT

150mg + 12.5mg, 300mg + 12.5mg, 300mg+25mg



**ΟΝΟΜΑΣΙΑ ΤΟΥ ΦΑΡΜΑΚΕΥΤΙΚΟΥ ΠΡΟΪΟΝΤΟΣ:** Lucidel επικαλυμμένα με λεπτό υμένιο δισκία 75mg, 150mg, 300mg.  
Lucidel plus επικαλυμμένα με λεπτό υμένιο δισκία 150mg+12.5mg, 300+12.5mg, 300+25mg.

**ΠΟΙΟΤΙΚΗ ΠΟΣΟΤΙΚΗ ΣΥΝΘΕΣΗ:** Κάθε δισκίο Lucidel περιέχει 75mg, 150mg, 300mg ιρβεσαρτάνης, αντίστοιχα.  
Κάθε δισκίο Lucidel plus περιέχει 150mg/12.5mg, 300mg/12.5mg, 300mg/25mg ιρβεσαρτάνης/υδροχλωροθειαζίδης αντίστοιχα.

Για συνταγογραφικές πληροφορίες συμβουλευτείτε την ΠΧΠ ή απευθυνθείτε στην εταιρεία ELPEN.



**ELPEN Α.Ε. Φαρμακευτική Βιομηχανία** Λεωφ. Μαραθώνος 95, Πικέρμι Αττικής 190 09, Τηλ.: 210 60 39 326-9  
Γραφεία Επιστημονικής Ενημέρωσης

• Παπαδιαμαντοπούλου 41, 115 28 Αθήνα, Τηλ.: 210 74 88 712. • Εθνικής Αντιστάσεως 114, 551 34 Θεσσαλονίκη, Τηλ.: 2310 459 920-1

## GENERAL INFORMATION

### Venue

---

#### **LARISSA IMPERIAL HOTEL**

182 Farsalon Str., GR 413 35 Larissa, Greece

Tel: +30 2410 687600, Fax: +30 2410 687687

Email: [li@classicalhotels.com](mailto:li@classicalhotels.com),

Website: <http://www.larissaimperial.com/>

### Dates & Hours

---

Thursday, March 17<sup>th</sup> 2016      14:00 - 21:00

Friday, March 18<sup>th</sup> 2016      08:00 - 21:00

Saturday, March 19<sup>th</sup> 2016      07:45 - 21:00

### Official Language

---

The official language of the Congress is **English**.

Simultaneous translation (interpretation) will not be provided.

### Webcasting

---

Watch the sessions of the 8th International Congress of Internal Medicine of Central Greece on demand, on **<http://www.livemedia.com/intmed2016>**.

Due to the importance of all presentations the organizing committee would like to request for the permission of all speakers to publish their presentations and talks on a specific area on the internet.

Sponsored by  **MSD**

### Accreditation

---

The Congress has been accredited with **16 C.M.E. Credits by the Panhellenic Medical Association**.

### e-Abstract Book

---

Abstracts of all Oral and e-Poster Presentations of the Congress will be included in the e-Abstract Book of the Congress. All registered participants are entitled to receive the e-Abstract Book in electronic format (included in the Congress material).

## Social Events

### WELCOME RECEPTION

Date: **Thursday, March 17<sup>th</sup> 2016**

Time: **21:00**

(upon completion of  
the Opening Ceremony)

Location: **Larissa Imperial Hotel**

("Achilleas" Hall)

Sponsored by  Bayer  
Platinum Sponsor

### DINNER

Date: **Saturday, March 19<sup>th</sup> 2016**

Time: **21:30**

For more information  
please check your invitation.

Sponsored by  Bayer  
Platinum Sponsor

**Upon Invitation**

## Registration

### Registration Fees (Euros/incl. VAT 23%)

CATEGORY	REGISTRATION FEE
<sup>1</sup> Doctors	<b>130,00€</b>
<sup>1</sup> Trainees	<b>90,00€</b>
<sup>2</sup> Nursing staff	<b>Free</b>
<sup>2</sup> Students	<b>Free</b>
<sup>3</sup> Other	<b>40,00€</b>

#### 1. Registration for doctors and trainees includes:

- Admission to the Congress area and scientific sessions
- Admission to the exhibition area
- Congress material
- Certificate of Attendance

#### 2. Registration for nursing staff and students includes

- Admission to the congress area and scientific sessions
- Admission to the exhibition area
- Certificate of Attendance

#### 3. Registration for other includes:

- Admission to the Congress area and scientific sessions
- Admission to the exhibition area
- Congress material
- Certificate of Attendance

## Receipts and Invoices

- Receipts and Invoices for Registration, Accommodation & other expenses paid to Conferre Ltd for individual services will be provided to participants during the Congress by the Secretariat, upon request.
- Invoices to companies will be issued and sent AFTER the Congress and within one month.



### **Name Badge-Scanning**

---

All participants, upon confirmation of their registration at the Secretariat, will be provided with a name badge that bears a unique barcode.

It must be clearly understood that barcode badges must be scanned **before entering AND after exiting the Lecture Halls.**

**According to the National Organization of Medicines Regulation participation for at least of 60% of the total duration of the scientific programme must be secured and recorded!**

Notes:

- It is obligatory - for all participants to wear their badges always during the Congress.
- Name badges are also necessary for admittance to the social events.
- Please be returned to the Secretariat for receiving the Certificate of Attendance.
- Time slots for breaks and satellite symposiums/lectures will not be recorded.

### **Certificate of Attendance**

---

All registered participants are entitled to receive a Certificate of Attendance. The Certificate will be issued on Saturday, March 19<sup>th</sup> 2016 at the end of the Scientific Programme and only upon return of the name badge and the completed Evaluation Form at the Secretariat desk.

### **Sponsors/ Exhibition**

---

A major exhibition will accompany the Congress, where pharmaceutical and/or equipment/device industries will display relevant products, services and therapeutic developments, reach and interact with the medical community, promote their activities, research and technologies.

### **Mobile Phones**

---

Everyone is requested to switch off his/her mobile phone while in session Halls.

### **Liability and Insurance**

---

The Organizers as well as the Organizing-Administrative Bureau will assume no liability for injuries or losses of any nature incurred by participants and/or accompanying persons, or for the damage, loss or theft of their personal property during the Congress. Participants are advised to take out their own health, travel and personal insurances.

### **Contact**

---

**Organizing-Administrative Bureau/Secretariat:**

**Conferre Ltd**

Stavrou Niarchou Avenue, GR 45110 Ioannina, Greece

Tel.: (+30) 26510 68610, Fax: (+30) 26510 68611

E-mail: [info@conferre.gr](mailto:info@conferre.gr), Website: [www.conferre.gr](http://www.conferre.gr)

## Guidelines for Invited Faculty & Presenting Authors

---

### For PPT Presentations (applies to all presenters)

#### **Formal Requirements**

**Advertising:** Advertising of products is **prohibited**. Be sure your slides are free of any commercial bias (e.g. company names or logos).

**Patient anonymity:** Kindly make sure that no patient names or any other information allowing the identification of a patient appearing in your presentation.

**Copyright reserved:** It is the author's responsibility to ensure that any part of the slide show (figures, tables, images, etc.) is free of any third party right.

**Language:** The material for the presentation (PowerPoint slides, templates etc) should be prepared in **English Language**.

The presentation should be delivered in **English Language**.

#### **Technical Requirements**

**Format:** preferable format is MS PowerPoint (pptx or ppsx). *Macintosh presentations will be accepted.\**

**Versions:** up to MS PowerPoint 2010.

**Saving of files:** For onsite upload, the presentation has to be saved on a USB flash (recommended), CD-ROM or DVD-ROM drive.

**Video clips:** If you are using embedded video clips in your presentation, please remember to also have the video clips in a separate file (not only in the presentation).

**Fonts & character:** To avoid any possible compatibility problems, it is preferable not to use any special fonts or special characters.

### Onsite presentation

You are kindly requested to deliver your presentation(s) to the technical support personnel at least **one (1) hour before the beginning of the Session** (in order to ensure on time they run smoothly and to be able of making any possible changes). If the presentation is scheduled early in the morning, you are kindly requested to check your presentation with the technical support personnel the day before.

Your PPT presentation will be available in the lecture hall via computer network.

There will be no possibility of connecting your personal laptop in the lecture hall, due to the very restricted timeslots (row of the presentations).

*The main Hall will be equipped with the following:*

- LCD projector with remote control (operated by presenter-no mouse will be available)
- Screen & Lighted pointer • Podium mounted microphone • Audience aisle microphones

It is very important to respect the flow of the session and the exact time available for each presentation and therefore you are requested to be consistent with the time slots. It is advisable to rehearse your presentation prior to the meeting to ascertain that the **time is not exceeded**.

#### **\*To the attention of Mac users:**

Please make sure to have the suitable adapter and to also have a backup PPT for PC. You are kindly requested to meet with the technical support personnel at least **two(2) hours before the beginning of the session**, in order to assure compatibility (or backup solutions).

### **MCQ Voting System**

MCQ voting system will be available during all sessions.

In accordance with the educative nature of the Congress all speakers are kindly requested to prepare 2-3 multiple choice questions (including 4 possible answers) regarding the topic of their presentation. Speakers will make the questions (preferably at the end of their presentation) and the audience will vote using the electronically voting system. Subsequently, the presenter will give the right answer making the appropriate comments.

### **Conflict of Interest Disclosure (*applies to all Invited Faculty*)**

According to the Greek National Organization for Medicines policy, no invited presentation should have any commercial association. Therefore, in compliance with their guidelines, all invited faculty (speakers/chairmen/moderators etc) participating in the Congress are strictly requested to disclose or indicate potential conflicts of interest (with the Congress sponsors) that might cause a bias.

### **You are requested (if not already done) to:**

1. Advise the sponsors file
2. Declare any potential or actual conflict of interest regarding the above sponsors and topics of the presentation(s)
  - at the **Second Slide** of your PowerPoint Presentation (if speaker)
  - or **orally** at the beginning of the session (if chairperson etc)

The existence of potential conflicts of interest does not necessarily indicate a bias. However, it is your ethical obligation to inform organizers and participants, so that they become aware of any relationship with the sponsors that might cause unintentional bias. A potential conflict of interest may arise from various relationships, past or present, such as employment, consultancy, funding for research, investments, family relationship etc.

### **Publication**

All abstracts accepted for Oral & e-Poster Presentations will be included in the e-Abstract Book of the Congress which will be distributed to registered participants within the Congress material.

### **Presentation Certificate (*applies to Presenting Authors*)**

All presenting authors, who will participate in the scientific programme of the Congress with oral or/and e-poster presentations, will be entitled to also receive a Certificate for their presentation.

Certificates will be issued only upon confirmation of complete presentation.



## Oral Presentations

### Duration:

Each oral presentation should not exceed **8 minutes**.  
It will be followed by **2 minutes** discussion.

## Oral Presentations Schedule

<b>Thursday, March 17, 2016</b>	<b>14:30-16:00</b>
<b>OP01-OP09</b>	<i>Hall OLYMPOS</i>
<b>CARDIOVASCULAR MEDICINE</b>	
<i>Chairpersons:</i> <b>Konstantinos Makaritsis</b> (Larissa, Greece) <b>Dwaipayan Sen</b> (Manchester, UK)	
<b>Friday, March 18, 2016</b>	<b>08:00 - 09:30</b>
<b>OP10-OP18</b>	<i>Hall OLYMPOS</i>
<b>HEPATOLOGY - GASTROENTEROLOGY</b>	
<i>Chairpersons:</i> <b>Evangelos Cholongitas</b> (Thessaloniki, Greece) <b>Stylianos Karatapanis</b> (Rhodes, Greece)	
<b>OP19-OP27</b>	<i>Hall ACHILLEAS</i>
<b>HEPATOLOGY - GASTROENTEROLOGY - METABOLIC SYNDROME</b>	
<i>Chairpersons:</i> <b>Konstantinos Mimidis</b> (Alexandroupolis, Greece) <b>Dimitrios Samonakis</b> (Heraklion, Greece)	
<b>Saturday, March 19, 2016</b>	<b>07:45 - 09:00</b>
<b>OP28-OP34</b>	<i>Hall OLYMPOS</i>
<b>IMMUNOLOGY - ONCOLOGY - HAEMATOLOGY</b>	
<i>Chairpersons:</i> <b>Matthaios Speletas</b> (Larissa, Greece) <b>Christos Tolis</b> (Ioannina, Greece)	
<b>OP35-OP41</b>	<i>Hall ACHILLEAS</i>
<b>GERIATRIC MEDICINE - INFECTIOUS DISEASES</b>	
<i>Chairpersons:</i> <b>Efthimia Petinaki</b> (Larissa, Greece) <b>Christos Savopoulos</b> (Thessaloniki, Greece)	

## e-Poster Presentations

### Duration:

Each e-Poster presentation should not exceed **5 minutes**.  
It will be followed by **2 minutes** discussion.

## e-Poster Presentations Schedule

**Friday, March 18, 2016**

**14:00 - 15:30**

**e-PP01 - e-PP13 (Screen A)**

*Hall ALKISTIS - THETIDA*

**CARDIOVASCULAR MEDICINE - METABOLIC SYNDROME**

*Chairpersons:* **Dimitrios Papazoglou** (Alexandroupolis, Greece)  
**Vasileios Tsimihodimos** (Ioannina, Greece)

**e-PP14 - e-PP26 (Screen B)**

*Hall ALKISTIS - THETIDA*

**HEPATOLOGY - GASTROENTEROLOGY**

*Chairpersons:* **Melanie Deutsch** (Athens, Greece)  
**Grigorios Giannoulis** (Athens, Greece)

**e-PP27 - e-PP39 (Screen C)**

*Hall CHRISALIDA*

**HEPATOLOGY - GASTROENTEROLOGY**

*Chairpersons:* **Christos Triantos** (Patras, Greece)  
**Vasileios Sevastianos** (Athens, Greece)

**e-PP40 - e-PP52 (Screen D)**

*Hall NEFELI*

**GERIATRIC MEDICINE - IMMUNOLOGY - RHEUMATOLOGY**

*Chairpersons:* **Panagiotis Skendros** (Alexandroupolis, Greece)  
**Irene Rapti** (Athens, Greece)

**Saturday, March 19, 2016**

**14:15 - 15:45**

**e-PP53 - e-PP65 (Screen A)**

*Hall ALKISTIS - THETIDA*

**HAEMATOLOGY - ONCOLOGY**

*Chairpersons:* **Georgia Kaiafa** (Thessaloniki, Greece)  
**Eleni Bouronikou** (Larissa, Greece)

**e-PP66 - e-PP78 (Screen B)**

*Hall ALKISTIS - THETIDA*

**INFECTIOUS DISEASES**

*Chairpersons:* **Periklis Panagopoulos** (Alexandroupolis, Greece)  
**Efthymia Giannitsioti** (Athens, Greece)

**e-PP79 - e-PP91 (Screen C)**

*Hall CHRISALIDA*

**ONCOLOGY - INFECTIOUS DISEASES - MISCELLANEOUS**

*Chairpersons:* **Maria Ioannou** (Larissa, Greece)  
**Dimitra Dimitropoulou** (Patras, Greece)

## e-Poster Timetable

<b>FRIDAY, MARCH 18, 2016</b>				
	<i>Hall</i> <b>ALKISTIS-THETIDA</b> (Screen A)	<i>Hall</i> <b>ALKISTIS-THETIDA</b> (Screen B)	<i>Hall</i> <b>CHRISALIDA</b> (Screen C)	<i>Hall</i> <b>NEFELI</b> (Screen D)
<b>TIME</b>	<b>CARDIOVASCULAR MEDICINE - METABOLIC SYNDROME</b>	<b>HEPATOLOGY - GASTROENTEROLOGY</b>	<b>HEPATOLOGY - GASTROENTEROLOGY</b>	<b>GERIATRIC MEDICINE - IMMUNOLOGY - RHEUMATOLOGY</b>
14.00-14.07	e-PP01	e-PP14	e-PP27	e-PP40
14.07-14.14	e-PP02	e-PP15	e-PP28	e-PP41
14.14-14.21	e-PP03	e-PP16	e-PP29	e-PP42
14.21-14.28	e-PP04	e-PP17	e-PP30	e-PP43
14.28-14.35	e-PP05	e-PP18	e-PP31	e-PP44
14.35-14.42	e-PP06	e-PP19	e-PP32	e-PP45
14.42-14.49	e-PP07	e-PP20	e-PP33	e-PP46
14.49-14.56	e-PP08	e-PP21	e-PP34	e-PP47
14.56-15.03	e-PP09	e-PP22	e-PP35	e-PP48
15.03-15.10	e-PP10	e-PP23	e-PP36	e-PP49
15.10-15.17	e-PP11	e-PP24	e-PP37	e-PP50
15.17-15.24	e-PP12	e-PP25	e-PP38	e-PP51
15.24-15.30	e-PP13	e-PP26	e-PP39	e-PP52

<b>SATURDAY, MARCH 19, 2016</b>			
	<i>Hall</i> <b>ALKISTIS-THETIDA</b> (Screen A)	<i>Hall</i> <b>ALKISTIS-THETIDA</b> (Screen B)	<i>Hall</i> <b>CHRISALIDA</b> (Screen C)
<b>TIME</b>	<b>HAEMATOLOGY - ONCOLOGY</b>	<b>INFECTIOUS DISEASES</b>	<b>ONCOLOGY - INFECTIOUS DISEASES - MISCELLANEOUS</b>
14.15-14.22	e-PP53	e-PP66	e-PP79
14.22-14.29	e-PP54	e-PP67	e-PP80
14.29-14.36	e-PP55	e-PP68	e-PP81
14.36-14.43	e-PP56 - WITHDRAWN	e-PP69	e-PP82
14.43-14.50	e-PP57	e-PP70	e-PP83
14.50-14.57	e-PP58	e-PP71	e-PP84
14.57-15.04	e-PP59	e-PP72	e-PP85
15.04-15.11	e-PP60	e-PP73	e-PP86
15.11-15.18	e-PP61	e-PP74	e-PP87
15.18-15.25	e-PP62	e-PP75	e-PP88
15.25-15.32	e-PP63	e-PP76	e-PP89
15.32-15.39	e-PP64	e-PP77	e-PP90
15.39-15.45	e-PP65	e-PP78	e-PP91





# Cilos<sup>®</sup>

cilostazol

**Ποιοτική και Ποσοτική Σύνθεση:** cilostazol 50 mg και 100 mg

Για περισσότερες πληροφορίες απευθυνθείτε στο επιστημονικό τμήμα της WinMedica

 **WinMedica**  
Serving Health for Life

[www.winmedica.gr](http://www.winmedica.gr)

**ΑΘΗΝΑ:** Οιδίποδος 1-3 & Παράδρομος Αττικής Οδού 33-35, Χαλάνδρι 15238, Αθήνα. **Τηλ:** 210 7488 821,  
**Τηλ. Παραγγελιών:** 210 7488 839, **E-mail:** [info@winmedica.gr](mailto:info@winmedica.gr). **ΘΕΣΣΑΛΟΝΙΚΗ:** Εθν. Αντιστάσεως 74 & Αίαντος, 55133,  
**Τηλ:** 2310 488658. [www.winmedica.gr](http://www.winmedica.gr)

14:00 Registration

## 14:30 - 16:00 ORAL PRESENTATIONS

OP01-OP09

Hall OLYMPOS

## CARDIOVASCULAR MEDICINE

*Chairpersons: Konstantinos Makaritsis (Larissa, Greece)**Dwaipayan Sen (Manchester, UK)***OP01 ASTRAL PROGNOSTIC SCORE HAS A HIGH PROGNOSTIC ACCURACY IN BOTH THROMBOLYZED AND NON-THROMBOLYZED PATIENTS WITH ACUTE ISCHAEMIC STROKE**

<sup>1,2</sup> Vasileios Papavasileiou, <sup>3</sup> George Ntaios, <sup>4</sup> Christian Weimar (and on behalf of the VISTA collaborators), <sup>5</sup> Kennedy R Lees (and on behalf of the VISTA collaborators), <sup>6</sup> Ashraf Eskandari, <sup>7</sup> Konstantinos Vemmos, <sup>7</sup> Efstathios Manios, <sup>8</sup> Daniel Strbian, <sup>8</sup> Turgut Tatlisumak, <sup>9</sup> Ji Hoe Heo, <sup>9,10</sup> Tae-Jin Song, <sup>11</sup> David J Seiffge, <sup>12</sup> Julia Ferrari, <sup>13</sup> Solène Moulin, <sup>14</sup> Bernard Yan, <sup>15</sup> Bruno J. Weder, <sup>6,16</sup> Carlo W. Cereda, <sup>17</sup> Etsuro Mori, <sup>18</sup> Mohammad Kurniawan, <sup>6</sup> Patrik Michel

<sup>1</sup> Leeds Teaching Hospitals NHS Trust, Leeds General Infirmary, Leeds, United Kingdom;

<sup>2</sup> School of Medicine, Leeds Institute of Biomedical and Clinical Sciences, Faculty of Medicines and Health, University of Leeds, United Kingdom;

<sup>3</sup> Department of Medicine, Larissa University Hospital, School of Medicine, University of Thessaly, Larissa, Greece;

<sup>4</sup> Stroke Unit and Department of Neurology, University Hospital of Essen, Essen, Germany;

<sup>5</sup> Institute of Cardiovascular & Medical Sciences, University of Glasgow, BHF Cardiovascular Research Centre, Glasgow, UK;

<sup>6</sup> Neurology Service, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland;

<sup>7</sup> Department of Clinical Therapeutics, Medical School of Athens, Alexandra Hospital, Athens, Greece;

<sup>8</sup> Department of Neurology, Helsinki University Central Hospital, Helsinki, Finland;

<sup>9</sup> Department of Neurology, Severance Hospital, Yonsei University, College of Medicine, Seoul, Korea;

- <sup>10</sup> Ewha Womans University, School of Medicine, Seoul, Korea;  
<sup>11</sup> Stroke Center and Neurology, University Hospital Basel, University of Basel, Basel/Switzerland;  
<sup>12</sup> Department of Neurology, St. John 's of God Hospital, Vienna, Austria;  
<sup>13</sup> Stroke Unit, Department of Neurology, University of Lille, Roger Salengro Hospital, Lille, France, Lille, France;  
<sup>14</sup> Melbourne Brain Centre, Department of Neurology, University of Melbourne, Royal Melbourne Hospital, Australia;  
<sup>15</sup> Stroke Center, Department of Neurology, Kantonsspital St.Gallen, St.Gallen, Switzerland;  
<sup>16</sup> Stroke Center, Neurology department, Neurocenter of Southern Switzerland, Lugano, Switzerland;  
<sup>17</sup> Department of Behavioral Neurology and Cognitive Neuroscience, Tohoku University Graduate School of Medicine, Sendai, Japan;  
<sup>18</sup> Stroke Unit, Department of Neurology, Cipto Mangunkusumo National Hospital, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia;

## **OP02 ASTRAL, DRAGON & SEDAN SCORES PREDICT STROKE OUTCOME MORE ACCURATELY THAN STROKE-TREATING PHYSICIANS**

- <sup>1</sup> Fotios Gioulekas, <sup>2</sup> George Ntaios, <sup>3</sup> Vasileios Papavasileiou, <sup>4</sup> Daniel Strbian, <sup>5</sup> Patrik Michel  
<sup>1</sup> Sub-Directorate of Informatics, University General Hospital of Larissa, Larissa, Greece;  
<sup>2</sup> Department of Medicine, Larissa University Hospital, School of Medicine, University of Thessaly, Larissa, Greece;  
<sup>3</sup> Comprehensive Stroke Centre, Salford Royal NHS Foundation Trust, Manchester Academic Health Sciences Centre, Salford Royal Foundation Trust, Manchester M6 8HD, UK;  
<sup>4</sup> Department of Neurology, Helsinki University Central Hospital, Helsinki, Finland;  
<sup>5</sup> Stroke Center, Neurology Service, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland;

**OP03 WHICH CVS RISK REDUCTION STRATEGY FITS BETTER TO CAROTID US FINDINGS?**

<sup>1</sup> Apostolos Dougalis, <sup>1</sup> Stergios Soulaïdopoulos,  
<sup>1</sup> Evangelos Cholongitas, <sup>1</sup> Parthenis Chalevas, <sup>1</sup> Christos Vettas,  
<sup>1</sup> Petros Doumstis, <sup>1</sup> Konstantina Vaitsi, <sup>1</sup> Mariana Diavasti,  
<sup>1</sup> Evdokia Mandala, <sup>1</sup> Garyfallos Alexandros  
<sup>1</sup> 4<sup>th</sup> Department of Internal Medicine, Medical School of Aristotle University, Hippokration General Hospital of Thessaloniki;

**OP04 RISK STRATIFICATION FOR RECURRENCE AND MORTALITY IN EMBOLIC STROKE OF UNDETERMINED SOURCE**

<sup>1</sup> George Athanasakis, <sup>1,14</sup> Vasileios Papavasileiou,  
<sup>2</sup> Konstantinos Vemmos, <sup>3</sup> Gregory Y.H. Lip, <sup>2</sup> Elena Koroboki,  
<sup>2</sup> Efstathios Manios, <sup>2</sup> Anastasia Vemmou, <sup>4</sup> Ana Rodríguez-Campello,  
<sup>4</sup> Elisa Cuadrado-Godia, <sup>4</sup> Eva Giralt-Steinhauer, <sup>5</sup> Valentina Arnao,  
<sup>5</sup> Valeria Caso, <sup>5</sup> Maurizio Paciaroni, <sup>6</sup> Exuperio Diez-Tejedor,  
<sup>6</sup> Blanca Fuentes, <sup>6</sup> Josefa Pérez Lucas, <sup>7</sup> Antonio Arauz,  
<sup>8</sup> Sebastian F. Ameriso, <sup>8</sup> Maximiliano A. Hawkes, <sup>8</sup> Lucía Pertierra,  
<sup>8</sup> Maia Gómez-Schneider, <sup>9</sup> Fabio Bandini, <sup>10</sup> Beatriz Chavarria Cano,  
<sup>10</sup> Ana Maria Iglesias Mohedano, <sup>10</sup> Andrés García Pastor,  
<sup>10</sup> Antonio Gil-Núñez, <sup>11</sup> Jukka Putaala, <sup>11,12</sup> Turgut Tatlisumak,  
<sup>13</sup> Miguel A. Barboza, <sup>1</sup> Konstantinos Makaritsis, <sup>1</sup> George Ntaios  
<sup>1</sup> Department of Medicine, Larissa University Hospital, School of Medicine, University of Thessaly, Larissa, Greece;  
<sup>2</sup> Department of Clinical Therapeutics, Medical School of Athens, Alexandra Hospital, Athens, Greece;  
<sup>3</sup> University of Birmingham Institute of Cardiovascular Sciences, City Hospital, Birmingham, UK;  
<sup>4</sup> Stroke Unit, Department of Neurology, Hospital del Mar. Neurovascular Research Group, IMIM-Hospital del Mar (Institut Hospital del Mar d'Investigacions Mèdiques), Universitat Autònoma de Barcelona. Barcelona, Spain  
<sup>5</sup> Stroke Unit, University of Perugia, Perugia, Italy;  
<sup>6</sup> Department of Neurology and Stroke Center, La Paz University Hospital - Autònoma University of Madrid, IdiPAZ Health Research Institute, Madrid, Spain;  
<sup>7</sup> Stroke Clinic. Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez. Mexico City, Mexico;  
<sup>8</sup> Department of Neurology, Institute for Neurological Research, FLENI, Buenos Aires, Argentina;  
<sup>9</sup> Department of Neurology, S. Paolo Hospital, Savona, Italy;

<sup>10</sup> Vascular Neurology Section, Stroke Center, Hospital General Universitario Gregorio Marañón, IiSGM Health Research Institute, Universidad Complutense de Madrid, Spain;

<sup>11</sup> Department of Neurology, Helsinki university Central Hospital and University of Helsinki, Helsinki, Finland;

<sup>12</sup> Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden; Department of Neurology, Sahlgrenska University Hospital, Gothenburg, Sweden;

<sup>13</sup> Neurosciences Department, Hospital Dr. Rafael A. Calderón Guardia, CCSS. University of Costa Rica, Costa Rica;

<sup>14</sup> Comprehensive Stroke Centre, Salford Royal NHS Foundation Trust, Manchester Academic Health Sciences Centre, Salford Royal Foundation Trust, Manchester M6 8HD, UK;

#### **OP05 PROTOCOL AND GUIDELINE COMPLIANCE IN STROKE MORTALITY: THE EXPERIENCE OF A COMPREHENSIVE STROKE CENTRE**

<sup>1</sup> Aisha Iftikhar Syeda, <sup>1</sup> Kaniz Rabia Sindhu, <sup>1,2</sup> Adrian Parry-Jones, <sup>1</sup> Jane Molloy, <sup>1,2</sup> Pippa J. Tyrrell, <sup>1</sup> [Vasileios Papavasileiou](#)

<sup>1</sup> *Comprehensive Stroke Centre, Salford Royal NHS, Foundation Trust, Department of Neurosciences;*

<sup>2</sup> *Stroke and Vascular Research Centre, Institute of Cardiovascular Sciences, University of Manchester, Manchester;*

#### **OP06 PROGNOSTIC SIGNIFICANCE OF STRESS HYPERGLYCEMIA IN ACUTE ISCHEMIC STROKE**

<sup>1</sup> Konstantinos Tziomalos, <sup>1</sup> Panagiotis Dimitriou, <sup>1</sup> Stella Bouziana,

<sup>1</sup> Marianna Spanou, <sup>1</sup> Stavroula Kostaki,

<sup>1</sup> [Stella-Maria Angelopoulou](#), <sup>1</sup> Maria Papadopoulou,

<sup>1</sup> Vasiliós Giampatzis, <sup>1</sup> Christos Savopoulos, <sup>1</sup> Apostolos Hatzitolios

<sup>1</sup> *First Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki;*

#### **OP07 COGNITION AND NUTRITIONAL FACTORS IN PREDICTING POOR OUTCOMES IN GERIATRIC REHABILITATION**

<sup>1</sup> [Dwaipayan Sen](#), <sup>2</sup> N. Saravanon, <sup>2</sup> Jason Raw

<sup>1</sup> *Comprehensive Stroke Centre, Neurosciences Department, Salford Royal NHS Foundation Trust, Manchester, United Kingdom;*

<sup>2</sup> *Department of Geriatric medicine, Fairfield General Hospital, Bury, United Kingdom;*



**OP08 PLATELET-MEDIATED RELEASE OF NEUTROPHIL EXTRACELLULAR TRAPS LEADS TO THE EXPOSURE OF ACTIVE TISSUE FACTOR AT THE SITE OF PLAQUE RUPTURE DURING MYOCARDIAL INFARCTION**

<sup>1</sup> Konstantinos Kambas, <sup>2</sup> Dimitrios Stakos, <sup>1</sup> Theocharis Konstantinidis,

<sup>3</sup> Ioannis Mitroulis, <sup>1,5</sup> Eirini Apostolidou, <sup>4</sup> Stella Arelaki,

<sup>1,5</sup> Panagiotis Skendros, <sup>2,6</sup> Stavros Konstantinides, <sup>1,5</sup> Konstantinos Ritis

<sup>1</sup> Laboratory of Molecular Hematology, Democritus University of Thrace, Alexandroupolis, Greece;

<sup>2</sup> Cardiology Department, Democritus University of Thrace, Alexandroupolis, Greece;

<sup>3</sup> Department of Clinical Pathobiochemistry and Institute for Clinical Chemistry and Laboratory Medicine, Faculty of Medicine Technische Universität Dresden, Dresden;

<sup>4</sup> Department of Pathology, University General Hospital of Alexandroupolis, Alexandroupolis, Greece;

<sup>5</sup> First Department of Internal Medicine, University Hospital of Alexandroupolis, Alexandroupolis, Greece;

<sup>6</sup> Center for Thrombosis and Hemostasis, University Medical Center Mainz, Mainz, Germany;

**OP09 LIPID RED BLOOD CELL MEMBRANES FOLLOWS THE PROGRESSION OF ISCHEMIC HEART DISEASE: AN NMR-BASED STUDY**

<sup>1</sup> Ioanna Kastani, <sup>1</sup> Christina Kostara, <sup>2</sup> Georgios Christou,

<sup>3</sup> Kostas Tsiafoulis, <sup>2</sup> Vasileios Tsimihodimos, <sup>2</sup> John Goudevenos,

<sup>2</sup> Moses Elisaf, <sup>1</sup> Eleni Bairaktari

<sup>1</sup> Laboratory of Clinical Chemistry, Medical School, University of Ioannina, Ioannina, Greece;

<sup>2</sup> Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece;

<sup>3</sup> NMR Center, Laboratory of Analytical Chemistry, Department of Chemistry, University of Ioannina, Ioannina, Greece;

**16:00 - 16:30 STATE-OF-THE-ART LECTURE**

**Hellenic Stroke Organization**

*Chairperson: Konstantinos Fountas (Larissa, Greece)*

Intracerebral haemorrhage: what is the cause?

**Charlotte Cordonnier (Lille, France)**

**16:30 - 17:00 Coffee break**

Hall OLYMPOS

**17:00 - 17:30 SATELLITE LECTURE**  
**Defining the role of PCSK9 inhibitor alirocumab  
 in the treatment of hyperlipidemia**

Sponsored by Sanofi

**17:30 - 19:00 ROUND TABLE**  
**Stroke in 2020**

**Hellenic Stroke Organization**

*Chairpersons:* **Charlotte Cordonnier** (Lille, France)  
**Konstantinos Vemmos** (Athens, Greece)

Patent foramen ovale: closure or not?

**Roland Veltkamp** (London, UK)

Organization of stroke care in the era of endovascular treatment

**Urs Fischer** (Bern, Switzerland)

Direct oral anticoagulants for embolic strokes of undetermined source?

**George Ntaios** (Larissa, Greece)

Proprotein convertase subtilisin/kexin type 9 inhibitors for stroke prevention?

**Eivind Berge** (Oslo, Norway)

**19:00 - 19:30 STATE-OF-THE-ART LECTURE**

*Chairperson:* **Eivind Berge** (Oslo, Norway)

Conflicts of interest: how to handle them?

**Bart Van Der Worp** (Utrecht, The Netherlands)

**19:30 - 19:45 Break**

**19:45 - 21:00 OPENING CEREMONY**

**Welcome**

**Inaugural Lecture**

Too much or too little medicine

**Dimitrios Sideris** (Athens, Greece)

**21:00 WELCOME RECEPTION**

*Hall Achilleas*

**08:00 - 09:30 ORAL PRESENTATIONS**

**OP10-OP18**

Hall OLYMPOS

**HEPATOLOGY - GASTROENTEROLOGY**

*Chairpersons: Evangelos Cholongitas (Thessaloniki, Greece)*

*Stylianos Karatapanis (Rhodes, Greece)*

**OP10 NUCLEOS(T)IDE ANALOGUE PROPHYLAXIS AFTER HEPATITIS B IMMUNOGLOBIN WITHDRAWAL IS SAFE AND EFFECTIVE AGAINST HEPATITIS B AND D RECURRENCE AFTER LIVER TRANSPLANTATION**

<sup>1</sup> Evangelos Cholongitas, <sup>1</sup> Parthenis Chalevas,  
<sup>1</sup> Theodora Oikonomou, <sup>1</sup> Zoi Valari, <sup>1</sup> Stergios Soulaïdopoulos, <sup>1</sup> Ioannis Goulis, <sup>2</sup> Ioannis Fouzas, <sup>2</sup> Vasilios Papanikolaou,  
<sup>1</sup> Evangelos Akriavidis, <sup>3</sup> Themistoklis Vasiliadis  
<sup>1</sup> *4<sup>th</sup> Department of Internal Medicine, Medical School of Aristotle University, Hippokration General Hospital of Thessaloniki, Greece;*  
<sup>2</sup> *Department of Transplant Surgery, Medical School of Aristotle University, Greece;*  
<sup>3</sup> *3<sup>rd</sup> Department of Internal Medicine, Medical School of Aristotle University Papageorgiou General Hospital of Thessaloniki, Greece;*

**OP11 URINE ALBUMIN-TO-CREATININE RATIO IS ASSOCIATED WITH THE SEVERITY OF LIVER DISEASE, RENAL FUNCTION AND SURVIVAL IN PATIENTS WITH DECOMPENSATED CIRRHOSIS**

<sup>1</sup> Evangelos Cholongitas, <sup>1</sup> Ioannis Goulis,  
<sup>1</sup> Stergios Soulaïdopoulos, <sup>1</sup> Parthenis Chalevas,  
<sup>1</sup> Evangelia Vetsiou, <sup>1</sup> Ioannis Doulgeris, <sup>1</sup> Aikaterini Kolotsiou,  
<sup>1</sup> Konstantina Vaitisi, <sup>1</sup> Mariana Diavasti, <sup>1</sup> Evangelos Akriavidis  
<sup>1</sup> *4<sup>th</sup> Department of Internal Medicine, Hippokration General Hospital, Medical School Aristotle University of Thessaloniki, Greece;*

**OP12 ALLOPURINOL ABROGATES THIOPURINE INDUCED LIVER INJURY**

<sup>1,2</sup> Polychronis Pavlidis, <sup>3</sup> Azhar Ansari

<sup>1</sup> Department of Gastroenterology, King's College Hospital, London, UK;

<sup>2</sup> Department of Experimental Immunobiology and Immunoregulation, Division of Transplantation Immunology and Mucosal Biology, King's College London, UK;

<sup>3</sup> Department of Gastroenterology, East Surrey Hospital, Redhill, UK;

**OP13 GEOEPIDEMIOLOGY OF PRIMARY BILIARY CIRRHOSIS IN CENTRAL GREECE**

<sup>1</sup> K. Azariadis, <sup>1</sup> N.K. Gatselis, <sup>1</sup> K. Zachou, <sup>1</sup> V. Lygoura,

<sup>1</sup> P. Arvaniti, <sup>1</sup> E.I. Rigopoulou, <sup>1</sup> G. Papadamou, <sup>2</sup> G.K. Koukoulis, <sup>1</sup> G.N. Dalekos

<sup>1</sup> Department of Medicine and Research Laboratory of Internal Medicine, Medical School, University of Thessaly, Larissa, Greece;

<sup>2</sup> Department of Pathology, Medical School, University of Thessaly, Larissa, Greece;

**OP14 HEPATIC STEATOSIS AND/OR STEATOHEPATITIS IN PRIMARY BILIARY CIRRHOSIS: AN INNOCENT BYSTANDER OR A GUILTY PLAYER?**

<sup>1</sup> V. Lygoura, <sup>1</sup> N.K. Gatselis, <sup>1</sup> K. Zachou, <sup>1</sup> K. Azariadis,

<sup>1</sup> P. Arvaniti, <sup>2</sup> G.K. Koukoulis, <sup>1</sup> G.N. Dalekos

<sup>1</sup> Department of Medicine and Research Laboratory of Internal Medicine, Medical School, University of Thessaly, Larissa, Greece;

<sup>2</sup> Department of Pathology, Medical School, University of Thessaly, Larissa, Greece;

**OP15 AUTOIMMUNE HEPATITIS (AIH): IMPACT OF AGE AT DISEASE ONSET ON DISEASE SEVERITY, OUTCOME AND RESPONSE TO TREATMENT**

<sup>1</sup> K. Azariadis, <sup>1</sup> P. Arvaniti, <sup>1</sup> K. Zachou, <sup>1</sup> G.N. Dalekos,

<sup>1</sup> N.K. Gatselis

<sup>1</sup> Department of Medicine and Research Laboratory of Internal Medicine, Medical School, University of Thessaly, Larissa, Greece;

**OP16 PROMPT INITIATION OF INTRAVENOUS CORTICOSTEROIDS PREVENTS DETERIORATION OF ACUTE/SEVERE AUTOIMMUNE HEPATITIS (AS-AIH) AND THE NEED OF LIVER TRANSPLANTATION (LT)**

<sup>1</sup> Pinelopi Arvaniti, <sup>1</sup> Kalliopi Azariadi, <sup>1</sup> Nikolaos Gatselis,  
<sup>1</sup> George N. Dalekos, <sup>1</sup> Kalliopi Zachou  
<sup>1</sup> Department of Medicine and Research Laboratory of Internal  
 Medicine, Medical School, University of Thessaly, Larissa, Greece;

**OP17 EARLY CHANGE IN FAECAL CALPROTECTIN PREDICTS PRIMARY NON- RESPONSE TO ANTI-TNFA THERAPY IN CROHN'S DISEASE**

<sup>1</sup> Polychronis Pavlidis, <sup>1</sup> Shraddha Gulati, <sup>1</sup> Patrick Dubois,  
<sup>1</sup> Guy Chung- Faye, <sup>2</sup> Roy Sherwood, <sup>1</sup> Ingvar Bjarnason,  
<sup>1</sup> Bu'Hussain Hayee  
<sup>1</sup> Department of Gastroenterology, King's College Hospital, London, UK;  
<sup>2</sup> Department of Biochemistry, Viapath Laboratory, King's College  
 Hospital, London, UK;

**OP18 NEUTROPHIL EXTRACELLULAR TRAPS ARE SPATIALLY DISTRIBUTED IN COLON CANCER TISSUE AND MAY BE IMPLICATED IN TUMOUR GROWTH BY INDUCING CANCER CELL APOPTOSIS**

<sup>1</sup> Athanasios Arampatzioglou, <sup>2</sup> Stella Arelaki,  
<sup>1</sup> Konstantinos Kambas, <sup>3</sup> Paraskevi Miltiades, <sup>1</sup> Iliana Angelidou,  
<sup>1</sup> Alexandros Mitsios, <sup>1,4</sup> Panagiotis Skendros,  
<sup>5</sup> Ioanna Maroulakou, <sup>2</sup> Alexandra Giatromanolaki,  
<sup>1,4</sup> Konstantinos Ritis  
<sup>1</sup> Laboratory of Molecular Hematology, Democritus University of  
 Thrace, Alexandroupolis, Greece;  
<sup>2</sup> Pathology Department, Democritus University of Thrace,  
 Alexandroupolis, Greece;  
<sup>3</sup> Hematology Department, Democritus University of Thrace,  
 Alexandroupolis, Greece;  
<sup>4</sup> First Department of Internal Medicine, Democritus University of  
 Thrace, Alexandroupolis, Greece;  
<sup>5</sup> Department of Molecular Biology and Genetics, Democritus  
 University of Thrace, Alexandroupolis, Greece;



**08:00 - 09:30 ORAL PRESENTATIONS****OP19-OP27**

Hall ACHILLEAS

**HEPATOLOGY - GASTROENTEROLOGY - METABOLIC SYNDROME**

*Chairpersons:* **Konstantinos Mimidis** (Alexandroupolis, Greece)  
**Dimitrios Samonakis** (Heraklion, Greece)

**OP19 HIGH IL6 LEVELS ARE POSITIVELY CORRELATED WITH HIGH FREE CORTISOL LEVELS IN PATIENTS WITH ACUTE VARICEAL BLEEDING**

<sup>1</sup> Maria Kalafateli, <sup>2</sup> Dimitrios Samonakis, <sup>3</sup> Panagiota Spadidea,  
<sup>4</sup> Marina Michalaki, <sup>4</sup> Venetsanea Kyriazopoulou,  
<sup>1</sup> Konstantinos Thomopoulos, <sup>3</sup> Athanasia Mouzaki,  
<sup>1</sup> Christos Triantos  
<sup>1</sup> Department of Gastroenterology, University Hospital of Patras,  
 Patras, Greece;  
<sup>2</sup> Department of Gastroenterology, University Hospital of  
 Heraklion, Heraklion, Greece;  
<sup>3</sup> Division of Hematology, Department of Internal Medicine,  
 Medical School, University of Patras, Patras, Greece;  
<sup>4</sup> Department of Endocrinology, University Hospital of Patras,  
 Patras, Greece;

**OP20 SPONTANEOUS BACTERIAL PERITONITIS IN PATIENTS WITH DECOMPENSATED CIRRHOSIS. MICROBIAL CAUSES AND CHARACTERISTICS**

<sup>1</sup> Evangelos Cholongitas, <sup>2</sup> A.M. Markantonatou,  
<sup>1</sup> Petros Doumtsis, <sup>1</sup> Stergios Soulaïdopoulos, <sup>2</sup> O. Gkeka,  
<sup>1</sup> Areti Karasmani, <sup>1</sup> Ioannis Goulis, <sup>2</sup> A. Diamantopoulou,  
<sup>2</sup> E. Vagdatli, <sup>1</sup> Evangelos Akriavidis  
<sup>1</sup> 4<sup>th</sup> Department of Internal Medicine, Medical School of Aristotle  
 University, Hippokraton General Hospital of Thessaloniki, Greece;  
<sup>2</sup> Microbiology Laboratory, Hippokraton General Hospital of  
 Thessaloniki, Greece;

**OP21 A NATURAL HISTORY STUDY OF DECOMPENSATED ALCOHOLIC CIRRHOSIS: RECENT IMPROVEMENT IN SURVIVAL**

<sup>1</sup> Dimitrios N. Samonakis, <sup>1</sup> Aekaterini Augoustaki,  
<sup>2</sup> Antonios Bertias, <sup>1</sup> Eirini Theodoraki, <sup>1</sup> Elina Orfanoudaki,  
<sup>3</sup> Maria Tzardi, <sup>1</sup> Meri Koulentaki, <sup>1</sup> Erminia Matrella,  
<sup>1</sup> Elias A. Kouroumalis  
<sup>1</sup> *Department of Gastroenterology & Hepatology, University Hospital of Heraklion Crete, Greece;*  
<sup>2</sup> *Department of Social Medicine, University of Crete, Greece;*  
<sup>3</sup> *Department of Histopathology, University Hospital of Heraklion, Crete Greece;*

**OP22 TIPS FOR THE MANAGEMENT OF COMPLICATIONS OF LIVER CIRRHOSIS: A RETROSPECTIVE AUDIT**

<sup>1</sup> Dimitrios N. Samonakis, <sup>2</sup> Dimitrios Tsetis, <sup>2</sup> Nikolaos Galanakis,  
<sup>2</sup> Elias Kehagias, <sup>1</sup> Meri Koulentaki, <sup>1</sup> Erminia Matrella,  
<sup>1</sup> Ioannis A. Mouzas, <sup>1</sup> Elias A. Kouroumalis, <sup>2</sup> Adam Hatzidakis  
<sup>1</sup> *Department of Gastroenterology & Hepatology, University Hospital of Heraklion, Crete, Greece;*  
<sup>2</sup> *Interventional Radiology Unit, Department of Medical Imaging, University Hospital of Heraklion, Crete, Greece;*

**OP23 BILLROTH II VERSUS BILLROTH II AND BRAUN**

<sup>1</sup> Konstantinos Perivoliotis, <sup>1</sup> Alexandros Diamantis,  
<sup>1</sup> Grigorios Christodoulidis, <sup>1</sup> Georgios Tzovaras,  
<sup>1</sup> Dimitrios Zacharoulis, <sup>1</sup> Konstantinos Tepetes  
<sup>1</sup> *Department of General Surgery, University Hospital of Larissa, Larissa, Greece;*

**OP24 EXTRAINTESTINAL MANIFESTATIONS AT THE TIME OF DIAGNOSIS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE**

<sup>1</sup> Vasilios Papastergiou, <sup>2</sup> Ioannis Familias, <sup>1</sup> Georgios Ntetskas,  
<sup>1</sup> Maria Stampori, <sup>1</sup> Despoina Diakonikola,  
<sup>1</sup> Konstantinos Roufas, <sup>1</sup> Nikitas Katsilis, <sup>1</sup> Foteini Lamprianou, <sup>1</sup>  
 Athanasios Hastas, <sup>1</sup> Stylianos Karatapanis  
<sup>1</sup> *First Department of Internal Medicine, General Hospital of Rhodes, Greece;*  
<sup>2</sup> *Gastroenterology Dept, General Hospital of Rhodes, Greece*

Hall ACHILLEAS

**OP25 INTESTINAL METAPLASIA IN PATIENTS WITH MULTIFOCAL ATROPHIC GASTRITIS**

- <sup>1</sup> Nikolaos Chrysanthos, <sup>1</sup> Evagelia Anagnostopoulou,  
<sup>2</sup> Achileas Melios, <sup>1</sup> Stamatia Patsavela, <sup>3</sup> Pinelopi Korkolopoulou  
<sup>1</sup> *Gastrointestinal Department St George General Hospital of Chania;*  
<sup>2</sup> *Anatomopathological Department St George General Hospital of Chania;*  
<sup>3</sup> *Anatomopathological Department Athens Medical School;*

**OP26 METABOLIC PROFILE OF PATIENTS WITH SEVERE MENTAL DISORDERS IN AN INTERNAL MEDICINE CLINIC**

- <sup>1</sup> Vasileiadis Panagiotis, <sup>1</sup> Mavridis Giorgos, <sup>1</sup> Chliara Maria,  
<sup>1</sup> Keramidas Angelos, <sup>1</sup> Papageorgiou Chrysoula, <sup>1</sup> Petrou Danae,  
<sup>1</sup> Charalampous Charalampos  
<sup>1</sup> *Internal medicine department, General Hospital "G.Papanikolaou" - Psychiatric Hospital Thessaloniki, Organic Unit of Psychiatric Hospital;*

**OP27 THE MEASUREMENT OF SERUM LEVEL OF IL-18 IN TYPE II DIABETIC PATIENTS SUFFERED FROM NEPHROPATHY IN ZAHEDAN CITY**

- Hossein Ali Khazaei, Zahra Heydari, Javid Dehghan, Amin Khazaei, Amin Rostami, Ehsan Khazaei, Hadi Pordel Ghasemi, Nasereh Arabzadeh  
<sup>1</sup> *Zahedan University of Medical Sciences, Zahedan, Iran;*

Hall OLYMPOS

**09:30 - 10:30 SYMPOSIUM  
Prostate disease in 2016***Chairperson: Stavros Gravas (Larissa, Greece)*

Is there a link between benign prostate hyperplasia, prostate cancer and inflammation?

**Dionysios Mitropoulos** (Athens, Greece)

Benign prostatic hyperplasia and metabolic syndrome

**Mauro Gacci** (Florence, Italy)

10:30 - 11:00 Coffee Break

11:00 - 13:00 **ROUND TABLE**

**Advances in therapeutic strategies for HBV and HCV**  
*Hellenic Association for the Study of the Liver*

*Chairpersons:* **Rafael Esteban** (Barcelona, Spain)  
**George N. Dalekos** (Larissa, Greece)

Is HBsAg loss an achievable target for therapy?  
**Spilios Manolakopoulos** (Athens, Greece)

Difficult to treat patients with HBV infection  
**George Papatheodoridis** (Athens, Greece)

Current challenges in non-HCV-1 genotype therapy  
**Markus Cornberg** (Hannover, Germany)

Cost effectiveness, barriers and access to HCV treatment in Europe  
**Maria Buti** (Barcelona, Spain)

Future treatment options in failures to any antiviral therapy  
**Rafael Esteban** (Barcelona, Spain)

13:00 - 14:00 **SATELLITE SYMPOSIUM**

**Chronic hepatitis C: managing "special" populations**

*Sponsored by Abbvie Pharmaceuticals SA*

**14:00 - 15:30 E-POSTER PRESENTATIONS****(Screen A) e-PP01 - e-PP13**

Hall ALKISTIS - THETIDA

**CARDIOVASCULAR MEDICINE - METABOLIC SYNDROME***Chairpersons: Dimitrios Papazoglou (Alexandroupolis, Greece)  
Vasileios Tsimihodimos (Ioannina, Greece)***e-PP01 INCREASED SERUM LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR-A AND HYPOVITAMINAEMIA D ARE ASSOCIATED WITH PRECLINICAL ATHEROSCLEROSIS IN INFLAMMATORY CAUSES OF CHRONIC KIDNEY DISEASE**

<sup>1</sup> Anna Mavromanoli, <sup>1</sup> Grigorios Dimas, <sup>2</sup> Sofia Spiroglou, <sup>2</sup> Ioannis Karamouzis, <sup>1</sup> Antigoni Spirou, <sup>1</sup> Nikoleta Pirou, <sup>1</sup> Nikolaos Tsiaras, <sup>1</sup> Christos Savvopoulos, <sup>1</sup> Apostolos Hatzitolios, <sup>1</sup> Dimitrios Grekas  
<sup>1</sup> *1<sup>st</sup> Propaedeutic Medical Department, AHEPA University Hospital, Aristotle University of Thessaloniki, Greece;*  
<sup>2</sup> *Biochemistry Laboratory, AHEPA University Hospital, Aristotle University of Thessaloniki, Greece;*

**e-PP02 BASELINE CEREBRAL OXIMETRY VALUES IN CARDIO-VASCULAR SURGERY PATIENTS: A SINGLE CENTER PROSPECTIVE OBSERVATIONAL STUDY**

<sup>1,2</sup> Nikolaos G. Baikoussis, <sup>3</sup> Chrysoula Verra, <sup>3</sup> Georgios Kakouris, <sup>4</sup> Miltiadis Matsagas, <sup>1</sup> Stavros Siminelakis, <sup>5</sup> Georgios Papadopoulos  
<sup>1</sup> *Cardiac Surgery Department, University Hospital of Ioannina, Ioannina, Greece;*  
<sup>2</sup> *Cardiovascular and Thoracic Surgery Department, Evangelismos General Hospital of Athens, Greece;*  
<sup>3</sup> *Medical Biopathology - Microbiology, Patras General Hospital, Patras, Greece;*  
<sup>4</sup> *Vascular Surgery Department, University of Ioannina, Ioannina, Greece;*  
<sup>5</sup> *Clinical Anaesthesiology and Intensive Postoperative Care Unit, University Hospital of Ioannina, Ioannina, Greece;*



**e-PP03 MONITORING OF THE CARDIAC SURGERY PATIENTS WITH SVO2 AND CEREBRAL OXIMETRY; THEIR SIGNIFICANCE AS EARLY PROGNOSTIC FACTORS**

<sup>1,2</sup> Nikolaos G. Baikoussis, <sup>3</sup> Chrysoula Verra, <sup>3</sup> Georgios Kakouris,  
<sup>1</sup> Stavros N. Siminelakis, <sup>4</sup> Georgios S. Papadopoulos  
<sup>1</sup> Cardiac Surgery Department, University Hospital of Ioannina, Ioannina, Greece;  
<sup>2</sup> Cardiovascular and Thoracic Surgery Department, Evangelismos General Hospital of Athens, Greece;  
<sup>3</sup> Medical Biopathology - Microbiology, Patras General Hospital, Patras, Greece;  
<sup>4</sup> Clinical Anaesthesiology and Intensive Postoperative Care Unit, University Hospital of Ioannina, Ioannina, Greece;

**e-PP04 THE CONTRIBUTION OF A SPECIAL LIPID UNIT OF A GENERAL HOSPITAL TO THE SECONDARY PREVENTION OF ISCHEMIC STROKE IN DIABETICS**

<sup>1</sup> Stamatis Papadatos, <sup>2</sup> Christina Dalampira,  
<sup>3</sup> Adamantios Bourdakis  
<sup>1</sup> Internal medicine resident, <sup>2<sup>nd</sup></sup> Internal medicine clinic Trikala General Hospital, Trikala, Greece;  
<sup>2</sup> Health visitor, Trikala, Greece;  
<sup>3</sup> Internal medicine director, <sup>2<sup>nd</sup></sup> Internal medicine clinic Trikala General Hospital, Trikala, Greece;

**e-PP05 SHORT AND LONG-TERM COURSE OF PATIENTS WITH ISCHEMIC STROKE, WITHOUT THROMBOLYTIC THERAPY**

<sup>1</sup> Apostolos Dougalis, <sup>1</sup> Chalevas Parthenis,  
<sup>1</sup> Cholongitas Evangelos, <sup>1</sup> Soulaidopoulos Stergios,  
<sup>1</sup> Lygdi Loukia, <sup>1</sup> Vettas Christos, <sup>1</sup> Kolotsiou Katerina,  
<sup>1</sup> Doulgeris Ioannis, <sup>1</sup> Mandala Evdokia, <sup>1</sup> Garyfallos Alexandros  
<sup>1</sup> <sup>4<sup>th</sup></sup> Department of Internal Medicine, Medical School of Aristotle University, Hippokraton General Hospital of Thessaloniki;

**e-PP06 ASTRAL PROGNOSTIC SCORE HAS A HIGH PROGNOSTIC ACCURACY IN DIFFERENT ISCHAEMIC STROKE MECHANISMS**

- <sup>1,2</sup> Vasileios Papavasileiou, <sup>3</sup> George Ntaios, <sup>4</sup> Christian Weimar (and on behalf of the VISTA collaborators), <sup>5</sup> Kennedy R Lees (and on behalf of the VISTA collaborators), <sup>6</sup> Nikolaos Kakaletsis, <sup>7</sup> Konstantinos Vemmos, <sup>7</sup> Efstathios Manios, <sup>8</sup> Daniel Strbian, <sup>8</sup> Turgut Tatlisumak, <sup>9</sup> Ji Hoe Heo, <sup>9,10</sup> Tae-Jin Song, <sup>11</sup> David J Seiffge, <sup>12</sup> Julia Ferrari, <sup>13</sup> Solène Moulin, <sup>14</sup> Bernard Yan, <sup>15</sup> Bruno J. Weder, <sup>6,16</sup> Carlo W. Cereda, <sup>17</sup> Etsuro Mori, <sup>18</sup> Mohammad Kurniawan, <sup>6</sup> Patrik Michel
- <sup>1</sup> Leeds Teaching Hospitals NHS Trust, Leeds General Infirmary, Leeds, United Kingdom;
- <sup>2</sup> School of Medicine, Leeds Institute of Biomedical and Clinical Sciences, Faculty of Medicines and Health, University of Leeds, United Kingdom;
- <sup>3</sup> Department of Medicine, Larissa University Hospital, School of Medicine, University of Thessaly, Larissa, Greece;
- <sup>4</sup> Stroke Unit and Department of Neurology, University Hospital of Essen, Essen, Germany;
- <sup>5</sup> Institute of Cardiovascular & Medical Sciences, University of Glasgow, BHF Cardiovascular Research Centre, Glasgow, UK;
- <sup>6</sup> Neurology Service, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland;
- <sup>7</sup> Department of Clinical Therapeutics, Medical School of Athens, Alexandra Hospital, Athens, Greece;
- <sup>8</sup> Department of Neurology, Helsinki University Central Hospital, Helsinki, Finland;
- <sup>9</sup> Department of Neurology, Severance Hospital, Yonsei University, College of Medicine, Seoul, Korea;
- <sup>10</sup> Ewha Womans University, School of Medicine, Seoul, Korea;
- <sup>11</sup> Stroke Center and Neurology, University Hospital Basel, University of Basel, Basel/Switzerland;
- <sup>12</sup> Department of Neurology, St. John's of God Hospital, Vienna, Austria;
- <sup>13</sup> Stroke Unit, Department of Neurology, University of Lille, Roger Salengro Hospital, Lille, France;
- <sup>14</sup> Melbourne Brain Centre, Department of Neurology, University of Melbourne, Royal Melbourne Hospital, Australia;
- <sup>15</sup> Stroke Center, Department of Neurology, Kantonsspital St.Gallen, St.Gallen, Switzerland;

<sup>16</sup> Stroke Center, Neurology department, Neurocenter of Southern Switzerland, Lugano, Switzerland;

<sup>17</sup> Department of Behavioral Neurology and Cognitive Neuroscience, Tohoku University Graduate School of Medicine, Sendai, Japan;

<sup>18</sup> Stroke Unit, Department of Neurology, Cipto Mangunkusumo National Hospital, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia;

**e-PP07 NON-THROMBOTIC PULMONARY EMBOLISM AFTER INTRA-ARTICULAR HYALURONIC ACID INJECTION**

<sup>1</sup> Eleni Paschou, <sup>2</sup> Nikos Sabanis, <sup>3</sup> Eleni Gavriilaki,

<sup>2</sup> Christos Dontsos, <sup>4</sup> Petros Faliagkas, <sup>4</sup> Evaggelia Liougka,

<sup>4</sup> Charikleia Tsolakidou, <sup>5</sup> Nikolaos Papanikolaou, <sup>4</sup> Eleni Tsotsiou,

<sup>4</sup> Stylianos Dolgyras

<sup>1</sup> Department of General Practice & Family Medicine, General Hospital of Pella, Edessa, Greece;

<sup>2</sup> Department of Nephrology, General Hospital of Pella, Edessa, Greece;

<sup>3</sup> Hematology Department and Hematopoietic Cell Transplantation (HCT) Unit, G. Papanikolaou Hospital, Thessaloniki; Greece;

<sup>4</sup> Department of Internal Medicine, General Hospital of Pella, Edessa, Greece;

<sup>5</sup> Department of General Surgery, General Hospital of Pella, Edessa, Greece;

**e-PP08 GUT MICROBIOTA AND ITS IMPACT ON BLOOD PRESSURE**

<sup>1</sup> Christina Laspa, <sup>2</sup> Eugenia Laspa, <sup>3</sup> Evangelos Kalogiannis,

<sup>4</sup> Anna Papakonstantinou, <sup>5</sup> Maria Mironidou-Tzouveleki

<sup>1</sup> Medical Doctor, Postgraduate Student, Aristotle University of Thessaloniki, Thessaloniki, Greece;

<sup>2</sup> Medical Doctor, Aristotle University of Thessaloniki, Thessaloniki, Greece;

<sup>3</sup> Medical Doctor, Aristotle University of Thessaloniki, Thessaloniki, Greece;

<sup>4</sup> Medical Doctor, Postgraduate Student, Aristotle University of Thessaloniki, Thessaloniki, Greece;

<sup>5</sup> Anaesthesiologist, Professor of Pharmacology, A'Laboratory of Pharmacology, Medical School, Aristotle University of Thessaloniki, Greece;

**e-PP09 FROM GLUTATHIONE DETOXIFICATION SYSTEM IN THE LIVER OF ANIMALS TO TIMP-1, OX-LDL AND 15-F2T-ISOP OF HUMANS WITH DIABETES MELLITUS TYPE 2: THE OXIDATIVE STRESS MODEL**

<sup>1</sup> Christos Chatzakis, <sup>2</sup> Grigorios Dimas, <sup>3</sup> Ioannis Karamouzis, <sup>3</sup> Sofia Spiroglou, <sup>2</sup> Maria Larissi, <sup>2</sup> Konstantinos Pavlopoulos, <sup>2</sup> Christos Savopoulos, <sup>1</sup> Ladislav Turecky, <sup>2</sup> Apostolos Hatzitolios  
<sup>1</sup> Institute of Biochemistry, Comenius University In Bratislava;  
<sup>2</sup> 1st Propaedeutic Department of Internal Medicine, Medical School of Aristotle University Hospital of Thessaloniki;  
<sup>3</sup> Biochemistry Laboratory, AHEPA University Hospital, Aristotle University of Thessaloniki, Greece;

**e-PP10 ASSOCIATION OF FGF – 23 AND IL-6 IN ALBUMINURIC PATIENTS WITH TYPE 2 DIABETES MELLITUS**

<sup>1</sup> Grigorios Dimas, <sup>2</sup> Ioannis Karamouzis, <sup>2</sup> Sofia Spiroglou, <sup>1</sup> Georgios Spagos, <sup>1</sup> Christos-Panagiotis Stragalas, <sup>1</sup> Athanasios Samaras, <sup>1</sup> Antigoni Spirou, <sup>1</sup> Christos Savopoulos, <sup>1</sup> Apostolos Hatzitolios, <sup>1</sup> Dimitrios Grekas  
<sup>1</sup> 1<sup>st</sup> Propaedeutic Medical Department of Internal Medicine, AHEPA University Hospital, Medical School, Aristotle University of Thessaloniki Greece;  
<sup>2</sup> Biochemistry Laboratory, AHEPA University Hospital, Aristotle University of Thessaloniki Greece;

**e-PP11 ALTERED HDL LIPID PROFILING IN HEALTHY INDIVIDUALS WITH LOW AND HIGH SERUM HDL-CHOLESTEROL LEVELS**

<sup>1</sup> Christina Kostara, <sup>2</sup> Vasileios Tsimihodimos, <sup>3</sup> Kostas Tsiafoulis, <sup>2</sup> Moses Elisaf, <sup>1</sup> Eleni Bairaktari  
<sup>1</sup> Laboratory of Clinical Chemistry, University of Ioannina, Ioannina, Greece;  
<sup>2</sup> Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece;  
<sup>3</sup> NMR Center, Laboratory of Analytical Chemistry, Department of Chemistry, University of Ioannina, Ioannina, Greece;

**e-PP12 GENETIC PROFILE OF MOUSE EMBRYONIC LIVER AFTER MATERNAL CALORIC LIMITATION**

<sup>1</sup> Athanasios Niarchos, <sup>1</sup> Dionysios Chartoumpakis, <sup>1</sup> Ioannis Habeos  
<sup>1</sup> Department of Medicine, University of Patras, Greece;

**e-PP13 MAY NORADRENALINE MAXIMAL DOSAGE RATE BE EXPANDED IN LATE SHOCK?**

<sup>1</sup> Christos Stefanou, <sup>1</sup> Lakis Palazis, <sup>1</sup> Areti Loizou,  
<sup>1</sup> Chrystalla Timiliotou  
<sup>1</sup> *Limassol General Hospital, ICU;*

(Screen B)

**e-PP14 - e-PP26**

Hall ALKISTIS - THETIDA

**HEPATOLOGY - GASTROENTEROLOGY**

*Chairpersons:* **Melanie Deutsch** (Athens, Greece)

**Grigorios Giannoulis** (Athens, Greece)

**e-PP14 SPUR CELL ANEMIA IS ASSOCIATED WITH SEVERE LIVER DISEASE AND POOR OUTCOME IN STABLE PATIENTS WITH DECOMPENSATED CIRRHOSIS**

<sup>1</sup> Parthenis Chalevas, <sup>1</sup> Evangelos Cholongitas,  
<sup>1</sup> Stergios Soulaïdopoulos, <sup>1</sup> Maria Ioannidou,  
<sup>1</sup> Evangelia Vetsiou, <sup>1</sup> Alexandros Stamatopoulos,  
<sup>1</sup> Theodosia Stamatopoulos, <sup>1</sup> Christos Vetas, <sup>1</sup> Ioannis Goulis,  
<sup>1</sup> Evangelos Akriviadis  
<sup>1</sup> *4<sup>th</sup> Department of Internal Medicine, Medical School of Aristotle University, Hippokration General Hospital of Thessaloniki, Greece;*

**e-PP15 HEPATOPULMONARY SYNDROME IS ASSOCIATED WITH THE PRESENCE OF HEPATOCELLULAR CARCINOMA AND ADRENAL INSUFFICIENCY IN PATIENTS WITH DECOMPENSATED CIRRHOSIS**

<sup>1</sup> Evangelos Cholongitas, <sup>1</sup> Stergios Soulaïdopoulos,  
<sup>1</sup> Ioannis Goulis, <sup>1</sup> Parthenis Chalevas, <sup>1</sup> Evangelia Vetsiou,  
<sup>1</sup> Kleanthi Manika, <sup>1</sup> Petros Doumtsīs, <sup>1</sup> Christos Vetas,  
<sup>1</sup> Theodora Oikonomou, Evangelos Akriviadis  
<sup>1</sup> *4<sup>th</sup> Department of Internal Medicine, Medical School of Aristotle University, Hippokration General Hospital of Thessaloniki, Greece;*

**e-PP16 HEPATITIS B VIRUS INFECTION IN GREECE: A COST OF ILLNESS ANALYSIS**

<sup>1</sup> Athina Chounta, <sup>2</sup> Kostas Athanasakis, <sup>1</sup> Fani Pliarchopoulou,  
<sup>1</sup> Dimitrios Mpoumpas  
<sup>1</sup> *4<sup>th</sup> Department of Internal Medicine, "ATTIKON" Hospital, Medical School, National and Kapodistrian University of Athens;*  
<sup>2</sup> *National School of Public Health, Greece;*



**e-PP17 NEUROLOGICAL PARESIS AS AN INITIAL SYMPTOM OF PRIMARY BILIARY CIRRHOSIS**

<sup>1</sup> Athina Chounta, <sup>1</sup> Fani Pliarchopoulou, <sup>2</sup> George Papadimitropoulos, <sup>1</sup> Orestis Sidiropoulos, <sup>3</sup> Christiana Kaliouli-Antonopoulou, <sup>2</sup> Konstantinos Voumvourakis  
<sup>1</sup> 4<sup>th</sup> Department of Internal Medicine, "ATTIKON" Hospital, Medical School, National and Kapodistian University of Athens;  
<sup>2</sup> 2<sup>nd</sup> Department of Neurology, "ATTIKON" Hospital, Medical School, National and Kapodistian University of Athens;  
<sup>3</sup> Department of Immunology and Histocompatibility, "S. Panteleimon" General State Hospital, Nikaia, Piraeus;

**e-PP18 SIMULTANEOUS APPEARANCE OF HEPATOMA AND CHOLANGIOCARCINOMA IN A PATIENT WITH CHRONIC HEPATITIS B**

<sup>3</sup> Christos Kokalis, <sup>1</sup> Stelios Kokkoris, <sup>1</sup> Katerina Kontoriga,  
<sup>1</sup> Christos Champakis, <sup>4</sup> Alina - Roxani Gouloumi,  
<sup>2</sup> Dimitris Filippiadis, <sup>3</sup> Adamantia Psyrris, <sup>4</sup> Ioannis Panayiotides,  
<sup>5</sup> Vasiliki Katsiva, <sup>1</sup> Christos Drakoulis  
<sup>1</sup> Hepatology Outpatient Clinic, 2<sup>nd</sup> Department of Internal Medicine, Nikaia General Hospital 'Agios Panteleimon', Nikaia, Greece;  
<sup>2</sup> 2<sup>nd</sup> Radiology Department, University of Athens Medical School, "Attikon" University Hospital, Greece;  
<sup>3</sup> Section of Medical Oncology, 2<sup>nd</sup> Department of Internal Medicine, University of Athens Medical School, "Attikon" University Hospital, Greece;  
<sup>4</sup> 2<sup>nd</sup> Department of Pathology, University of Athens Medical School, "Attikon" University Hospital, Greece;  
<sup>5</sup> Radiology Department, Nikaia General Hospital 'Agios Panteleimon', Nikaia, Greece;

**e-PP19 CAROLI, DISEASE OR SYNDROME? A CASE REPORT-REVIEW OF LITERATURE**

<sup>1</sup> Christina Ellina, <sup>1</sup> Xanthi Koufomichali, Kontoriga Katerina,  
<sup>1</sup> Ioannidou Anastasia, <sup>1</sup> Eleftheriadou Athina,  
<sup>1</sup> Christina Karampampa, Karasavidou Larisa, <sup>2</sup> Nikolaou Vasilios,  
<sup>3</sup> Kourousis Dimitrios, <sup>1</sup> Drakoulis Christos  
<sup>1</sup> 2<sup>nd</sup> Department of Internal Medicine, General State Hospital of Nikaia-Piraeus "Agios Panteleimon";  
<sup>2</sup> Radiology Department, General State of Nikaia-Piraeus "Agios Panteleimon";  
<sup>3</sup> Radiology Department, Rea Maternity Hospital;

**e-PP20 SOLITARY NECROTIC NODULE (SNN) OF THE LIVER: A CASE REPORT**

<sup>1</sup> Nikolaos Papadopoulos, <sup>2</sup> Christos Liatsos, <sup>2</sup> Nikolaos Kyriakos, <sup>3</sup> Dimitra Rontogianni, <sup>4</sup> Eleni Antypa, <sup>5</sup> Stefanos Lachanis, <sup>1</sup> Lazaros Karnesis

<sup>1</sup> 1<sup>st</sup> department of Internal medicine, 401 General Army Hospital of Athens, Greece;

<sup>2</sup> Gastroenterology department, 401 General Army Hospital of Athens, Greece;

<sup>3</sup> Department of Pathology, Evangelismos Hospital, Athens, Greece;

<sup>4</sup> Department of Radiology, Evangelismos Hospital, Athens, Greece;

<sup>5</sup> Department of Radiology, 401 General Army Hospital of Athens, Greece;

**e-PP21 DUCTAL PLATE MALFORMATIONS: A REPORT OF TWO CASES**

<sup>1</sup> Christos Tsaitas, <sup>1</sup> Emmanouil Sinakos, <sup>1</sup> Vassilios Zioganas,

<sup>2</sup> Prodromos Hytiroglou, <sup>1</sup> Evangelos Akriviadis

<sup>1</sup> 4<sup>th</sup> Medical Department, Hippokratio Hospital, Aristotle University of Thessaloniki;

<sup>2</sup> Department of Pathology, Aristotle University of Thessaloniki;

**e-PP22 ACUTE NECROTIZING PANCREATITIS AFTER CHEMOEMBOLIZATION FOR HEPATOCELLULAR CARCINOMA**

<sup>1</sup> Stergios Soulaïdopoulos, <sup>1</sup> Parthenis Chalevas,

<sup>1</sup> Evangelos Cholongitas, <sup>1</sup> Maria Ioannidou, <sup>1</sup> Evangelia Vetsiou,

<sup>1</sup> Alexandros Stamatopoulos, <sup>1</sup> Theodosia Stamatopoulos,

<sup>1</sup> Petros Doumtsis, <sup>1</sup> Ioannis Goulis, <sup>1</sup> Evangelos Akriviadis

<sup>1</sup> 4<sup>th</sup> Department of Internal Medicine, Medical School of Aristotle University, Hippokratation General Hospital of Thessaloniki, Greece;

- e-PP23 SPONTANEOUS EPISODES OF BACTEREMIA IN A CIRRHOTIC PATIENT WITH HEPATITIS C- SUCCESSFUL MANAGEMENT WITH NEWER ANTIVIRAL DRUGS**  
<sup>1</sup> Georgios Ntetskas, <sup>1</sup> Vasilios Papastergiou, <sup>2</sup> Ioannis Familias, <sup>1</sup> Mihail Marias, <sup>1</sup> Nikitas Katsilis, <sup>1</sup> Maria Stampori, <sup>1</sup> Athanasios Hastas, <sup>1</sup> Chrysostomos Paellas, <sup>1</sup> Konstantinos Roufas, <sup>1</sup> Stylianos Karatapanis  
<sup>1</sup> *First Department of Internal Medicine, General Hospital of Rhodes, Greece;*  
<sup>2</sup> *Gastroenterology Department, General Hospital of Rhodes, Greece;*
- e-PP24 PARTIAL SPLENIC ARTERY EMBOLIZATION- AN ALTERNATIVE THERAPEUTIC APPROACH TO SEVERE THROMBOCYTOPENIA IN CIRRHOSIS-RELATED HYPERSPLENISM. A CASE REPORT**  
<sup>1</sup> Evangelos Stournaras, <sup>2</sup> Stefanos Finitis, <sup>1</sup> Georgios Neokosmidis, <sup>1</sup> Stylianos Stylianidis, <sup>1</sup> Achilleas Papagiannis, <sup>1</sup> Andreas Protopapas  
<sup>1</sup> *First Propedeutic Department of Internal Medicine, AHEPA Hospital, Medical School, Aristotle University of Thessaloniki;*  
<sup>2</sup> *Radiology Department, AHEPA Hospital, Medical School, Aristotle University of Thessaloniki;*
- e-PP25 RECCURENT ERYTHEMA NOSODUM AND ATYPICAL CELIAC DISEASE**  
<sup>1</sup> Maria Agrogianni, <sup>1</sup> Ekaterini Kontoriga, <sup>1</sup> Anastasia Ioannidou, <sup>1</sup> Christina Ellina, <sup>1</sup> Christina Karampampa, <sup>1</sup> Athina Eleftheriadou, <sup>1</sup> Evangelos Michelakis, <sup>1</sup> Christiana Kaliouli, <sup>1</sup> Larisa Karasavidou, <sup>1</sup> Christos Drakoulis  
<sup>1</sup> *Hepatology Outpatient Clinic, 2nd Department of Internal Medicine, Nikaia General Hospital 'Agios Panteleimon', Nikaia, Greece;*
- e-PP26 METACHRONOUS METASTATIC MELANOMA OF THE SMALL INTESTINE. A CASE REPORT**  
<sup>1</sup> Andreas Protopapas, <sup>1</sup> Stylianos Stylianidis, <sup>1</sup> Evangelos Stournaras, <sup>1</sup> Pavlina Koulara, <sup>1</sup> Georgios Neokosmidis, <sup>1</sup> Apostolos I. Hatzitolios  
<sup>1</sup> *First Propedeutic Department of Internal Medicine, AHEPA Hospital, Medical School, Aristotle University of Thessaloniki;*

(Screen C)

e-PP27 - e-PP39

Hall CHRISALIDA

**HEPATOLOGY - GASTROENTEROLOGY**

*Chairpersons:* **Christos Triantos** (Patras, Greece)

**Vasileios Sevastianos** (Athens, Greece)

**e-PP27 DESPITE THE USE OF NUCLEOS(T)IDE ANALOGUES FOR CHRONIC HEPATITIS B, HCC IS OFTEN DEVELOPED IN ELDERLY PATIENTS**

<sup>1</sup> Ioannis Ketikoglou, <sup>1</sup> Elina El Nteik, <sup>1</sup> Sotiria Papadaki,

<sup>1</sup> Antonis Kyritsis, <sup>1</sup> Emmanuel Koulias

<sup>1</sup> Department of Internal Medicine, Hippocratio General Hospital, Athens Greece;

**e-PP28 SIGNIFICANT INCREASE OF AUTOIMMUNE DISEASES OF THE LIVER DURING THE LAST SIX YEARS**

<sup>1</sup> Ioannis Ketikoglou, <sup>2</sup> Christina Zoumbouli, <sup>1</sup> Elina El Nteik,

<sup>1</sup> Sotiria Papadaki

<sup>1</sup> Department of Internal Medicine, Hippocratio General Hospital, Athens, Greece;

<sup>2</sup> Pathology Department, Hippocratio General Hospital, Athens, Greece;

**e-PP29 HEPATOCELLULAR CARCINOMA IN CRETE: EPIDEMIOLOGY, CLINICAL CHARACTERISTICS AND THE INFLUENCE OF VARIOUS TREATMENT MODALITIES ON SURVIVAL**

<sup>1</sup> Eirini Theodoraki, <sup>1</sup> Maria Kalafateli, <sup>2</sup> Dimitrios Tsetis,

<sup>3</sup> Evaggelia Chryssou, <sup>2</sup> Elias Kehagias, <sup>4</sup> Maria Tzardi,

<sup>3</sup> Maria Daskalogiannaki, <sup>1</sup> Nikolaos Papiamonis, <sup>1</sup> Ioannis Mouzas, <sup>1</sup> Elias Kouroumalis, <sup>2</sup> Adam Hatzidakis,

<sup>1</sup> Dimitrios N. Samonakis

<sup>1</sup> Department of Gastroenterology & Hepatology, University Hospital of Heraklion;

<sup>2</sup> Interventional Radiology Unit, University Hospital of Heraklion;

<sup>3</sup> Department of Medical Imaging – CT & MRI Unit, University Hospital of Heraklion;

<sup>4</sup> Department of Histopathology, University Hospital of Heraklion;

**e-PP30 HEPATOCELLULAR CARCINOMA IN ADULTS CORRELATION WITH HEPATITIS/AGE AND SEX**

<sup>1</sup> T. Karaoulani, <sup>2</sup> S. Solomou, <sup>2</sup> E. Stavropoulou, <sup>2</sup> E. Sideri, <sup>2</sup> E. Uranou, <sup>2</sup> M. Pavlou, <sup>2</sup> K. Karamanli, <sup>1</sup> A. Papanastasiou, <sup>2</sup> A. Kapatais  
<sup>1</sup> Biopathology Section of G.H.N.P.-Agios Panteleimon-G.H.W.A.-Agia Varvara, Athens;  
<sup>2</sup> Pathology department of G.H.N.P.-Agios Panteleimon-G.H.W.A.-Agia Varvara, Athens;

**e-PP31 THE SIGNIFICANCE OF A PROMPT EVALUATION OF PATIENTS WITH CIRRHOSIS WHO DEVELOP ENCEPHALOPATHY OR HEPATORENAL SYNDROME**

<sup>1</sup> T. Karaoulani, <sup>2</sup> S. Solomou, <sup>2</sup> E. Stavropoulou, <sup>2</sup> E. Sideri, <sup>2</sup> E. Uranou, <sup>2</sup> M. Pavlou, <sup>2</sup> K. Karamanli, <sup>1</sup> A. Papanastasiou, <sup>2</sup> A. Kapatais  
<sup>1</sup> Biopathology Section of G.H.N.P.-Agios Panteleimon-G.H.W.A.-Agia Varvara, Athens;  
<sup>2</sup> Pathology department of G.H.N.P.-Agios Panteleimon-G.H.W.A.-Agia Varvara, Athens;

**e-PP32 STATINS AS A PALLIATIVE THERAPY FOR HEPATOCELLULAR CARCINOMA**

<sup>1</sup> Eugenia Laspa, <sup>2</sup> Christina Laspa, <sup>1</sup> Evangelos Kalogiannis, <sup>1</sup> Anna Papakonstantinou, <sup>3</sup> Maria Mironidou-Tzouveleki  
<sup>1</sup> Medical Doctor, Aristotle University of Thessaloniki;  
<sup>2</sup> Medical Doctor, Postgraduate Student, Aristotle University of Thessaloniki;  
<sup>3</sup> Anaesthesiologist, Professor of Pharmacology, A'Laboratory of Pharmacology, Medical School, Aristotle University of Thessaloniki, Greece;

**e-PP33 PSYCHOLOGICAL CHANGES DURING CHEMOTHERAPY FOR STOMACH CANCER**

<sup>1,2</sup> Panagiotis Heras, <sup>1,2</sup> Anastasios Stefanopoulos, <sup>1,2</sup> Ilias Georgopoulos, <sup>2</sup> Andreas Hatzopoulos, <sup>1,2</sup> Maria Koutroubi  
<sup>1</sup> Hellenic Medical Society of Psychosomatic Problems, Athens, Greece;  
<sup>2</sup> Department of Internal Medicine General Hospital of Nafplio;

**e-PP34 IFN-ALPHA RELATED THYROID DISEASE IN HEPATITIS C PATIENT: A CASE REPORT**

<sup>1</sup> Ourania Triantafyllou, <sup>1</sup> Konstantinos Krapis, <sup>1</sup> Dimitra TSIONARA,  
<sup>1</sup> George Gkountouras, <sup>1</sup> Flora Koumoutsou,  
<sup>1</sup> Spiridon Karamagkiolis, <sup>1</sup> Konstantinos Karamitsos  
<sup>1</sup> *Outpatient Clinic, Department of Internal Medicine, General Hospital of Larissa, Greece;*

**e-PP35 A CASE OF FOCAL SEGMENTAL GLOMERULONEPHRITIS IN A PATIENT WITH HBV INFECTION**

<sup>1</sup> Christos Paliouras, <sup>1</sup> Giorgos Ntetskas, <sup>1</sup> Foteini Lamprianou,  
<sup>1</sup> Konstantinos Roufas, <sup>1</sup> Nikolaos Karvouniaris,  
<sup>1</sup> Emmanouil Anastasakis, <sup>2</sup> Stylianos Karatapanis  
<sup>1</sup> *Nephrology Department, General Hospital of Rhodes, Rhodes, Greece;*  
<sup>2</sup> *1<sup>st</sup> Department of Internal Medicine, General Hospital of Rhodes, Rhodes, Greece;*

**e-PP36 ACUTE PORTAL VEIN THROMBOSIS IN A PATIENT WITH CHRONIC HEPATITIS B TREATED WITH PEGYLATED INTERFERON- A CASE REPORT**

<sup>1</sup> Georgios Ntetskas, <sup>1</sup> Vasilios Papastergiou, <sup>1</sup> Mihail Marias,  
<sup>1</sup> Eustathia Anastasiou, <sup>1</sup> Maria Stampori, <sup>1</sup> Konstantinos Roufas,  
<sup>1</sup> Nikitas Katsilis, <sup>1</sup> Athanasios Hastas, <sup>1</sup> Despoina Diakonikola,  
<sup>1</sup> Stylianos Karatapanis  
<sup>1</sup> *First Department of Internal Medicine, General Hospital of Rhodes, Greece;*

**e-PP37 ACUTE NON-ICTERIC TYPE OF HEPATITIS ACCOMPANIED WITH EOSINOPHILIA AND SKIN RUSH ATTRIBUTED TO FEBUXOSTAT ADMINISTRATION IN A PATIENT WITH CHRONIC KIDNEY DISEASE**

<sup>1</sup> Eleni Paschou, <sup>2</sup> Eleni Gavriilaki, <sup>2</sup> George Papaioannou,  
<sup>2</sup> Aliko Tsompanakou, <sup>3</sup> Asterios Kalaitzoglou, <sup>4</sup> Efthimios Pappas,  
<sup>4</sup> Nikos Sabanis  
<sup>1</sup> *Department of General Practice & Family Medicine, General Hospital of Pella, Edessa, Greece;*  
<sup>2</sup> *Hematology Department and Hematopoietic Cell Transplantation (HCT) Unit, G. Papanikolaou Hospital, Thessaloniki, Greece;*  
<sup>3</sup> *Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece;*  
<sup>4</sup> *Department of Nephrology, General Hospital of Pella, Edessa, Greece;*



Hall CHRISALIDA

**e-PP38 A PSYCHIATRIC PATIENT WITH CHILAIIDITI'S SYNDROME**

<sup>1</sup> Vasileiadis Panagiotis, <sup>1</sup> Mavridis Giorgos, <sup>1</sup> Keramidas Angelos,  
<sup>1</sup> Charalampous Charalampos  
<sup>1</sup> Internal medicine department, General Hospital "G.  
 Papanikolaou" - Psychiatric Hospital Thessaloniki, Organic Unit of  
 Psychiatric Hospital;

**e-PP39 COMPLICATIONS OF UNTREATED ACHALASIA**

Antonios Alaveras, Lamprini Skorda, Krystalia Diamantidi,  
Panagiota Chalmouki, Maria Tsekeri, Triantafyllia Toska  
 Internal Medicine Department, Korgialeneio-Mpenakio Hospital,  
 Athens, Greece;

Hall NEFELI

PARALLEL SESSIONS

(Screen D)

**e-PP40 - e-PP52**

Hall NEFELI

**GERIATRIC MEDICINE - IMMUNOLOGY - RHEUMATOLOGY**

*Chairpersons:* **Panagiotis Skendros** (Alexandroupolis, Greece)  
**Irene Rapti** (Athens, Greece)

**e-PP40 ANALYSIS OF FALLS IN PATIENTS WITH SEVERE KNEE OSTEOARTHRITIS**

<sup>1</sup> Grigorios Gkaskaris, <sup>1</sup> Eirini Giannopoulou,  
<sup>1</sup> Konstantinos Chaniotakis, <sup>1</sup> Eleftherios Chatzimichael,  
<sup>1</sup> Konstantinos Giatroudakis, <sup>1</sup> Nikolaos Gkantsinikoudis,  
<sup>1</sup> Stylianos Kapetanakis  
<sup>1</sup> Department of Anatomy, Medical School, Democritus University  
 of Thrace, Alexandroupolis, Greece;

**e-PP41 TRANSFORAMINAL PERCUTANEOUS ENDOSCOPIC DISCECTOMY FOR LUMBAR DISC HERNIATION IN PARKINSON'S DISEASE: A CASE-CONTROL STUDY WITH A YEAR FOLLOW-UP**

<sup>1</sup> Eirini Giannopoulou, <sup>1</sup> Grigorios Gkaskaris,  
<sup>1</sup> Nikolas Gkantsinikoudis, <sup>1</sup> Konstantinos Giatroudakis,  
<sup>1</sup> Konstantinos Chaniotakis, <sup>1</sup> Eleftherios Chatzimichael,  
<sup>1</sup> Stylianos Kapetanakis  
<sup>1</sup> Spine Department and Deformities, Interbalkan European  
 Medical Center, Thessaloniki, Greece;

**e-PP42 POLYPHARMACY AND ASSOCIATED FACTORS IN CONSECUTIVELY ADMITTED ELDERLY PATIENTS AT THE TIME OF ADMISSION**

<sup>1</sup> Panagiota Voukelatou, <sup>1</sup> Ioannis Vrettos, <sup>1</sup> Athina Bitsikokou,  
<sup>1</sup> Elissavet Sfendouraki, <sup>1</sup> Athanasios Didaskalou,  
<sup>1</sup> Andreas Kalliakmanis  
<sup>1</sup> 2<sup>nd</sup> Department of Internal Medicine, General Oncological  
Hospital of Kifissia "Ag. Anargyroi", Athens, Greece;

**e-PP43 OSELTAMIVIR INDUCED DELIRIUM: NOTABLE COMPLICATION IN ELDERLY PATIENTS**

<sup>1</sup> Liang Yoong Chia, <sup>2</sup> Jia Wern Lee, <sup>1</sup> Francis Lo, <sup>1</sup> Teik Joo Quah  
<sup>1</sup> General Medicine Department, Tan Tock Seng Hospital;  
<sup>2</sup> Pharmacy Department, Kk Hospital, Singapore;

**e-PP44 NUTRITIONIST AND NEUROLOGICAL REHABILITATION**

<sup>1</sup> Skoufi Georgia, <sup>1</sup> Kotoula Paraskevi, <sup>1</sup> Lialios Georgios,  
<sup>1</sup> Galliopoulos Demos, <sup>1</sup> Stogianni Eleftheria, <sup>1</sup> Valais Sotirios,  
<sup>1</sup> Triantaris Apostolos, <sup>1</sup> Stogianni Aikaterini, <sup>1</sup> Papakosta Styliani  
<sup>1</sup> Arogi Rehabilitation Center, Larisa, Greece;

**e-PP45 TREATING EBV RELATED HLH: BEDSIDE LESSONS & LITERATURE REVIEW**

<sup>1</sup> Christos Stefanou, <sup>2</sup> Nikolaos Neokleous, <sup>1</sup> Fotini Georgiou,  
<sup>1</sup> Tzortzi Christiana, <sup>1</sup> Lakis Palazis, <sup>1</sup> Areti Loizou,  
<sup>3</sup> Ekaterini Choutri, <sup>1</sup> Chrystalla Timiliotou  
<sup>1</sup> Limassol General Hospital, ICU;  
<sup>2</sup> Limassol General Hospital, Hematology;  
<sup>3</sup> Nicosia General Hospital, Pathology;

**e-PP46 ANTI-IL-1B TREATMENT IN A CASE OF SEVERE PUSTULAR PSORIASIS**

<sup>1</sup> Panagiotis Skendros, <sup>1</sup> Charalampos Papagoras,

<sup>2</sup> Ioanna Lefaki, <sup>1</sup> Sadi Mechet, <sup>3</sup> Alexandra Giatromanolaki,

<sup>4</sup> Ioannis Kotsianidis, <sup>5</sup> Matthaios Speletas, <sup>6</sup> Ioannis Theodorou,

<sup>1</sup> Vasiliki Dalla, <sup>1</sup> Konstantinos Ritis

<sup>1</sup> *First Department of Internal Medicine, University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece;*

<sup>2</sup> *State Clinic of Dermatology, Hospital for Skin and Venereal Diseases, Thessaloniki, Greece;*

<sup>3</sup> *Department of Pathology, University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece;*

<sup>4</sup> *Department of Haematology, University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece;*

<sup>5</sup> *Department of Immunology & Histocompatibility, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece;*

<sup>6</sup> *UF d'Histocompatibilité et Immunogénétique, Département d'Immunologie, Groupe Hospitalier Pitié Salpêtrière – Charles Foix, Paris, France;*

**e-PP47 KIKUCHI-FUJIMOTO DISEASE (HISTIOCYTIC NECROTIZING LYMPHADENITIS): REPORT OF A CASE CLINICALLY MIMICKING SYSTEMIC LUPUS ERYTHEMATOSUS**

<sup>1</sup> Stauroula Papadopoulou, <sup>1</sup> Kyriakos Chatzopoulos,

<sup>1</sup> Aspasia Deliligka, <sup>1</sup> Georgios Hahalis, <sup>1</sup> Christina Nikolaidou,

<sup>1</sup> Ioannis Venizelos

<sup>1</sup> *Department of Pathology, Hippokrateion General Hospital, Thessaloniki, Greece;*

**e-PP48 DETECTION OF ANTINUCLEAR ANTIBODIES IN PATIENTS POSITIVE FOR ANTI-CCP ANTIBODIES**

<sup>1</sup> Nikolaos Zotos, <sup>2</sup> Maria Gianniki, <sup>1</sup> Eirini Tatsina,

<sup>2</sup> Dimitrios Bougias, <sup>1</sup> Apostolina Papadopoulou,

<sup>1</sup> Christos Georgiou, <sup>1</sup> Athanasia Fasouloglou,

<sup>1</sup> Evaggelia Chrisostomou, <sup>2</sup> Niki Tsifetaki, <sup>1</sup> Anastasia Pournou

<sup>1</sup> *Microbiology Department, General Hospital of Ioannina, Greece;*

<sup>2</sup> *Rheumatology Department, General Hospital of Ioannina, Greece;*

- e-PP49 DETECTION OF ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES (ANCA) IN PATIENTS POSITIVE FOR ANTI-CCP ANTIBODIES**  
<sup>1</sup> Nikolaos Zotos, <sup>2</sup> Maria Gianniki, <sup>1</sup> Eirini Tatsina,  
<sup>2</sup> Dimitrios Bougias, <sup>1</sup> Apostolina Papadopoulou,  
<sup>1</sup> Christos Georgiou, <sup>1</sup> Athanasia Fasouloglou,  
<sup>1</sup> Evaggelia Chrisostomou, <sup>2</sup> Niki Tsifetaki, <sup>1</sup> Anastasia Pournou  
<sup>1</sup> *Microbiology Department, General Hospital of Ioannina, Greece;*  
<sup>2</sup> *Rheumatology Department, General Hospital of Ioannina, Greece;*
- e-PP50 FULMINANT PRESENTATION OF DERMATOMYOSITIS WITH CATASTROPHIC COMPLICATIONS**  
<sup>1</sup> Nikos Sabanis, <sup>2</sup> Eleni Paschou, <sup>3</sup> Eleni Gavriilaki,  
<sup>4</sup> Eleni Tsotsiou, <sup>2</sup> Tzamal Al-Nofal, <sup>4</sup> Charikleia Tsolakidou,  
<sup>4</sup> Evaggelia Liougka, <sup>4</sup> Michalis Mpiternas, <sup>4</sup> Alexandra Gaitanaki,  
<sup>4</sup> Stylianos Dolgyras  
<sup>1</sup> *Department of Nephrology, General Hospital of Pella, Edessa, Greece;*  
<sup>2</sup> *Department of General Practice & Family Medicine, General Hospital of Pella, Edessa, Greece;*  
<sup>3</sup> *Hematology Department and Hematopoietic Cell Transplantation (HCT) Unit, G. Papanikolaou Hospital, Thessaloniki, Greece;*  
<sup>4</sup> *Department of Internal Medicine, General Hospital of Pella, Edessa, Greece;*
- e-PP51 CASE REPORT: GIANT CELL ARTERITIS AS A REVERSIBLE CAUSE OF COGNITIVE DECLINE**  
<sup>1</sup> Dwaipayan Sen, <sup>1</sup> Vasileios Papavasileiou, <sup>2</sup> Raymond Hyatt  
<sup>1</sup> *Comprehensive Stroke Centre, Neurosciences Department, Salford Royal NHS Foundation Trust, Manchester, United Kingdom;*  
<sup>2</sup> *Department of Geriatric Medicine, Royal Blackburn Hospital, Blackburn, United Kingdom;*
- e-PP52 SCLERODERMA (SYSTEMATIC SCLEROSIS): A CASE REPORT**  
<sup>1</sup> Georgios Gkountouras, <sup>1</sup> Melpomeni Barka, <sup>1</sup> Dimitra Tsonara,  
<sup>1</sup> Georgia Samakidou, <sup>1</sup> Ourania Triantafyllou, <sup>1</sup> Nikolaos Aggelis,  
<sup>1</sup> Theodora Konstantoula, <sup>1</sup> Konstantinos Krapis, <sup>1</sup> Vasileios Lalos,  
<sup>1</sup> Konstantinos Karamitsos  
<sup>1</sup> *Department of Internal Medicine, General Hospital of Larissa, Greece;*

**15:30-16:00** Leisure time

**16:00 - 17:30** **ROUND TABLE**  
**Resistant hypertension**

*Chairpersons:* **Dimitrios Vlahakos** (Athens, Greece)  
**Konstantinos Tsioufis** (Athens, Greece)

Diagnosis and evaluation  
**Konstantinos Makaritsis** (Larissa, Greece)

Medical management  
**Michel Burnier** (Lausanne, Switzerland)

New invasive treatment modalities  
**Konstantinos Tsioufis** (Athens, Greece)

Long term effects of invasive therapy - Hints for the future  
**Roland Schmieder** (Nuremberg, Germany)

**17:30 - 18:15** **SATELLITE SYMPOSIUM**  
**The role of echinocandins in clinical practice**

*Sponsored by Astellas*

**18:15 - 18:45** Coffee Break

**18:45 - 20:15** **ROUND TABLE**  
**Intestinal microbiota and metabolic disorders**

*Chairpersons:* **Apostolos Hatzitolios** (Thessaloniki, Greece)  
**Alexandros Tselepis** (Ioannina, Greece)

Microbiota patterns and risk of glucometabolic disease  
**Peter Nilsson** (Malmö, Sweden)

Intestinal microbiota lipid metabolism and atherosclerosis  
**Alexandros Tselepis** (Ioannina, Greece)

Insights into the role of the microbiota in the natural history of obesity  
**Dimitrios Papazoglou** (Alexandroupolis, Greece)

**20:15 - 21:00** **SATELLITE SYMPOSIUM**  
**Recent advances targeting cardiovascular risk reduction and treatment of symptomatic peripheral artery disease**

*Sponsored by Winmedica*

## 07:45 - 09:00 ORAL PRESENTATIONS

OP28-OP34

Hall OLYMPOS

## IMMUNOLOGY - ONCOLOGY - HAEMATOLOGY

*Chairpersons: Matthaios Speletas (Larissa, Greece)**Christos Tolis (Ioannina, Greece)***OP28 UPDATED DATA OF A NATION-WIDE STUDY OF CLINICAL PHENOTYPES AND TAC1 MUTATIONS IN PATIENTS WITH COMMON VARIABLE IMMUNODEFICIENCY (CVID)**<sup>1</sup> [Eirini Sevdali](#), <sup>1</sup> Androniki Kapoussouzi, <sup>2</sup> Evangelia Farmaki,<sup>2</sup> Anna Taparkou, <sup>3</sup> Ioannis Kakkas, <sup>4</sup> George Paterakis,<sup>1</sup> Anastasios E. Germeris, <sup>1</sup> Matthaios Speletas, <sup>1,2,3,4</sup> On behalf of the Study Group of Primary Immunodeficiencies of the Hellenic Society of Hematology<sup>1</sup> *Department of Immunology & Histocompatibility, University of Thessaly, Larissa, Greece;*<sup>2</sup> *First Department of Pediatrics, Hippokration General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece;*<sup>3</sup> *Department of Immunology & Histocompatibility, Evangelismos General Hospital, Athens, Greece;*<sup>4</sup> *Department of Immunology & Histocompatibility, Gennimatas General Hospital, Athens, Greece;***OP29 DEFECTIVE POLYMORPHONUCLEAR NEUTROPHIL COMPARTMENT IN COMMON VARIABLE IMMUNODEFICIENCY (CVID)**<sup>1</sup> [Gerasimina Tsinti](#), <sup>1</sup> Anastasios E. Germeris,<sup>1</sup> Matthaios Speletas<sup>1</sup> *Department of Immunology & Histocompatibility, University of Thessaly, Larissa, Greece;***OP30 SECONDARY HAEMOPHAGOCYTIC SYNDROME (SHS) REVISITED: A 6-YEARS REAL-LIFE WORLD STUDY ON PRESENTATION, AETIOLOGY AND TREATMENT**<sup>1</sup> Aggelos Stefos, <sup>1</sup> [Polyxeni Lalou](#), <sup>1</sup> Mary Boulbou,<sup>1</sup> Sara Georgiadou, <sup>1</sup> Nikolaos Gatselis, <sup>1</sup> Konstantinos Makaritsis,<sup>1</sup> George N. Dalekos, <sup>1</sup> Eirini I. Rigopoulou<sup>1</sup> *Department of Medicine and Research Laboratory of Internal Medicine, Medical School, University of Thessaly, Larissa, Greece;*



**OP31 TNF REGULATES TIGHT JUNCTION'S CLAUDIN-5 / OCCLUDIN COMPLEX MEDIATED ALVEOLAR EPITHELIAL BARRIER PERMEABILITY IN EXPERIMENTAL MURINE LUNG INJURY MODEL**

<sup>1</sup> Vassiliki Karavana, <sup>1</sup> Constantinos Glynos, <sup>2</sup> Christina Magkou, <sup>3</sup> Vreka Malamati, <sup>1</sup> Charikleia S. Vrettou, <sup>1</sup> Sotirios Malachias, <sup>1</sup> Eleni Ischaki, <sup>1</sup> Spyros Mentzelopoulos, <sup>3</sup> George Stathopoulos, <sup>1</sup> Spyros Zakynthinos  
<sup>1</sup> George P. Livanos and Marianthi Simou Laboratories, Evangelismos Hospital, 1st Department of Pulmonary and Critical Care Unit, University of Athens, Athens, Greece;  
<sup>2</sup> Pathology Department, "Evangelismos" Hospital, Athens, Greece;  
<sup>3</sup> Laboratory for Molecular Respiratory Carcinogenesis, Department of Physiology, Faculty of Medicine, University of Patras, Rio, Achaia, Greece;

**OP32 EGFR AND KRAS GENE PROFILE IN PATIENTS WITH COLORECTAL CANCER: CORRELATION WITH CLINICOPATHOLOGICAL PARAMETERS**

<sup>1</sup> Maria Samara, <sup>1</sup> Kassiani Kapatou, <sup>1</sup> Maria Ioannou, <sup>1</sup> Roidoula Papamichali, <sup>2</sup> Spyros Potamianos, <sup>2</sup> Andreas Kapsoritakis, <sup>3</sup> Christos Papandreou, <sup>4</sup> Athanasios Athanasiadis, <sup>1</sup> Maria Papathanasiou, <sup>1</sup> George Koukoulis  
<sup>1</sup> Department of Pathology, School of Medicine, University of Thessaly, Larissa, Greece;  
<sup>2</sup> Department of Gastroenterology, School of Medicine, University of Thessaly, Larissa, Greece;  
<sup>3</sup> Department of Medical Oncology, School of Medicine, University of Thessaly, Larissa, Greece;  
<sup>4</sup> Oncology Department, General Hospital of Larissa, Larissa, Greece;

**OP33 LYMPH NODE RATIO AS A PROGNOSTIC FACTOR IN GASTRIC CANCER FOLLOWING D1 GASTRECTOMY. COMPARISON WITH THE NEW TNM STAGING SYSTEM**

<sup>1</sup> Konstantinos Bouliaris, <sup>1</sup> Alexandros Diamantis,  
<sup>1</sup> Grigorios Christodoulidis, <sup>1</sup> Euaggelos Margonis,  
<sup>1</sup> Perivoliotis Konstantinos, <sup>1</sup> Erietta Polychronopoulou,  
<sup>1</sup> Konstantinos Tepetes  
<sup>1</sup> *Department of Surgery-University Hospital of Larissa;*

**OP34 MTHFR C677T POLYMORPHISM AND THROMBOTIC COMPLICATIONS IN GREEK SICKLE CELL DISEASE PATIENTS**

<sup>1</sup> Iakovos Armenis, <sup>1</sup> Vasiliki Kalotychou, <sup>1</sup> Zoe Kontogeorgiou,  
<sup>1,2</sup> Reveka Tzanetea, <sup>3</sup> Konstantinos Pantos,  
<sup>4</sup> Konstantinos Konstantopoulos, <sup>2</sup> Ioannis Rombos  
<sup>1</sup> *1<sup>st</sup> Department of Internal Medicine, Laiko General Hospital, University of Athens Medical School, Athens, Greece;*  
<sup>2</sup> *Metropolitan Hospital, Athens, Greece;*  
<sup>3</sup> *Experimental Pharmacology Laboratory, University of Athens Medical School, Athens, Greece;*  
<sup>4</sup> *Department of Hematology, Laiko General Hospital, University of Athens Medical School, Athens, Greece;*

**07:45 - 09:00 ORAL PRESENTATIONS**

**OP35-OP41**

**GERIATRIC MEDICINE - INFECTIOUS DISEASES**

*Chairpersons: Efthimia Petinaki (Larissa, Greece)*

*Christos Savopoulos (Thessaloniki, Greece)*

**OP35 ADVERSE DRUG REACTIONS AS A CAUSE FOR HOSPITAL ADMISSION IN THE ELDERLY**

<sup>1</sup> Panagiota Voukelatou, <sup>1</sup> Ioannis Vrettos, <sup>1</sup> Athina Bitsikokou,  
<sup>1</sup> Elissavet Sfindouraki, <sup>1</sup> Athanasios Didaskalou,  
<sup>1</sup> Andreas Kalliakmanis  
<sup>1</sup> *2<sup>nd</sup> Department of Internal Medicine, General Oncological Hospital of Kifissia "Ag. Anargyroi", Athens;*

**OP36 HIV INFECTION AND HYPERTENSION IN ATHEROSCLEROSIS**

<sup>1</sup> Galaktion Konstantinidis, <sup>1</sup> Grigorios Dimas, <sup>2</sup> Thomas Tegos, <sup>1</sup> Nikolaos Tsiaras, <sup>1</sup> Maria Larissi, <sup>1</sup> Konstantinos Kapanidis, <sup>1</sup> Evi Mavrantoni, <sup>1</sup> Christos Savopoulos, <sup>1</sup> Anastasios Orologas, <sup>1</sup> Apostolos Hatzitolios

<sup>1</sup> *1<sup>st</sup> Propaedeutic Medical Department of Internal Medicine, AHEPA University Hospital, Medical School, Aristotle University of Thessaloniki Greece;*

<sup>2</sup> *1<sup>st</sup> Department of Neurology, AHEPA University Hospital, Medical School, Aristotle University of Thessaloniki Greece;*

**OP37 THE ISOLATION OF CANDIDA STRAINS IN BRONCHIAL SECRETIONS SELECTED FROM PATIENTS IN THE INTENSIVE CARE UNIT OF A GENERAL HOSPITAL LOCATED IN WESTERN GREECE**

<sup>1</sup> Nikolaos Zotos, <sup>2</sup> Athanasios Margaritis, <sup>3</sup> Maria Gianniki, <sup>1</sup> Eirini Tatsina, <sup>1</sup> Christos Mitsis, <sup>1</sup> Apostolina Papadopoulou, <sup>3</sup> Dimitrios Bougias, <sup>3</sup> Niki Tsifetaki, <sup>1</sup> Evaggelia Chrisostomou, <sup>1</sup> Anastasia Pournou

<sup>1</sup> *Microbiology Department, General Hospital of Ioannina, Greece;*

<sup>2</sup> *Intensive Care Unit, General Hospital of Ioannina, Greece;*

<sup>3</sup> *Rheumatology Department, General Hospital of Ioannina, Greece;*

**OP38 A STUDY OF CASES OF BACTEREMIA DURING THE LAST FIVE YEARS IN A GENERAL HOSPITAL IN NORTH WESTERN GREECE**

<sup>1</sup> Nikolaos Zotos, <sup>1</sup> Apostolina Papadopoulou, <sup>2</sup> Maria Gianniki, <sup>1</sup> Christos Mitsis, <sup>1</sup> Eirini Tatsina, <sup>1</sup> Christos Georgiou,

<sup>2</sup> Dimitrios Bougias, <sup>2</sup> Niki Tsifetaki, <sup>1</sup> Evaggelia Chrisostomou,

<sup>1</sup> Anastasia Pournou

<sup>1</sup> *Microbiology Department, General Hospital of Ioannina, Greece;*

<sup>2</sup> *Rheumatology Department, General Hospital of Ioannina, Greece;*

**OP39 RAPID DETECTION OF VANCOMYCIN-RESISTANT ENTEROCOCCI (VRE) CARRIERS IN A TERTIARY GREEK HOSPITAL**

<sup>1</sup> Styliani Sarrou, <sup>1</sup> Zoi Florou, <sup>1</sup> Ergina Malli, <sup>1</sup> Efi Petinaki

<sup>1</sup> *Department of Microbiology, University Hospital of Larissa, Larissa, Greece;*

**OP40 MOLECULAR EPIDEMIOLOGY AND ANTIMICROBIAL SUSCEPTIBILITY OF CLOSTRIDIUM DIFFICILE ISOLATED FROM A UNIVERSITY TEACHING HOSPITAL IN GREECE**

<sup>1</sup> Christina Chatedaki, <sup>1</sup> Ioanna Voulgaridi, <sup>1</sup> Styliani Sarrou, <sup>1</sup> Zoi Florou, <sup>2</sup> Aggelos Stefanos, <sup>2</sup> Georgios N Dalekos, <sup>1</sup> Efi Petinaki  
<sup>1</sup> Department of Microbiology University Hospital of Larissa and Medical School, University of Thessalia, Larissa, Greece;  
<sup>2</sup> Department of Medicine and Research Laboratory of Internal Medicine, Medical School, University of Thessaly, Larissa, Greece;

**OP41 AUTOCHTHONOUS PLASMODIUM VIVAX INFECTION IN LARISA: ONE OF SIX CASES IN OUR COUNTRY DURING 2015**

<sup>1</sup> Kalliopi Azariadi, <sup>1</sup> Nikolaos Gatselis, <sup>1</sup> Kalliopi Zachou, <sup>2</sup> Efthymia Petinaki, <sup>1</sup> George N. Dalekos, <sup>1</sup> Sara Georgiadou  
<sup>1</sup> Department of Medicine and Research Laboratory of Internal Medicine, Medical School, University of Thessaly, Larissa, Greece;  
<sup>2</sup> Department of Microbiology, Medical School, University of Thessaly, Larissa;

**09:00 - 10:30 ROUND TABLE**

**Advances in autoimmune hepatitis (AIH)**

*Chairpersons:* **Diego Vergani** (London, UK)

**George N. Dalekos** (Larissa, Greece)

Advances in genetics of AIH

**Ynto de Boer** (Amsterdam, The Netherlands)

EASL CPG guidelines on AIH

**Harald Hofer** (Vienna, Austria)

AIH in special conditions

**Michael Heneghan** (London, UK)

AIH in the pediatric population

**Giorgina Mieli-Vergani** (London, UK)

**10:30 - 11:00 STATE-OF-THE-ART LECTURE**

*Chairperson: George K. Koukoulis (Larissa, Greece)*

The role of laboratory in the diagnosis and follow-up of autoimmune liver diseases

**Diego Vergani** (London, UK)

**11:00 - 11:30 Coffee Break****11:30 - 13:00 ROUND TABLE****Rheumatoid arthritis and the cardiovascular system**

*Chairpersons: George D. Kitas (Dudley, UK)*

*Petros P. Sfikakis (Athens, Greece)*

Cardiovascular disease in rheumatoid arthritis: Causes, consequences and open questions

**George D. Kitas** (Dudley, UK)

High grade inflammation and the lipid paradox: implications for treatment

**Anne Grete Semb** (Oslo, Norway)

Non-invasive assessment of accelerated atherosclerosis in chronic inflammatory conditions

**Athanasios Protogerou** (Athens, Greece)

Cardiac magnetic resonance imaging in rheumatoid arthritis: promising or misleading?

**Sophie Mavrogeni** (Athens, Greece)

**13:00 - 13:30 STATE-OF-THE-ART LECTURE**

*Chairperson: John Koskinas (Athens, Greece)*

Acute-on-chronic liver failure

**Rajiv Jalan** (London, UK)

**13:30 - 14:15 SATELLITE SYMPOSIUM****The Role of sofosbuvir/ledipasvir in HCV cure**

*Sponsored by Gilead Sciences Hellas*

**14:15 - 15:45 E-POSTER PRESENTATIONS**

(Screen A) **e-PP53 - e-PP65** Hall ALKISTIS - THETIDA

**HAEMATOLOGY - ONCOLOGY**

*Chairpersons:* **Georgia Kaiafa** (Thessaloniki, Greece)  
**Eleni Bouronikou** (Larissa, Greece)

**e-PP53 PRIMARY THYROID LYMPHOMA**

<sup>1</sup> Papadatou Aggeliki, <sup>2</sup> Tsagkarousianos Christos,  
<sup>1</sup> Moschouris Hipocrates, <sup>3</sup> Aggelidi Maria, <sup>4</sup> Kapros Elias  
<sup>1</sup> Radiology Department, TZANEIO General Hospital of Piraeus;  
<sup>2</sup> Surgical Department, General Hospital of Zakinthos;  
<sup>3</sup> Department of Anesthesia, General Hospital of Zakinthos;  
<sup>4</sup> Radiology Department, General Hospital of Zakinthos;

**e-PP54 EFFECT OF THYROID DYSFUNCTIONS ON BLOOD CELL COUNT AND RED BLOOD CELL INDICE**

<sup>1</sup> Nikolaos Vaitsis, <sup>1</sup> Stamatina Aggelakou-Vaitsi  
<sup>1</sup> Private medical office, Farsala, Greece;

**e-PP55 HEPATOCELLULAR CARCINOMA OCCURING 24 YEARS AFTER TREATMENT FOR HODGKIN'S LYMPHOMA**

<sup>1</sup> Maria Tsitsia, <sup>1</sup> Vasiliki Syrmou, <sup>1</sup> Nikolaos Gatselis,  
<sup>2</sup> Christos Rountas, <sup>3</sup> George K. Koukoulis, <sup>1</sup> George N. Dalekos,  
<sup>1</sup> Kalliopi Zachou  
<sup>1</sup> Department of Medicine and Research Laboratory of Internal Medicine, Medical School, University of Thessaly, Larissa, Greece;  
<sup>2</sup> Department of Radiology, University Hospital of Larissa, Medical School, University of Thessaly, Larissa, Greece;  
<sup>3</sup> Department of Pathology, Medical School, University of Thessaly, Larissa, Greece;

**e-PP56 NOT AN ORDINARY UTI: A CASE OF MULTIPLE MYELOMA - WITHDRAWN STAGE III, WITH NO MANIFESTATION OF BONE PAIN, HYPERCALCEMIA, OR OSTEOLYTIC LESIONS**

<sup>1</sup> Yue Shi, <sup>1</sup> Zarah Lucas, <sup>1</sup> Kavita Kalra  
<sup>1</sup> Hematology/ Oncology, University of Maryland, Midtown Campus, Baltimore, MD;



**e-PP57 A CASE OF MULTIFOCAL BONE LYMPHOMA**

<sup>2,1</sup> Athanasios Koutsoukis, <sup>1</sup> Georgeta Lascu,  
<sup>1</sup> Constance Guillaud  
<sup>1</sup> Acute Medical Unit , APHP Henri Mondor, Creteil, France;  
<sup>2</sup> Cardiology Department, St Thoma's Hospital, London, UK;

**e-PP58 NON-HODGKIN LYMPHOMA OF THE URINARY BLADDER AS AN INCIDENTAL FINDING FROM PATHOLOGICAL ASSESSMENT OF TISSUE IMPACTED IN FOLEY CATHETER: A RARE CASE REPORT**

<sup>1</sup> Kyriakos Chatzopoulos, <sup>1</sup> Stauroula Papadopoulou,  
<sup>1</sup> Aspasia Deliligka, <sup>1</sup> Georgios Hahalis, <sup>1</sup> Christina Nikolaidou,  
<sup>1</sup> Ioannis Venizelos  
<sup>1</sup> Department of Pathology, Hippokrateion General Hospital, Thessaloniki, Greece;

**e-PP59 ACQUIRED FANCONI'S SYNDROME SECONDARY TO MONOCLONAL LIGHT CHAIN GAMMOPATHY**

<sup>1</sup> Nikos Sabanis, <sup>2</sup> Eleni Paschou, <sup>3</sup> Eleni Gavriilaki,  
<sup>1</sup> Christos Dontsos, <sup>1</sup> Efthimios Pappas, <sup>1</sup> Sotirios Vasileiou,  
<sup>3</sup> Georgios Papaioannou  
<sup>1</sup> Department of Nephrology, General Hospital of Pella, Edessa, Greece;  
<sup>2</sup> Department of General Practice & Family Medicine, General Hospital of Pella, Edessa, Greece;  
<sup>3</sup> Hematology Department and Hematopoietic Cell Transplantation (HCT) Unit, G. Papanikolaou Hospital, Thessaloniki, Greece;

**e-PP60 PORTAL VEIN THROMBOSIS: AN UNEXPECTED FINDING IN A 34-YEAR-OLD MALE WITH ABDOMINAL PAIN: A CASE REPORT**

<sup>1</sup> Dimitra Tsionara, <sup>1</sup> Georgia Samakidou,  
<sup>1</sup> Georgios Gkountouras, <sup>1</sup> Oyrania Triantafyllou,  
<sup>1</sup> Georgios Banis, <sup>1</sup> Konstantinos Karakousis,  
<sup>1</sup> Theodora Konstantoula, <sup>1</sup> Konstantinos Krapis,  
<sup>1</sup> Konstantinos Karamitsos  
<sup>1</sup> Department of Internal Medicine, General Hospital of Larissa;

- e-PP61 EVALUATION OF GABAPENTIN IN PATIENTS WITH CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY**  
P. Heras, I. Georgopoulos, M Koutroumbi, A. Stefanopoulos  
*Department of Internal Medicine of General Hospital of Nafplio;*
- e-PP62 DYSPNEA AND FATIGUE IN LUNG CANCER PATIENTS**  
<sup>1</sup>Kerasina Papastergiou, <sup>2</sup>Maria Lavdaniti, <sup>3</sup>Sofia Zyga  
<sup>1</sup> Nurse Thessaloniki, Greece;  
<sup>2</sup> Nursing Department, Alexander Technological Educational Institute, Thessaloniki, Greece;  
<sup>3</sup> Nursing Department, University of Peloponnesus, Sparta, Greece;
- e-PP63 EFFICACY AND SAFETY OF THE ZOLENDRONIC ACID IN THE MANAGEMENT OF BONE METASTASES FOLLOWING RAPID INFUSION IN PATIENTS WITH LUNG CANCER**  
P. Heras, I. Georgopoulos, A. Hatzopoulos, M. Koutroumpi, A. Stefanopoulos, M. Hera  
*Department of Internal Medicine of General Hospital of Nafplio;*
- e-PP64 SPLENIC INFLAMMATORY PSEUDOTUMOR LIKE FOLLICULAR DENDRITIC CELL TUMOR: A CASE REPORT**  
<sup>1</sup> Nikolaos Papadopoulos, <sup>2</sup> Paraskeyas Patouras,  
<sup>3</sup> Thomas Georgiadis, <sup>4</sup> Vassilios Parasyris, <sup>1</sup> Lazaros Karnesis  
<sup>1</sup> 1st department of Internal medicine, 401 General Army Hospital of Athens, Greece;  
<sup>2</sup> Department of Radiology, 401 General Army Hospital of Athens, Greece;  
<sup>3</sup> Department Of Pathology, Hygeia Hospital, Athens, Greece;  
<sup>4</sup> Department of Surgery, Hygeia Hospital, Athens, Greece;
- e-PP65 THE NEEDS AMONG GREEK COLORECTAL CANCER PATIENTS DURING AND AFTER TREATMENT**  
<sup>1,2</sup> Panagiotis Heras, <sup>1,2</sup> Anastasios Stefanopoulos,  
<sup>1,2</sup> Ilias Georgopoulos, <sup>2</sup> Andreas Hatzopoulos,  
<sup>1,2</sup> Maria Koutroubi  
<sup>1</sup> Hellenic Medical Society of Psychosomatic Problems, Athens, Greece;  
<sup>2</sup> Department of Internal Medicine General Hospital of Nafplio;

(Screen B) **e-PP66 - e-PP78** Hall ALKISTIS - THETIDA**INFECTIOUS DISEASES***Chairpersons:* **Periklis Panagopoulos** (Alexandroupolis, Greece)  
**Efthymia Giannitsioti** (Athens, Greece)**e-PP66 A PATIENT WITH AUSTRIAN SYNDROME**<sup>1</sup> E. Manoulakas, <sup>1</sup> G. Papadamou, <sup>1</sup> G. Ntaios, <sup>1</sup> K. Makaritsis,  
<sup>1</sup> G.N. Dalekos, <sup>1</sup> S. Georgiadou<sup>1</sup> Department of Medicine and Research Laboratory of Internal  
Medicine, Medical School, University of Thessaly, Larissa, Greece;**e-PP67 HUMAN SUBCUTANEOUS DIROFILARIASIS**<sup>1</sup> Christos Tsagkarousianos, <sup>2</sup> Aggeliki Papadatou,<sup>3</sup> Maria Aggelidi, <sup>4</sup> Elias Kapros, <sup>5</sup> Irene Katsarou<sup>1</sup> Surgical Department, General Hospital of Zakynthos;<sup>2</sup> Radiology Department, Tzaneio General Hospital of Piraeus;<sup>3</sup> Department of Anesthesia, General Hospital of Zakynthos;<sup>4</sup> Radiology Department, General Hospital of Zakynthos;<sup>5</sup> Department of Nephrology, General Hospital of Zakynthos;**e-PP68 ASEPTIC MENINGITIS AS THE FIRST SIGN IN A PATIENT  
BEING INFECTED BY HIV VIRUS**<sup>1</sup> Christos Zissis, <sup>1</sup> Efterpi Theodoroula, <sup>1</sup> Dimitra Maritsa,<sup>1</sup> Athanasios Tsiampalis, <sup>1</sup> Charalampos Karageorgos,<sup>1</sup> Ioannis Lolos, <sup>1</sup> Konstantinos Kalantzis, <sup>1</sup> Stefanos Milonas<sup>1</sup> 2<sup>nd</sup> Internal Medicine Clinic, General Hospital of Trikala, Trikala,  
Greece;**e-PP69 PERIPELVIC PYOMYOSITIS IN A DIABETIC PATIENT**<sup>1</sup> Spiridoula Mpika, <sup>1</sup> Georgios Gkogkos, <sup>2</sup> Nikitas Karavidas,<sup>1</sup> Ourania Droggoula, <sup>3</sup> Fani Nakopoulou, <sup>1</sup> Aggelos Zormpas<sup>1</sup> First Department of Internal Medicine, General Hospital of Trikala,  
Greece;<sup>2</sup> Department of Cardiology, General Hospital of Trikala, Greece;<sup>3</sup> Department of Radiology, General Hospital of Trikala, Greece;

**e-PP70 CASES OF LEPTOSPIROSIS IN A HOSPITAL LOCATED IN NORTH-WESTERN GREECE DURING THE LAST 15 YEARS: A SERO-EPIDEMIOLOGICAL RETROSPECTIVE STUDY**

<sup>1</sup> Nikolaos Zotos, <sup>2</sup> Maria Gianniki, <sup>1</sup> [Eirini Tatsina](#),  
<sup>1</sup> Christos Briasoulis, <sup>1</sup> Christos Mitsis, <sup>1</sup> Lambros Papageorgiou,  
<sup>1</sup> Sotiria Kitsou, <sup>2</sup> Dimitrios Bougias, <sup>2</sup> Niki Tsifetaki,  
<sup>1</sup> Anastasia Pournou  
<sup>1</sup> *Microbiology Department, General Hospital of Ioannina, Greece;*  
<sup>2</sup> *Rheumatology Department, General Hospital of Ioannina, Greece;*

**e-PP71 CASES OF LEISHMANIASIS IN NORTH-WESTERN GREECE DURING A PERIOD OF TWENTY YEARS**

<sup>1</sup> Nikolaos Zotos, <sup>2</sup> Maria Gianniki, <sup>1</sup> [Eirini Tatsina](#),  
<sup>2</sup> Dimitrios Bougias, <sup>1</sup> Apostolina Papadopoulou,  
<sup>1</sup> Christos Georgiou, <sup>1</sup> Lampros Papageorgiou,  
<sup>1</sup> Evaggelia Chrisostomou, <sup>2</sup> Niki Tsifetaki, <sup>1</sup> Anastasia Pournou  
<sup>1</sup> *Microbiology Department, General Hospital of Ioannina, Greece;*  
<sup>2</sup> *Rheumatology Department, General Hospital of Ioannina, Greece;*

**e-PP72 A SEROEPIDEMIOLOGICAL STUDY OF ECHINOCOCCOSIS IN NORTH-WESTERN GREECE DURING A PERIOD OF TWENTY YEARS**

<sup>1</sup> Nikolaos Zotos, <sup>2</sup> Maria Gianniki, <sup>1</sup> [Eirini Tatsina](#),  
<sup>2</sup> Dimitrios Bougias, <sup>1</sup> Athanasia Fasouloglou, <sup>1</sup> Eleni Mosheta,  
<sup>1</sup> George Katagis, <sup>1</sup> Konstantinos Tolis, <sup>1</sup> Niki Tsifetaki,  
<sup>1</sup> Anastasia Pournou  
<sup>1</sup> *Microbiology Department, General Hospital of Ioannina, Greece;*  
<sup>2</sup> *Rheumatology Department, General Hospital of Ioannina, Greece;*

**e-PP73 ESBL POSITIVE ENTEROBACTERIACEAE STRAINS ISOLATED FROM PATIENTS IN THE HOSPITAL AND THE COMMUNITY**

<sup>1</sup> Nikolaos Zotos, <sup>1</sup> Apostolina Papadopoulou, <sup>1</sup> [Eirini Tatsina](#),  
<sup>2</sup> Maria Gianniki, <sup>2</sup> Dimitrios Bougias, <sup>1</sup> Eleni Mosheta,  
<sup>1</sup> George Katagis, <sup>1</sup> Athanasia Fasouloglou, <sup>1</sup> Konstantinos Tolis,  
<sup>1</sup> Anastasia Pournou  
<sup>1</sup> *Microbiology Department, General Hospital of Ioannina, Greece;*  
<sup>2</sup> *Rheumatology Department, General Hospital of Ioannina, Greece;*

**e-PP74 A COMPARATIVE STUDY OF CULTURES OF PERITONEAL FLUID SAMPLES FROM INPATIENTS WITH PERITONITIS DURING A THREE YEAR PERIOD**

<sup>1</sup> Nikolaos Zotos, <sup>1</sup> [Eirini Tatsina](#), <sup>2</sup> Maria Gianniki,  
<sup>2</sup> Dimitrios Bougias, <sup>1</sup> Christos Briasoulis, <sup>1</sup> Christos Mitsis,  
<sup>1</sup> Lampros Papageorgiou, <sup>1</sup> Sotiria Kitsou, <sup>2</sup> Niki Tsifetaki,  
<sup>1</sup> Anastasia Pournou  
<sup>1</sup> *Microbiology Department, General Hospital of Ioannina, Greece;*  
<sup>2</sup> *Rheumatology Department, General Hospital of Ioannina, Greece;*

**e-PP75 CULTIVATION RESULTS OF SPECIMENS SELECTED FROM ABSCESSSES AND TRAUMAS IN PATIENTS OF A GENERAL HOSPITAL DURING A PERIOD OF THREE YEARS**

<sup>1</sup> Nikolaos Zotos, <sup>2</sup> Maria Gianniki, <sup>1</sup> [Eirini Tatsina](#),  
<sup>1</sup> Lampros Papageorgiou, <sup>1</sup> Apostolina Papadopoulou,  
<sup>1</sup> Christos Georgiou, <sup>2</sup> Dimitrios Bougias,  
<sup>1</sup> Evaggelia Chrisostomou, <sup>2</sup> Niki Tsifetaki, <sup>1</sup> Anastasia Pournou  
<sup>1</sup> *Microbiology Department, General Hospital of Ioannina, Greece;*  
<sup>2</sup> *Rheumatology Department, General Hospital of Ioannina, Greece;*

**e-PP76 A CASE OF VISCERAL LEISHMANIASIS- CASE DESCRIPTION**

<sup>1</sup> Nikolaos Zotos, <sup>2</sup> Nikolaos Varsamis,  
<sup>1</sup> Apostolina Papadopoulou, <sup>1</sup> [Eirini Tatsina](#), <sup>3</sup> Maria Gianniki,  
<sup>3</sup> Dimitrios Bougias, <sup>1</sup> Christos Georgiou, <sup>3</sup> Niki Tsifetaki,  
<sup>1</sup> Evaggelia Chrisostomou, <sup>1</sup> Anastasia Pournou  
<sup>1</sup> *Microbiology Department, General Hospital of Ioannina, Greece;*  
<sup>2</sup> *Pathology Department, General Hospital of Ioannina, Greece;*  
<sup>3</sup> *Rheumatology Department, General Hospital of Ioannina, Greece;*

**e-PP77 THE PREVALENCE OF NURSING DIAGNOSES IN PEOPLE WITH HIV/AIDS RECEIVING OUTPATIENT CARE IN HEALTH INSTITUTIONS IN VLORE, ALBANIA**

<sup>1</sup> [Glodiana Sinanaj](#), <sup>2</sup> Arjan Harxhi, <sup>2</sup> Mikel Nakuci,  
<sup>2</sup> Brunilda Miftari, <sup>3</sup> Llambi Subashi, <sup>2</sup> Denada Selfo,  
<sup>2</sup> Brunilda Subashi, <sup>2</sup> Rozeta Luci  
<sup>1</sup> *Department of Public Health, Faculty of Public Health, University of Vlore, Albania;*  
<sup>2</sup> *Faculty of Technical Medical Sciences, University of Medicine, Tirana, Albania;*  
<sup>3</sup> *Vlora Regional Hospital, Albania;*

Hall ALKISTIS - THETIDA

**e-PP78 THE EVALUATION OF ANTIMICROBIAL RESISTANCE IN HOSPITALIZED PATIENTS AT INTERNAL DISEASES WARD**

<sup>1</sup> Majlinda Zahaj, <sup>2</sup> Rozeta Luci, <sup>1</sup> Brunilda Subashi, <sup>1</sup> Sonila Nikaj,  
<sup>1</sup> Evis Alushi  
<sup>1</sup> Public Health Faculty, University "Ismail Qemali", Vlore Albania;  
<sup>2</sup> Regional Hospital of, Vlore, Albania;

Hall CHRISALIDA

(Screen C)

**e-PP79 - e-PP91**

Hall CHRISALIDA

**ONCOLOGY - INFECTIOUS DISEASES - MISCELLANEOUS**

*Chairpersons: Maria Ioannou (Larissa, Greece)*

**Dimitra Dimitropoulou (Patras, Greece)**

**e-PP79 PRIMARY EWING'S SARCOMA OF THE BREAST**

<sup>1</sup> Stauroula Papadopoulou, <sup>1</sup> Kyriakos Chatzopoulos,  
<sup>1</sup> Aspasia Deliligka, <sup>1</sup> Georgios Hahalis, <sup>1</sup> Christina Nikolaidou,  
<sup>1</sup> Ioannis Venizelos  
<sup>1</sup> Department of Pathology, Hippokrateion General Hospital,  
 Thessaloniki, Greece;

**e-PP80 SOLITARY FIBROUS TUMOR OF THE SPINAL CORD: A RARE CASE REPORT**

<sup>1</sup> Stauroula Papadopoulou, <sup>1</sup> Kyriakos Chatzopoulos,  
<sup>1</sup> Aspasia Deliligka, <sup>1</sup> Georgios Hahalis, <sup>1</sup> Christina Nikolaidou,  
<sup>1</sup> Ioannis Venizelos  
<sup>1</sup> Department of Pathology, Hippokrateion General Hospital,  
 Thessaloniki, Greece;

**e-PP81 OSTEOLASTIC METASTASES AS A PRESENTATION OF SIGNET RING CELL GASTRIC CARCINOMA**

<sup>1</sup> Stauroula Papadopoulou, <sup>1</sup> Kyriakos Chatzopoulos,  
<sup>1</sup> Aspasia Deliligka, <sup>1</sup> Christina Nikolaidou, <sup>1</sup> Ioannis Venizelos  
<sup>1</sup> Department of Pathology, Hippokrateion General Hospital,  
 Thessaloniki, Greece;

PARALLEL SESSIONS

Saturday, March 19, 2016



- e-PP82 LYMPHOEPITHELIAL-LIKE CARCINOMA OF THE PAROTID GLAND: CASE REPORT**  
<sup>1</sup> Stauroula Papadopoulou, <sup>1</sup> Kyriakos Chatzopoulos,  
<sup>1</sup> Aspasia Deliligka, <sup>1</sup> Georgios Hahalis, <sup>1</sup> Christina Nikolaidou,  
<sup>1</sup> Ioannis Venizelos  
<sup>1</sup> *Department of Pathology, Hippokrateion General Hospital, Thessaloniki, Greece;*
- e-PP83 ASSESSMENT OF DEPRESSION IN PATIENTS WITH COLOSTOMY USING THE CES-DEPRESSION SCALE**  
<sup>1</sup> Maria Lavdaniti, <sup>2</sup> Evangelos Dimopoulos,  
<sup>3</sup> Kerasina Papastergiou, <sup>4</sup> Helen Dokoutsidou, <sup>5</sup> Sofia Zyga  
<sup>1</sup> *Nursing Department, Alexander Technological Educational Institute, Thessaloniki, Greece;*  
<sup>2</sup> *Economic, Athens, Greece;*  
<sup>3</sup> *University of Thessaly, Larissa, Greece;*  
<sup>4</sup> *Nursing Department, TEI of Athens, Athens, Greece;*  
<sup>5</sup> *Nursing Department, University of Peloponesus, Sparta, Greece;*
- e-PP84 INFLAMMATORY MYOFIBROBLASTIC TUMOR OF THE PAROTID GLAND**  
<sup>1</sup> Kyriakos Chatzopoulos, <sup>1</sup> Stauroula Papadopoulou,  
<sup>1</sup> Aspasia Deliligka, <sup>1</sup> Georgios Hahalis, <sup>1</sup> Christina Nikolaidou,  
<sup>1</sup> Ioannis Venizelos  
<sup>1</sup> *Department of Pathology, Hippokrateion General Hospital, Thessaloniki, Greece;*
- e-PP85 MALARIA - REAPPEARANCE OF "FORGOTTEN" INFECTIOUS DISEASES**  
<sup>1</sup> Christos Zissis, <sup>1</sup> Dimitra Maritsa, <sup>1</sup> Athanasios Tsiabalis,  
<sup>1</sup> Euterpi Theodoroula, <sup>1</sup> Charis Karageorgos, <sup>1</sup> Ioannis Lolos,  
<sup>1</sup> Dimitris Oikonomou, <sup>2</sup> Eleni Gatsa, <sup>3</sup> Vasiliki Samara,  
<sup>1</sup> Stefanos Milonas  
<sup>1</sup> *2<sup>nd</sup> Internal Medicine Clinic, General Hospital of Trikala, Trikala, Greece;*  
<sup>2</sup> *Haematology Clinic/Lab, General Hospital of Trikala, Trikala, Greece;*  
<sup>3</sup> *Microbiology Lab, General Hospital of Trikala, Trikala, Greece;*

**e-PP86 CANDIDA PARAPSILOSIS PROSTHETIC VALVE ENDOCARDITIS**

<sup>1</sup> Spiridoula Mpika, <sup>2</sup> Nikitas Karavidas, <sup>1</sup> Georgios Gkogkos,  
<sup>1</sup> Apostolos Tziortziotis, <sup>1</sup> Anastasia Theodora Kalliaras,  
<sup>1</sup> Aggelos Zormpas  
<sup>1</sup> First Department of Internal Medicine, General Hospital of Trikala, Greece;  
<sup>2</sup> Department of Cardiology, General Hospital of Trikala, Greece;

**e-PP87 RUPTURED PULMONARY HYDATIC CYST**

<sup>1</sup> Papadatou Aggeliki, <sup>2</sup> Tsagkarousianos Christos,  
<sup>1</sup> Moschouris Hipocrates, <sup>3</sup> Kapros Elias, <sup>2</sup> Mauraki Eugenia  
<sup>1</sup> Radiology Department, TZANEIO General Hospital of Piraeus;  
<sup>2</sup> Surgery Department, General Hospital of Zakinthos;  
<sup>3</sup> Radiology Department, General Hospital of Zakinthos;

**e-PP88 NITROFURANTOIN IN EVERY-DAY CLINICAL PRACTICE: BE AWARE OF SIDE-EFFECTS**

<sup>1</sup> Marianna Bakarozzi, <sup>1</sup> Aggelos Stefos, <sup>1</sup> Mary Boulbou,  
<sup>1</sup> Asterios Polyzos, <sup>1</sup> George N. Dalekos, <sup>1</sup> Eirini I. Rigopoulou  
<sup>1</sup> Department of Medicine and Research Laboratory of Internal Medicine, Medical School, University of Thessaly, Larissa, Greece;

**e-PP89 GUILLAIN-BARRE SYNDROME DEVELOPMENT FOLLOWING A BITE BY A CENTIPEDE- A CASE REPORT**

<sup>2</sup> Anastasia Kaliotzoglou, <sup>2</sup> Foteini Alourda, <sup>1</sup> Georgios Ntetskas,  
<sup>2</sup> Ioannis Lapis, <sup>1</sup> Mihail Marias, <sup>1</sup> Eustathia Anastasiou,  
<sup>1</sup> Maria Stampori, <sup>1</sup> Georgios Psellakis, <sup>1</sup> Nikitas Katsilis,  
<sup>1</sup> Stylianos Karatapanis  
<sup>1</sup> First Department of Internal Medicine, General Hospital of Rhodes, Greece;  
<sup>2</sup> Neurology Dept, General Hospital of Rhodes, Greece;

**e-PP90 A MILLER FISHER SYNDROME IN A YOUNG WOMAN- A CASE REPORT**

<sup>2</sup> Foteini Alourda, <sup>1</sup> Georgios Ntetskas, <sup>1</sup> Euthymia Anastasiou,  
<sup>1</sup> Maria Stampori, <sup>2</sup> Anastasia Kaliotzoglou, <sup>2</sup> Ioannis Lapis,  
<sup>1</sup> Georgios Zaharis, <sup>1</sup> Mihail Marias, <sup>1</sup> Vasilios Papastergiou,  
<sup>1</sup> Stylianos Karatapanis  
<sup>1</sup> First Department of Internal Medicine, General Hospital of Rhodes, Greece;  
<sup>2</sup> Neurology Dept, General Hospital of Rhodes, Greece;

Hall CHRISALIDA

**e-PP91 EPILEPTIC FITS IN A PATIENT WITH THE SYNDROME OF HYPERZINCAEMIA AND HYPERCALPROTECTINAEMIA - A CASE REPORT**

<sup>2</sup> Foteini Alourdani, <sup>2</sup> Anastasia Kaliotzoglou,  
<sup>1</sup> Georgios Ntetskas, <sup>2</sup> Ioannis Lapis, <sup>1</sup> Mihail Marias,  
<sup>1</sup> Maria Stampori, <sup>1</sup> Nikitas Katsilis, <sup>1</sup> Foteini Lampranou,  
<sup>1</sup> Vasilios Papastergiou, <sup>1</sup> Stylianos Karatapanis  
<sup>1</sup> First Department of Internal Medicine, General Hospital of Rhodes, Greece;  
<sup>2</sup> Neurology Dept, General Hospital of Rhodes, Greece;

Hall OLYMPOS

15:45 - 16:00 Leisure time

**16:00 - 17:30 ROUND TABLE  
Invasive fungal infections (IFI)***Chairperson: George Petrikos (Athens, Greece)*

Allogeneic hematopoietic stem cell transplantation in patients with prior invasive aspergillosis

**Nikolai Klimko** (Saint Petersburg, Russia)

Invasive fungal infections in solid organ transplants

**Emmanuel Roilides** (Thessaloniki, Greece)

Newer guidelines for the treatment of invasive candidiasis in non-neutropenic patients

**Sarah Georgiadou** (Larissa, Greece)

Newer (ECIL and ESCMID/ECMM) guidelines in the treatment of IFI in leukemic patients

**Anna Skiada** (Athens, Greece)

**17:30 - 19:00 ROUND TABLE  
Inflammatory bowel disease (IBD) and the liver**

*Chairpersons: Alessio Aghemo (Milan, Italy)  
Joost P.H. Drenth (Nijmegen, The Netherlands)*

Management of viral hepatitis in patients with IBD  
**Alessio Aghemo (Milan, Italy)**

Primary sclerosing cholangitis  
**Tom Hemming Karlsen (Oslo, Norway)**

Liver enzyme elevations as a result from IBD therapy  
**Joost P.H. Drenth (Nijmegen, The Netherlands)**

Reasons for ALT elevation in IBD: autoimmune liver disease?  
**Eric Tjwa (Nijmegen, The Netherlands)**

**19:00 - 19:30 Coffee Break**

**19:30 - 21:00 SATELLITE SYMPOSIUM  
Chronic hepatitis C treatment management:  
From clinical trials to clinical practice!**

*Sponsored by Bristol-Myers Squibb*


**21:30 Dinner**

*Upon invitation*



# Liptruzet<sup>®</sup>

(ezetimibe and atorvastatin) tablets



Για περισσότερες συνταγογραφικές πληροφορίες συμβουλευτείτε  
την Περίληψη Χαρακτηριστικών του Προϊόντος.



Υπεύθυνος  
Άδειας Κυκλοφορίας  
MSD Α.Φ.Β.Ε.Ε  
Αγ. Δημητρίου 63, 174 56 Άλιμος,  
Αθήνα, Τηλ.: 210 9897300  
[www.msd.gr](http://www.msd.gr)



Συμπροώθηση από την εταιρεία:

**BIANEX A.E. ΒΙΟΜΗΧΑΝΙΑ ΦΑΡΜΑΚΩΝ**

ΕΤΑΙΡΕΙΑ ΤΟΥ ΟΜΙΛΟΥ ΓΙΑΝΝΑΚΟΠΟΥΛΟΥ

LICENSEE / DISTRIBUTOR OF MERCK SHARP & DOHME,  
Division of MERCK & Co., Inc., Whitehouse Station, N.J., USA

Γραφεία Επιστημονικής Ενημέρωσης

ΑΘΗΝΑ: Οδός Τατοΐου, 146 71 Ν. Ερυθραία, Τηλ.: 210 8009111

• E-mail: [mailbox@vianex.gr](mailto:mailbox@vianex.gr) • INTERNET: <http://www.vianex.gr>

• ΘΕΣΣΑΛΟΝΙΚΗ: Ακαδημίου 113, Κόμβος Μακρυγιάννη,

Εύσμος Θεσσαλονίκης, ΤΚ 56224, Τηλ: 2310 833893

• ΠΑΤΡΑ: Μαιζώνος 131, Τηλ.: 2610 221397

## INDEX OF INVITED FACULTY

### **AGHEMO ALESSIO**

*Professor of Gastroenterology, 1<sup>st</sup> Division of Gastroenterology, Fondazione IRCCS Ca' Granda Ospedale Maggiore, University of Milan, Milan, Italy*

### **BERGE EIVIND**

*Stroke Physician, Department of Internal Medicine, Oslo University Hospital, Oslo, Norway*

### **BOURONIKOU ELENI**

*Hematology Consultant, Hematology Department, University General Hospital of Larissa, Larissa, Greece*

### **BURNIER MICHEL**

*Professor of Medicine, Head, Division of Nephrology and Hypertension Consultation, University Hospital of Lausanne, Lausanne, Switzerland*

### **BUTI MARIA**

*Professor of Medicine, Department of Internal Medicine II and Hepatology, BarcelonaVall d'Hebron University Hospital, Barcelona, Spain*

### **CHOLONGITAS EVANGELOS**

*Assistant Professor of Internal Medicine, Faculty of Medicine, School of Health Sciences, Aristotle University of Thessaloniki, 4<sup>th</sup> Academic Department of Internal Medicine, Hippokration General Hospital of Thessaloniki, Thessaloniki, Greece*

### **CORDONNIER CHARLOTTE**

*Professor of Neurology, Faculty of Medicine, University of Lille, Head, Neurovascular Intensive Care Unit, Department of Neurology & Stroke Unit, Lille University Hospital, Lille, France*

### **CORNBERG MARKUS**

*Professor of Gastroenterology, Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany*

### **DALEKOS GEORGE**

*Professor of Medicine, President, Institute of Internal Medicine and Hepatology, President, Hellenic Association for the Study of the Liver, Vice President, Internal Medicine Society of Northern Greece, Head, Department of Medicine and Research Laboratory of Internal Medicine, Medical School, University of Thessaly, Larissa, Greece*

### **DE BOER YNTO**

*Gastroenterologist, Department of Gastroenterology and Hepatology, VU University Medical Center, Amsterdam, The Netherlands*

### **DEUTSCH MELANIE**

*Assistant Professor of Hepatology-Internal Medicine, Faculty of Medicine, School of Health Sciences, National & Kapodistrian University of Athens, Athens, Greece*

### **DIMITROPOULOU DIMITRA**

*Physician in Internal Medicine and Infectious Diseases Specialist, Patras, Greece*

### **DRENTH JOOST**

*Professor of Gastroenterology, Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, The Netherlands*



### **ESTEBAN RAFAEL**

*Professor of Medicine, Head, Department of Internal Medicine II & Hepatology, Vall d'Hebron University Hospital, Barcelona, Spain*

### **FISCHER URS**

*Professor for Acute Neurology and Stroke, Co-Director Clinical Trial Unit Bern, University of Bern, Bern, Switzerland*

### **FOUNTAS KONSTANTINOS**

*Associate Professor of Neurosurgery, Faculty of Medicine, University of Thessaly, Director, Department of Neurosurgery, University General Hospital of Larissa, Larissa, Greece*

### **GACCI MAURO**

*Urology Consultant, Department of Urology, University of Florence, Italy*

### **GEORGIADOU SARAH**

*Internal Medicine Consultant and Infectious Diseases Specialist, Department of Medicine & Research Laboratory of Internal Medicine, University Hospital of Larissa, Larissa, Greece*

### **GIANNITSIOTI EFTHYMIA**

*Internal Medicine Consultant and Infectious Diseases Specialist, 4<sup>th</sup> Department of Internal Medicine, University of Athens Medical School, "Attikon" University Hospital of Athens, Athens, Greece*

### **GIANNOULIS GRIGORIOS**

*Director, Department of Hepatology, Metropolitan Hospital, Athens, Greece*

### **GRAVAS STAVROS**

*Associate Professor of Urology, University of Thessaly Medical School, University Hospital of Larissa, Larissa, Greece*

### **HATZITOLIOS APOSTOLOS**

*Professor of Internal Medicine, Faculty of Medicine, School of Health Sciences, Aristotle University of Thessaloniki, Vice President, Internal Medicine Society of Northern Greece, Director, 1<sup>st</sup> Propaedeutic Department of Internal Medicine, AHEPA University General Hospital of Thessaloniki, Thessaloniki, Greece*

### **HENEGHAN MICHAEL**

*Clinical Director for Liver Services, Consultant Hepatologist & Reader in Hepatology, Institute of Liver Studies, King's College Hospital, London, United Kingdom*

### **HOFER HARALD**

*Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria*

### **IOANNOU MARIA**

*Associate Professor of Pathology, Faculty of Medicine, School of Health Sciences University of Thessaly, Larissa, Greece*

### **JALAN RAJIV**

*Professor of Hepatology, Editor in Chief, Journal of Hepatology, Liver Failure Group, Institute for Liver and Digestive Health, University College London Medical School, London, UK*



## INDEX OF INVITED FACULTY

### **KAIIFA GEORGIA**

*Lecturer of Hematology, Faculty of Medicine, School of Health Sciences, Aristotle University of Thessaloniki, 1<sup>st</sup> Medical Propedeutic Department of Internal Medicine AHEPA Hospital Thessaloniki, Greece*

### **KARATAPANIS STYLIANOS**

*Director, 1<sup>st</sup> Department of Internal Medicine, General Hospital of Rhodes, Rhodes, Greece*

### **KARLSEN TOM HEMMING**

*Professor at Research Institute of Internal Medicine, Leader of Norwegian PSC Research Center, Oslo University Hospital, Oslo, Norway*

### **KITAS GEORGE**

*Professor of Clinical Rheumatology, Arthritis Research UK Centre for Epidemiology, University of Manchester, Professor of Behavioural Rheumatology, College of Health and Life Sciences, University of Birmingham, Head of Research and Development – Academic Affairs, Dudley Group NHS Foundation Trust (Teaching), Clinical Research Unit, Russells Hall Hospital, Dudley, UK*

### **KLIMKO NIKOLAI**

*Professor, Head of Department of Clinical Mycology, Allergy and Immunology, I. Mechnikov North-Western State Medical University, Saint Petersburg, Russia*

### **KOSKINAS JOHN**

*Professor of Internal Medicine-Hepatology, Faculty of Medicine, School of Health Sciences, National & Kapodistrian University of Athens, 2<sup>nd</sup> Department of Internal Medicine, Hippokration General Hospital of Athens, Athens, Greece*

### **KOUKOULIS GEORGE**

*Professor of Pathology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece*

### **MAKARITSIS KONSTANTINOS**

*Associate Professor of Medicine, Department of Medicine & Research Laboratory of Internal Medicine, University of Thessaly Medical School, University Hospital of Larissa, Larissa, Greece*

### **MANOLAKOPOULOS SPILIOS**

*Associate Professor in Medicine-Gastroenterology, Faculty of Medicine, National & Kapodistrian University of Athens, Athens, Greece*

### **MAVROGENI SOPHIE**

*Cardiologist, Onassis Cardiac Surgery Center, Athens, Greece*

### **MIELI VERGANI GIORGINA**

*Emeritus Professor of Paediatric Hepatology, Paediatric Liver, GI & Nutrition Centre, King's College Hospital, London, UK*

### **MIMIDIS KONSTANTINOS**

*Associate Professor of Internal Medicine-Hepatology, First Department of Internal Medicine, Democritus University of Thrace, Alexandroupolis, Greece*

### **MITROPOULOS DIONYSIOS**

*Professor of Urology, Faculty of Medicine, School of Health Sciences, National & Kapodistrian University of Athens, Athens, Greece*

### **NILSSON PETER**

*Professor of Clinical Cardiovascular Research, Department of Clinical Sciences, Lund University, Skane University Hospital, Malmö, Sweden*

### **NTAIOS GEORGE**

*Assistant Professor of Medicine, Department of Medicine & Research Laboratory of Internal Medicine, University of Thessaly Medical School, University Hospital of Larissa, Larissa, Greece*

### **PANAGOPOULOS PERIKLIS**

*Assistant Professor of Internal Medicine, 2<sup>nd</sup> University Department of Internal Medicine, Democritus University of Thrace, Alexandroupolis, Greece*

### **PAPATHEODORIDIS GEORGE**

*Professor of Medicine & Gastroenterology, Faculty of Medical School, National and Kapodistrian University of Athens, Director, Academic Department of Gastroenterology, Laiko General Hospital of Athens, Greece*

### **PAPAZOGLU DIMITRIOS**

*Professor of Internal Medicine, Faculty of Medicine, School of Health Sciences, Democritus University of Thrace, 2<sup>nd</sup> Academic Department of Internal Medicine, University General Hospital of Evros, Alexandroupolis, Greece*

### **PETINAKI EFTHIMIA**

*Associate Professor of Microbiology, Faculty of Medicine, Department of Microbiology, University of Thessaly, Director of Microbiology Laboratory, University Hospital of Larissa, Larissa, Greece*

### **PETRIKKOS GEORGE**

*Emeritus Professor of Internal Medicine and Infectious Diseases National and Kapodistrian University of Athens, Professor of Immunology, Medical Microbiology and Infectious Diseases Medical Training Coordinator European University Cyprus*

### **PROTOGEROU ATHANASIOS**

*Associate Professor of Internal Medicine, Faculty of Medicine, University of Athens, Athens, Greece*

### **RAPTI IRENE**

*Consultant Physician in Internal Medicine and Hepatology, Athens Medical Center, Athens, Greece*

### **ROILIDES EMMANUEL**

*Professor of Paediatrics & Infectious Diseases, Faculty of Medicine, School of Health Sciences, Aristotle University of Thessaloniki, 3<sup>rd</sup> Academic Department of Paediatrics, Hippokration General Hospital of Thessaloniki, Thessaloniki, Greece*

### **SAMONAKIS DIMITRIOS**

*Consultant in Gastroenterology and Hepatology, University Hospital of Heraklion Crete, Greece*

### **SAVOPOULOS CHRISTOS**

*Associate Professor of Internal Medicine, Faculty of Medicine, School of Health Sciences, Aristotle University of Thessaloniki, Stroke Unit, 1st Propaedeutic Department of Internal Medicine, "AHEPA" University Hospital of Thessaloniki, Thessaloniki, Greece*

### **SCHMIEDER ROLAND**

*Professor of Internal Medicine, Nephrology and Hypertension, Head, Clinical Research Centre, Vice Chair, Department of Nephrology and Hypertension, University Hospital Erlangen, Nuremberg, Germany*

### **SEMB ANNE GRETE**

*Cardiologist, Senior Researcher, Leader Preventive Cardio-Rheuma Clinic, Chief CVD Research Group, Diakonhjemmet Hospital, Oslo, Norway*

### **SEN DWAIPAYAN**

*Consultant Stroke Physician, Comprehensive Stroke Centre, Alford Royal Hospital, Manchester, UK*

### **SEVASTIANOS VASILEIOS**

*Physician in Internal Medicine and Hepatology, 4<sup>th</sup> Department of Internal Medicine, "Evangelismos" General Hospital, Athens, Greece*

### **SFIKAKIS PETROS**

*Professor of Internal Medicine, Faculty of Medicine, University of Athens, Athens, Greece*

### **SIDERIS DIMITRIOS**

*Emeritus Professor of Cardiology, Faculty of Medicine, University of Ioannina, Athens, Greece*

### **SKENDROS PANAGIOTIS**

*Assistant Professor of Internal Medicine, Faculty of Medicine, Democritus University of Thrace, First Department of Internal Medicine, University Hospital of Alexandroupolis, Alexandroupolis, Greece*

### **SKIADA ANNA**

*1<sup>st</sup> Department of Propaedeutic Medicine, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece*

### **SPELETAS MATTHAIOS**

*Associate Professor of Immunology, Department of Immunology and Histocompatibility, School of Health Sciences Faculty of Medicine, University of Thessaly, Larissa, Greece*

### **TJWA ERIC**

*Department of Gastroenterology and Hepatology, Erasmus Medical Centre, Rotterdam, Radboud University, Nijmegen Medical Centre, Nijmegen, The Netherlands*

### **TOLIS CHRISTOS**

*Medical Oncology Specialist, Department of Medical Oncology, University General Hospital of Ioannina, Ioannina, Greece*

### **TRIANOS CHRISTOS**

*Gastroenterology Specialist, Academic Department of Gastroenterology, University Hospital, Patras, Greece*

### **TSELEPIS ALEXANDROS**

*Professor of Biochemistry-Clinical Chemistry, Department of Chemistry, University of Ioannina, Ioannina, Greece*

### **TSIMIHODIMOS VASILEIOS**

*Assistant Professor of Internal Medicine,  
Medical School, University of Ioannina,  
Greece*

### **TSIOUFIS KONSTANTINOS**

*Associate Professor of Cardiology, Faculty  
of Medicine, National & Kapodistrian  
University of Athens, Athens, Greece*

### **VAN DER WORP BART**

*Neurologist, Department of Neurology  
and Neurosurgery, Brain Center Rudolf  
Magnus, University Medical Centre  
Utrecht, Utrecht, The Netherlands*

### **VELTKAMP ROLAND**

*Professor of Neurology, Chair of  
Stroke Medicine, Faculty of Medicine,  
Department of Medicine, Imperial College  
London, London, UK*

### **VEMMOS KONSTANTINOS**

*Stroke Physician, President, Hellenic Stroke  
Organization, Athens, Greece*

### **VERGANI DIEGO**

*Professor of Liver Immunopathology,  
Institute of Liver Studies, King's College  
Hospital, London, UK*

### **VLAHAKOS DIMITRIOS**

*Professor of Medicine-Nephrology, Faculty  
of Medicine, National & Kapodistrian  
University of Athens, Director, Renal Unit,  
Attikon University General Hospital of  
Athens, Athens, Greece*

# INDEX OF ORAL & E-POSTER PRESENTATIONS

## A

Adrian Parry-Jones	OP05
Aggelakou-Vaitsi Stamatina	e-PP54
Aggelidi Maria	e-PP53, e-PP67
Aggelis Nikolaos	e-PP52
Agrogianni Maria	e-PP25
Akriavidis Evangelos	OP10, OP11, OP20, e-PP14, e-PP15, e-PP21, e-PP22
Alaveras Antonios	e-PP39
Al-Nofal Tzamal	e-PP50
Alourda Foteini	e-PP89, e-PP90, e-PP91
Alushi Evis	e-PP78
Ameriso F. Sebastian	OP04
Anagnostopoulou Evagelia	OP25
Anastasakis Emmanouil	e-PP35
Anastasiou Eustathia	e-PP36, e-PP89, e-PP90
Angelidou Iliana	OP18
Angelopoulou Stella-Maria	OP06
Ansari Azhar	OP12
Antypa Eleni	e-PP20
Apostolidou Eirini	OP08
Arabzadeh Nasereh	OP27
Arampatzioglou Athanasios	OP18
Arauz Antonio	OP04
Arelaki Stella	OP08, OP18
Armenis Iakovos	OP34
Arnao Valentina	OP04
Arvaniti Pinelopi	OP13, OP14, OP15, OP16
Athanasakis George	OP04
Athanasakis Kostas	e-PP16
Athanasiadis Athanasios	OP32
Athanasios Hastas	e-PP23
Augoustaki Aikaterina	OP21

Azariadi Kalliopi OP13, OP14, OP15,  
OP16, OP41

## B

Baikoussis G. Nikolaos	e-PP02, e-PP03
Bairaktari Eleni	OP09, e-PP11
Bakarozi Marianna	e-PP88
Bandini Fabio	OP04
Banis Georgios	e-PP60
Barboza A. Miguel	OP04
Barka Melpomeni	e-PP52
Bertsias Antonios	OP21
Bitsikokou Athina	OP35, e-PP42
Bjarnason Ingvar	OP17
Bougias Dimitrios	OP37, OP38, e-PP48, e-PP49, e-PP70, e-PP71, e-PP72, e-PP73, e-PP74, e-PP75, e-PP76
Boulbou Mary	OP30, e-PP88
Bouliaris Konstantinos	OP33
Bourdakis Adamantios	e-PP04
Bouziana Stella	OP06
Briasoulis Christos	e-PP70, e-PP74

## C

Cano Beatriz Chavarria	OP04
CasMaurizio Paciaroni Valeria	OP04
Cereda Carlo W.	OP01, e-PP06
Chalevas Parthenis	OP03, OP10, OP11, e-PP14, e-PP15, e-PP22
Chalmouki Panagiota	e-PP39
Champakis Christos	e-PP18
Chaniotakis Konstantinos	e-PP40, e-PP41
Charalampous Charalampos	OP26, e-PP38
Chartoumpakis Dionysios	e-PP12

## INDEX OF ORAL & E-POSTER PRESENTATIONS

Chatedaki Christina	OP40	Deliligka Aspasia	e-PP47, e-PP58,
Chatzakis Christos	e-PP09		e-PP79, e-PP80,
Chatzimichael Eleftherios	e-PP40,		e-PP81, e-PP82,
	e-PP41		e-PP84
Chatzopoulos Kyriakos	e-PP47, e-PP58,	Diakonikola Despoina	OP24, e-PP36
	e-PP79, e-PP80,	Diamantidi Krystalia	e-PP39
	e-PP81, e-PP82,	Diamantis Alexandros	OP23, OP33
	e-PP84	Diamantopoulou A.	OP20
Chia Liang Yoong	e-PP43	Diavasti Mariana	OP11, OP03
Chliara Maria	OP26	Didaskalou Athanasios	OP35, e-PP42
Cholongitas Evangelos	OP03, OP10,	Diez-Tejedor Exuperio	OP04
	OP11, OP20, e-PP05,	Dimas Grigorios	OP36, e-PP01,
	e-PP14, e-PP15,		e-PP09, e-PP10
	e-PP22	Dimitriou Panagiotis	OP06
Chounta Athina	e-PP16, e-PP17	Dimopoulos Evagelos	e-PP83
Choutri Ekaterini	e-PP45	Dokoutsidou Helen	e-PP83
Chrisostomou Evaggelia	OP37,	Dolgyras Stylianos	e-PP07, e-PP50
	OP38, e-PP48,	Dontsos Christos	e-PP07, e-PP59
	e-PP49, e-PP71,	Dougalis Apostolos	OP03, e-PP05
	e-PP75, e-PP76	Doulgeris Ioannis	OP11, e-PP05
Christodoulidis Grigorios	OP23,	Doumtsis Petros	OP03, OP20, e-PP15,
	OP33		e-PP22
Christou Georgios	OP09	Drakoulis Christos	e-PP18, e-PP19,
Chrysanthos Nikolaos	OP25		e-PP25
Chryssou Evaggelia	e-PP29	Droggoula Ourania	e-PP69
Chung- Faye Guy	OP17	Dubois Patrick	OP17
Cuadrado-Godia Elisa	OP04		

## D

Dalampira Christina	e-PP04
Dalekos George N.	OP13, OP14,
	OP15, OP16, OP30,
	OP40, OP41, e-PP55,
	e-PP66, e-PP88
Dalla Vasiliki	e-PP46
Daskalogiannaki Maria	e-PP29
David J Seiffge	OP01
Dehghan Javid	OP27

## E

Eleftheriadou Athina	e-PP19, e-PP25
Elisaf Moses	OP09, e-PP11
Ellina Christina	e-PP19, e-PP25
Eskandari Ashraf	OP01
Etsuro Mori	e-PP06

## F

Faliagkas Petros	e-PP07
Familias Ioannis	OP24
Farmaki Evangelia	OP28





## INDEX OF ORAL & E-POSTER PRESENTATIONS

Heo Ji Hoe	OP01, e-PP06	Kapros Elias	e-PP53, e-PP67, e-PP87
Hera M.	e-PP63	Kapsoritakis Andreas	OP32
Heras Panagiotis	e-PP33, e-PP61, e-PP63, e-PP65	Karageorgos Charalampos	e-PP85, e-PP68
Heydari Zahra	OP27	Karakousis Konstantinos	e-PP60
Hyatt Raymond	e-PP51	Karamagkiolis Spiridon	e-PP34
Hytiroglou Prodromos	e-PP21	Karamanli K.	e-PP30, e-PP31

### I

Iglesias Mohedano Ana Maria	OP04	Karamitsos Konstantinos	e-PP34, e-PP52, e-PP60
Ioannidou Anastasia	e-PP19, e-PP25	Karamouzis Ioannis	e-PP01, e-PP09, e-PP10
Ioannidou Maria	e-PP14, e-PP22	Karampampa Christina	e-PP19,
Ioannis Familias	e-PP23	Karaoulani Theofania	e-PP30, e-PP31
Ioannou Maria	OP32	Karasavidou Larisa	e-PP19, e-PP25
Ischaki Eleni	OP31	Karasmani Areti	OP20

### K

Kakaletsis Nikolaos	e-PP06	Karatapanis Stylianos	OP24, e-PP23, e-PP35, e-PP36, e-PP89, e-PP90, e-PP91
Kakkas Ioannis	OP28	Karavana Vassiliki	OP31
Kakouris Georgios	e-PP02, e-PP03	Karavidas Nikitas	e-PP69, e-PP86
Kalafateli Maria	OP19, e-PP29	Karnesis Lazaros	e-PP20, e-PP64
Kalaitzoglou Asterios	e-PP37	Karvouniaris Nikolaos	e-PP35
Kalantzis Konstantinos	e-PP68	Kastani Ioanna	OP09
Kaliotzoglou Anastasia	e-PP89, e-PP90, e-PP91	Katagis George	e-PP72, e-PP73
Kaliouli-Antonopoulou Christiana	e-PP17, e-PP25	Katsarou Irene	e-PP67
Kalliakmanis Andreas	OP35, e-PP42	Katsilis Nikitas	OP24, e-PP36, e-PP89, e-PP91
Kalliara Anastasia Theodora	e-PP86	Katsiva Vasiliki	e-PP18
Kalogiannis Evangelos	e-PP08, e-PP32	Kehagias Elias	OP22, e-PP29
Kalotychoou Vasiliki	OP34	Keramidas Angelos	OP26, e-PP38
Kalra Kavita	e-PP56	Ketikoglou Ioannis	e-PP27, e-PP28
Kambas Konstantinos	OP08, OP18	Khazaei Ali Hossein	OP27
Kapanidis Konstantinos	OP36	Khazaei Amin	OP27
Kapatais A.	e-PP30, e-PP31	Khazaei Ehsan	OP27
Kapatou Kassiani	OP32	Kitsou Sotiria	e-PP70, e-PP74
Kapetanakis Stylianos	e-PP40, e-PP41	Kokalis Christos	e-PP18
Kapoussouzi Androniki	OP28	Kokkoris Stelios	e-PP18

# INDEX OF ORAL & E-POSTER PRESENTATIONS

Kolotsiou Aikaterini	OP11, e-PP05	Lamprianou Foteini	OP24, e-PP35, e-PP91
Konstantinides Stavros	OP08	Lapis Ioannis	e-PP89, e-PP90, e-PP91
Konstantinidis Theocharis	OP08	Larissi Maria	OP36, e-PP09
Konstantopoulos Konstantinos	OP34	Lascu Georgeta	e-PP57
Konstantoula Theodora	e-PP52, e-PP60	Laspa Christina	e-PP08, e-PP32
Kontogeorgiou Zoe	OP34	Laspa Eugenia	e-PP08, e-PP32
Kontoriga Ekaterini	e-PP18, e-PP19, e-PP25	Lavdaniti Maria	e-PP62, e-PP83
Korkolopoulou Pinelopi	OP25	Lee Jia Wern	e-PP43
Koroboki Elena	OP04	Lees R Kennedy	OP01, e-PP06
Kostaki Stavroula	OP06	Lefaki Ioanna	e-PP46
Kostara Christina	OP09, e-PP11	Lialios Georgios	e-PP44
Kotoula Paraskevi	e-PP44	Liatsos Christos	e-PP20
Kotsianidis Ioannis	e-PP46	Liougka Evaggelia	e-PP07, e-PP50
Koufomichali Xanthi	e-PP19	Lip Y.H. Gregory	OP04
Koukoulis George K.	OP13, OP14, OP32, e-PP55	Lo Francis	e-PP43
Koulara Pavlina	e-PP26	Loizou Areti	e-PP13, e-PP45
Koulentaki Meri	OP21, OP22	Lolos Ioannis	e-PP68, e-PP85
Koulias Emmanuel	e-PP27	Lucas Josefa Pérez	OP04
Koumoutsou Flora	e-PP34	Lucas Zarah	e-PP56
Kouroumalis A. Elias	OP21, OP22, e-PP29	Luci Rozeta	e-PP77, e-PP78
Kourousis Dimitrios	e-PP19	Lygdi Loukia	e-PP05
Koutroubi Maria	e-PP33, e-PP61, e-PP63, e-PP65	Lygoura V.	OP13, OP14
Koutsoukis Athanasios	e-PP57		
Krapis Konstantinos	e-PP34, e-PP52, e-PP60	<b>M</b>	
Kurniawan Mohammad	OP01, e-PP06	Magkou Christina	OP31
Kyriakos Nikolaos	e-PP20	Makaritsis Konstantinos	OP04, OP30, e-PP66
Kyriazopoulou Venetsanea	OP19	Malachias Sotirios	OP31
Kyritsis Antonis	e-PP27	Malamati Vreka	OP31
		Malli Ergina	OP39
		Mandala Evdokia	OP03, e-PP05
		Manika Kleanthi	e-PP15
		Manios Efstathios	OP01, OP04, e-PP06
		Manoulakas E.	e-PP66
		Margaritis Athanasios	OP37
		Margonis Euaggelos	OP33
<b>L</b>			
Lachanis Stefanos	e-PP20		
Lalos Vasileios	e-PP52		
Lalou Polyxeni	OP30		

# INDEX OF ORAL & E-POSTER PRESENTATIONS

Marias Mihail	e-PP23, e-PP36, e-PP89, e-PP90, e-PP91		
Maritsa Dimitra	e-PP68, e-PP85		
Markantonatou A.M.	OP20		
Maroulakou Ioanna	OP18		
Matrella Erminia	OP21, OP22		
Matsagas Miltiadis	e-PP02		
Mauraki Eugenia	e-PP87		
Mavrantoni Evi	OP36		
Mavridis Giorgos	OP26, e-PP38		
Mavromanoli Anna	e-PP01		
Mechmet Sadi	e-PP46		
Melios Achileas	OP25		
Mentzelopoulos Spyros	OP31		
Michalaki Marina	OP19		
Michel Patrik	OP01, OP02, e-PP06		
Michelakis Evangelos	e-PP25		
Miftari Brunilda	e-PP77		
Milonas Stefanos	e-PP68, e-PP85		
Miltiades Paraskevi	OP18		
Mironidou-Tzouveleki Maria	e-PP08, e-PP32		
Mitroulis Ioannis	OP08		
Mitsios Alexandros	OP18		
Mitsis Christos	OP37, OP38, e-PP70, e-PP74		
Molloy Jane	OP05		
Mori Etsuro	OP01		
Moschouris Hipocrates	e-PP53, e-PP87		
Mosheta Eleni	e-PP72, e-PP73		
Moulin Solène	OP01, e-PP06		
Mouzaki Athanasia	OP19		
Mouzas Ioannis	OP22, e-PP29		
Mpika Spiridoula	e-PP69, e-PP86		
Mpiternas Michalis	e-PP50		
Mpoumpas Dimitrios	e-PP16		
<b>N</b>			
Nakopoulou Fani		e-PP69	
Nakuci Mikel		e-PP77	
Neokleous Nikolaos		e-PP45	
Neokosmidis Georgios	e-PP24, e-PP26		
Niarchos Athanasios		e-PP12	
Nikaj Sonila		e-PP78	
Nikitas Katsilis		e-PP23	
Nikolaidou Christina	e-PP47, e-PP58, e-PP79, e-PP80, e-PP81, e-PP82, e-PP84		
Nikolaou Vasilios		e-PP19	
Ntaios George	OP01, OP02, OP04, e-PP06, e-PP66		
Nteik El Elina		e-PP27, e-PP28	
Ntetskas Georgios	OP24, e-PP23, e-PP35, e-PP36, e-PP89, e-PP90, e-PP91		
<b>O</b>			
Oikonomou Dimitris		e-PP85	
Oikonomou Theodora	OP10, e-PP15		
Orfanoudaki Elina		OP21	
Orologas Anastasios		OP36	
<b>P</b>			
Paellas Chrysostomos		e-PP23	
Palazis Lakis		e-PP13, e-PP45	
Paliouras Christos		e-PP35	
Panayiotides Ioannis		e-PP18	
Pantos Konstantinos		OP34	
Papadaki Sotiria		e-PP27, e-PP28	
Papadamou G.	OP13, e-PP66		
Papadatos Stamatis		e-PP04	

# INDEX OF ORAL & E-POSTER PRESENTATIONS

Papadatou Aggeliki	e-PP53, e-PP67, e-PP87	Pappas Efthimios	e-PP37, e-PP59
Papadimitropoulos George	e-PP17	Parasyris Vassilios	e-PP64
Papadopoulos Georgios	e-PP02	Parthenis Chalevas	e-PP05
Papadopoulos Nikolaos	e-PP20, e-PP64	Paschou Eleni	e-PP07, e-PP37, e-PP50, e-PP59
Papadopoulos S. Georgios	e-PP03	Pastor Andrés García	OP04
Papadopoulou Apostolina	OP37, OP38, e-PP48, e-PP49, e-PP71, e-PP73, e-PP75, e-PP76	Patouras Paraskeyas	e-PP64
Papadopoulou Maria	OP06	Patsavela Stamatia	OP25
Papadopoulou Stauroula	e-PP47, e-PP58, e-PP79, e-PP80, e-PP81, e-PP82, e-PP84	Pavlidis Polychronis	OP12, OP17
Papageorgiou Chrysoula	OP26	Pavlopoulos Konstantinos	e-PP09
Papageorgiou Lampros	e-PP70, e-PP71, e-PP74, e-PP75	Pavlou M.	e-PP30, e-PP31
Papagiannis Achilleas	e-PP24	Perivoliotis Konstantinos	OP23, OP33
Papagoras Charalampos	e-PP46	Pertierra Lucía	OP04
Papaioannou Georgios	e-PP37, e-PP59	Petinaki Efthymia	OP39, OP40, OP41
Papakonstantinou Anna	e-PP08, e-PP32	Petrou Danae	OP26
Papakosta Styliani	e-PP44	Pirou Nikoleta	e-PP01
Papamichali Roidoula	OP32	Pliarchopoulou Fani	e-PP16, e-PP17
Papanastasiou A.	e-PP30, e-PP31	Polychronopoulou Erietta	OP33
Papandreou Christos	OP32	Polyzos Asterios	e-PP88
Papanikolaou Nikolaos	e-PP07	Potamianos Spyros	OP32
Papanikolaou Vasilios	OP10	Pournou Anastasia	OP37, OP38, e-PP48, e-PP49, e-PP70, e-PP71, e-PP72, e-PP73, e-PP74, e-PP75, e-PP76
Papastergiou Kerasina	e-PP62, e-PP83	Protopapas Andreas	e-PP24, e-PP26
Papastergiou Vasilios	OP24, e-PP36, e-PP90, e-PP91	Psellakis Georgios	e-PP89
Papathanasiou Maria	OP32	Psyrris Adamantia	e-PP18
Papavasileiou Vasileios	OP01, OP02, OP04, OP05, e-PP06, e-PP51	Putala Jukka	OP04
Papiamonis Nikolaos	e-PP29		

## Q

Quah Teik Joo e-PP43

## INDEX OF ORAL & E-POSTER PRESENTATIONS

### R

Raw Jason	OP07	Sidiropoulos Orestis	e-PP17
Rigopoulou Eirini I.	OP13, OP30, e-PP88	Siminelakis Stavros N.	e-PP02, e-PP03
Ritis Konstantinos	OP08, OP18, e-PP46	Sinakos Emmanouil	e-PP21
Rodríguez-Campello Ana	OP04	Sinanaj Glodiana	e-PP77
Rombos Ioannis	OP34	Sindhu Kaniz Rabia	OP05
Rontogianni Dimitra	e-PP20	Skendros Panagiotis	OP08, OP18, e-PP46
Rostami Amin	OP27	Skorda Lamprini	e-PP39
Roufas Konstantinos	OP24, e-PP23, e-PP35, e-PP36	Skoufi Georgia	e-PP44
Rountas Christos	e-PP55	Solomou S.	e-PP30, e-PP31
		Song Tae-Jin	OP01, e-PP06
		Soulaidopoulos Stergios	OP03, OP10, OP11, OP20, e-PP05, e-PP14, e-PP15, e-PP22

### S

Sabanis Nikos	e-PP07, e-PP37, e-PP50, e-PP59	Spadidea Panagiota	OP19
Samakidou Georgia	e-PP52, e-PP60	Spagos Georgios	e-PP10
Samara Maria	OP32	Spanou Marianna	OP06
Samara Vasiliki	e-PP85	Speletas Matthaios	OP28, OP29, e-PP46
Samaras Athanasios	e-PP10	Spiroglou Sofia	e-PP01, e-PP09, e-PP10
Samonakis Dimitrios N.	OP19, OP21, OP22, e-PP29	Spirou Antigoni	e-PP01, e-PP10
Saravanon N	OP07	Stakos Dimitrios	OP08
Sarrou Styliani	OP39, OP40	Stamatopoulos Alexandros	e-PP14, e-PP22
Savopoulos Christos	OP06, OP36, e-PP01, e-PP09, e-PP10	Stamatopoulos Theodosios	e-PP14, e-PP22
Seiffge J David	e-PP06	Stampori Maria	OP24, e-PP23, e-PP36, e-PP89, e-PP90, e-PP91
Selfo Denada	e-PP77	Stathopoulos George	OP31
Sen Dwaipayan	OP07, e-PP51	Stavropoulou E.	e-PP30, e-PP31
Sevdali Eirini	OP28	Stefanopoulos Anastasios	e-PP33, e-PP61, e-PP63, e-PP65
Sfendouraki Elissavet	OP35, e-PP42	Stefanou Christos	e-PP13, e-PP45
Sherwood Roy	OP17		
Shi Yue	e-PP56		
Sideri E.	e-PP30, e-PP31		



## INDEX OF ORAL & E-POSTER PRESENTATIONS

Valari Zoi	OP10	Zaharis Georgios	e-PP90
Varsamis Nikolaos	e-PP76	Zakynthinos Spyros	OP31
Vasileiadis Panagiotis	e-PP38, OP26	Zioganas Vassilios	e-PP21
Vasileiou Sotirios	e-PP59	Zissis Christos	e-PP68, e-PP85
Vasiliadis Themistoklis	OP10	Zormpas Aggelos	e-PP69, e-PP86
Vasilios Papastergiou	e-PP23	Zotos Nikolaos	OP37, OP38, e-PP48, e-PP49, e-PP70, e-PP71, e-PP72, e-PP73, e-PP74, e-PP75, e-PP76
Vemmos Konstantinos	OP01, OP04, e-PP06	Zoumbouli Christina	e-PP28
Vemmou Anastasia	OP04	Zyga Sofia	e-PP62, e-PP83
Venizelos Ioannis	e-PP47, e-PP58, e-PP79, e-PP80, e-PP81, e-PP82, e-PP84		
Verra Chrysoula	e-PP02, e-PP03		
Vetas Christos	e-PP14, e-PP15		
Vetsiou Evangelia	OP11, e-PP14, e-PP15, e-PP22		
Vettas Christos	OP03, e-PP05		
Voukelatou Panagiota	OP35, e-PP42		
Voulgaridi Ioanna	OP40		
Voumvourakis Konstantinos	e-PP17		
Vrettos Ioannis	OP35, e-PP42		
Vrettou S. Charikleia	OP31		

## W

Weder Bruno J.	OP01, e-PP06
Weimar Christian	OP01, e-PP06

## Y

Yan Bernard	OP01, e-PP06
-------------	--------------

## Z

Zacharoulis Dimitrios	OP23
Zachou Kalliopi	OP13, OP14, OP15, OP16, OP41, e-PP55
Zahaj Majlinda	e-PP78



# SPONSORS/ACKNOWLEDGEMENTS

The Organizing Committee of the Congress would like to express their sincere thanks to the following companies for their financial support and contribution to the accomplishment of this Congress:

## PLATINUM SPONSORS



Bayer



Bristol-Myers Squibb

## GOLD SPONSORS

abbvie



GILEAD

Advancing Therapeutics.  
Improving Lives.

## SILVER SPONSORS



Leading Light for Life



Bayer



MSD



SANOFI



WinMedica  
Serving Health for Life

## SPONSORS

AMGEN®



ANIMUS



APOLLONEIO  
REHABILITATION CENTER S.A.



THESSALIAN REHABILITATION CENTER



Boehringer  
Ingelheim



BIOSNA Α.Ε. ΜΠΑΪΣΚΑΛΑΒΑΝΗΣ - ΠΕΡΡΟΣ



PHARMACEUTICAL COMPANIES  
of Johnson & Johnson



MAVROGENIS  
Coloplast



NOVARTIS  
PHARMACEUTICALS





SPECIFAR  
PHARMACEUTICALS



VIANEX S.A.  
PHARMACEUTICAL MANUFACTURERS  
MEMBER OF GIANNAKOPOULOS GROUP

The Organizing Committee would also like to thank the Regional Association of Thessaly municipalities for their kind support to this year's organization.

# FLOOR PLAN (HALL)



	HALL
Main Hall	• Olympos
Oral Presentations	• Olympos • Achilleas
e-Poster Presentations	• Chrisalida • Alkistis - Thetida • Nefeli











## κινηθείτε ελεύθερα ΣΤΟ ΝΕΟ ΜΟΝΟΠΑΤΙ

### Ο πρώτος και ο μοναδικός εγκεκριμένος αναστολέας IL-17A

Έως και 80% των ασθενών με ΑΣ (αγκυλοποιητική σπονδυλίτιδα) που έλαβαν θεραπεία με **COSENTYX** δεν εμφάνισαν επιδείνωση της βλάβης της σπονδυλικής στήλης σύμφωνα με μετρήσεις μέσω ακτινογραφιών σε διάστημα δύο ετών.<sup>1</sup>

Έως και 84% των ασθενών με ΨΑ (ψωριασικά αρθρίτιδα) που έλαβαν θεραπεία με **COSENTYX** δεν εμφάνισαν επιδείνωση της βλάβης των αρθρώσεων στις ακτινογραφίες σε διάστημα δύο ετών.<sup>2</sup>

#### ■ Αγκυλοποιητική σπονδυλίτιδα

Το Cosentyx ενδείκνυται για τη θεραπεία της ενεργού αγκυλοποιητικής σπονδυλίτιδας σε ενήλικες οι οποίοι δεν έχουν ανταποκριθεί επαρκώς στη συμβατική θεραπεία.<sup>3</sup>

#### ■ Ψωριασική αρθρίτιδα

Το Cosentyx, σε μονοθεραπεία ή σε συνδυασμό με μεθοτρεξάτη (MTX), ενδείκνυται για τη θεραπεία της ενεργού ψωριασικής αρθρίτιδας σε ενήλικες ασθενείς όταν η ανταπόκριση σε προηγούμενη θεραπεία με τροποποιητικό της νόσου αντιρευματικό φάρμακο (DMARD) δεν ήταν επαρκής.<sup>3</sup>

#### Βιβλιογραφία

1. Baraliakos X, Deodhar A, Braun J et al. Effect of interleukin-17A inhibition on spinal radiographic changes through 2 years in patients with active ankylosing spondylitis: results of a phase 3 study with secukinumab. Late breaking abstract presented at the 2015 ACR/ARHP Annual Meeting, San Francisco, USA, November 10. Oral presentation, abstract number: 6L (ACR 2015 abstract book)
2. Mease P, McInnes IB, Kirkham B, et al. Secukinumab provides sustained improvements in psoriatic arthritis: 2-year efficacy and safety results from a phase 3 randomized, double-blind, placebo-controlled trial. Presented at the 2015 ACR/ARHP Annual Meeting, San Francisco, USA, November 9. Oral presentation, abstract number: 2148 (ACR 2015 abstract book).
3. Cosentyx Περίληψη Χαρακτηριστικών του Προϊόντος, Νοέμβριος 2015





# OLYSIO<sup>®</sup>

## SIMEPREVIR

150 mg capsule



OLY/tab/ADS//IAN.2016/GRE007

### ΠΕΡΙΛΗΨΗ ΤΩΝ ΧΑΡΑΚΤΗΡΙΣΤΙΚΩΝ ΤΟΥ ΠΡΟΪΟΝΤΟΣ

▼ Το φάρμακο αυτό τελεί υπό συμπληρωματική παρακολούθηση. Αυτό θα επιτρέψει τον ταχύ προσδιορισμό νέων πληροφοριών ασφαλείας. Ζητείται από τους επαγγελματίες του τομέα της υγειονομικής περίθαλψης να αναφέρουν οποιοδήποτε πιθανολογούμενες ανεπιθύμητες ενέργειες.

**ΟΝΟΜΑΣΙΑ ΤΟΥ ΦΑΡΜΑΚΕΥΤΙΚΟΥ ΠΡΟΪΟΝΤΟΣ:** OLYSIO 150 mg καψάκια, σκληρά. **ΠΟΙΟΤΙΚΗ ΚΑΙ ΠΟΣΟΤΙΚΗ ΣΥΝΘΕΣΗ:** Κάθε σκληρό καψάκιο περιέχει νατριούχο σιμεπρεβίρ που ισοδυναμεί με 150 mg σιμεπρεβίρης. **Έκδοχο με γνωστές δράσεις** κάθε καψάκιο περιέχει 78,4 mg λακτόζης (ως μονοδρική). **ΦΑΡΜΑΚΟΤΕΧΝΙΚΗ ΜΟΡΦΗ:** Σκληρό καψάκιο (καψάκιο). Λευκό καψάκιο (ελατίνης μήκους περίπου 22 mm, με την ένδειξη "TMC435 150" με μαύρο μελάνι. **ΚΑΤΟΧΟΣ ΤΗΣ ΑΔΕΙΑΣ**

**ΚΥΚΛΟΦΟΡΙΑΣ:** Janssen-Cilag International NV, Turnhoutseweg 30, B-2340 Beerse, Βέλγιο. **ΑΡΙΘΜΟΣ(ΟΙ) ΑΔΕΙΑΣ ΚΥΚΛΟΦΟΡΙΑΣ:** EU/1/14/924/002 (28 καψακίων). **ΗΜΕΡΟΜΗΝΙΑ ΑΝΑΘΕΩΡΗΣΗΣ ΤΟΥ ΚΕΙΜΕΝΟΥ:** 20 Αυγούστου 2015. Λεπτομερή πληροφοριακά στοιχεία για το παρόν φαρμακευτικό προϊόν είναι διαθέσιμα στον δικτυακό τόπο του Ευρωπαϊκού Οργανισμού Φαρμάκων: <http://www.ema.europa.eu> **ΤΡΟΠΟΣ ΔΙΑΘΕΣΗΣ:** Περιορισμένη ιατρική συνταγή από ειδικό ιατρό και παρακολούθηση κατά τη διάρκεια της αγωγής.

### ΣΥΣΚΕΥΑΣΙΑ / ΤΙΜΗ

Περιεκτικότητα	Μέγεθος συσκευασίας	Λιανική τιμή	Νοσοκομειακή τιμή
ΣΚΛΗΡΟ ΚΑΨΑΚΙΟ 150MG/CAP	BT x 28 CAPS (4 BLISTER x 7 CAPS)	9.094,89	7.563,03€

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και  
Αναφέρετε  
ΟΛΕΣ τις ανεπιθύμητες ενέργειες για  
ΟΛΑ τα φάρμακα  
Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»

### JANSSEN-CILAG ΦΑΡΜΑΚΕΥΤΙΚΗ Α.Ε.Β.Ε.

Λεωφόρος Ειρήνης 56, 151 21, Πεύκη, Αθήνα, Τηλ.: 210 8090000  
[www.janssen.com.gr](http://www.janssen.com.gr)

**Janssen**  
PHARMACEUTICAL COMPANIES  
OF **Johnson & Johnson**

**Tygacil**<sup>TM</sup>  
tigecycline

**Ecalta**<sup>TM</sup>  
Anidulafungin

**VFEND**<sup>®</sup>  
(voriconazole)

**ZYVOXID**<sup>®</sup>  
Linezolid

AL01-FEB14

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και  
Αναφέρετε  
ΟΛΕΣ τις ανεπιθύμητες ενέργειες για  
ΟΛΑ τα φάρμακα  
Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»



Συμβουλευτείτε τις Περιλήψεις Χαρακτηριστικών των Προϊόντων που διατίθενται από τη Pfizer Hellas A.E.  
PFIZER HELLAS A.E. Λεωφ. Μεσογείων 243, 154 51 Ν. Ψυχικό, Τηλ. Επιστημονικής Ενημέρωσης: 210 67 85 800



# Μετατρέποντας τον κώδικα της ζωής σε καινοτόμα φάρμακα

Στην Amgen πιστεύουμε ότι οι απαντήσεις στα πλέον επιτακτικά ιατρικά ζητήματα είναι καταγεγραμμένες στο DNA μας.

Ως ηγέτιδα εταιρεία στο χώρο της βιοτεχνολογίας παγκοσμίως, η Amgen χρησιμοποιεί τη βαθιά κατανόηση του κώδικα του DNA για την ανάπτυξη στοχευμένων θεραπειών που καλύπτουν τις ανάγκες των ανθρώπων με σοβαρές ασθένειες και βελτιώνουν σημαντικά τη ζωή τους.

Για περισσότερες πληροφορίες σχετικά με την Amgen, το πρωτοποριακό επιστημονικό της έργο και τα καινοτόμα φάρμακά της, επισκεφθείτε το [www.amgen.com](http://www.amgen.com) και το [www.amgen.gr](http://www.amgen.gr).

**AMGEN**

Pioneering science delivers vital medicines™





## ΟΙ ΜΕΓΑΛΕΣ ΕΠΙΣΤΗΜΟΝΙΚΕΣ ΑΝΑΚΑΛΥΨΕΙΣ ΕΞΕΛΙΣΣΟΝΤΑΙ ΣΤΑ ΕΡΓΑΣΤΗΡΙΑ ΓΕΝΝΙΟΥΝΤΑΙ ΟΜΩΣ ΣΤΗΝ ΨΥΧΗ ΜΑΣ

Εδώ και 150 χρόνια, οι άνθρωποι της MSD μοιραζόμαστε το ίδιο πάθος. Στόχος μας είναι να αναπτύσσουμε καινοτόμα φαρμακευτικά και καταναλωτικά προϊόντα, εμβόλια και κτηνιατρικά φάρμακα που βελτιώνουν τις ζωές εκατομμυρίων ανθρώπων και ζώων.

Γνωρίζουμε πολύ καλά πως έχουμε ακόμα πολλά να προσφέρουμε. Εργαζόμαστε εντατικά, προσηλωμένοι στη μακροχρόνια δέσμευσή μας για συνεχή έρευνα και ανάπτυξη νέων προϊόντων.

Βασικό μας μέλημα είναι να επεκτείνουμε την πρόσβαση των ανθρώπων σε προϊόντα και υπηρεσίες υγείας και συνεργαζόμαστε στενά με όλους όσους μοιράζονται το πάθος μας για έναν υγιέστερο κόσμο. Μια πρόκληση που μαζί μπορούμε να επιτύχουμε. Με όλη μας την ψυχή.

**Για να μάθετε περισσότερα για τις προσπάθειές μας, επισκεφτείτε το [msd.gr](http://msd.gr)**

Στην Ελλάδα, η MSD έχει αναπτύξει τέσσερις πυλώνες Εταιρικής Κοινωνικής Ευθύνης στους οποίους επενδύει υλοποιώντας σημαντικές δράσεις με επίκεντρο πάντα τον άνθρωπο. Οι δράσεις αυτές αφορούν στην ενίσχυση της καινοτομίας και της επιχειρηματικότητας, στην επίτευξη αριστείας στην έρευνα για νέες θεραπείες, στην κατάθεση προτάσεων και λύσεων στον τομέα υγειονομικής πολιτικής αλλά και στην ανάπτυξη προγραμμάτων ενημέρωσης και πρόληψης για σοβαρές ασθένειες.



**Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και  
Αναφέρετε  
ΟΛΕΣ τις ανεπιθύμητες ενέργειες για  
ΟΛΑ τα φάρμακα  
Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»**

Η διαφήμιση είναι σύμφωνη με την ισχύουσα νομοθεσία -  
Υπουργική Απόφαση ΔΥΓ3(α)Π 32221 - ΦΕΚ Β' 1049/29.4.2013  
και τον κώδικα δεοντολογίας του ΣΦΕΕ.

Πριν τη συνταγογράφηση συμβουλευθείτε την πλήρη  
Περίληψη Χαρακτηριστικών των Προϊόντων.  
Για περισσότερες πληροφορίες απευθυνθείτε στην εταιρεία:

**AbbVie ΦΑΡΜΑΚΕΥΤΙΚΗ Α.Ε.**  
Μαρίνου Αντύπα 41-45, Νέο Ηράκλειο, 14121, Τηλ.: 214 4165555



**viekirax®**  
ombitasvir / paritaprevir /  
ritonavir



**exviera®**  
dasabuvir



# Nexavar<sup>®</sup>

(sorafenib) tablets

L.GP.SM.05.2014.0137



## Bayer

Κάτοχος της άδειας κυκλοφορίας:  
Bayer Pharma AG 13342 Berlin, Γερμανία  
Τοπικός αντιπρόσωπος του κατόχου άδειας  
κυκλοφορίας στην Ελλάδα: Bayer Ελλάς ΑΒΕΕ  
Σωρού 18-20, 151 25 Μαρούσι,  
Τοπικός αντιπρόσωπος του κατόχου άδειας  
κυκλοφορίας στην Κύπρο:  
Novagem Ltd, Τηλ: 00357 22483858

Τμήμα Επιστημονικής Ενημέρωσης  
Τηλ: +30 210 6187742, Fax: +30 210 6187522  
Email: [medinfo.gr.cy@bayer.com](mailto:medinfo.gr.cy@bayer.com)

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και  
Αναφέρετε  
ΟΛΕΣ τις ανεπιθύμητες ενέργειες για  
ΟΛΑ τα φάρμακα  
Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»

Πριν τη συνταγογράφηση συμβουλευτείτε την Περίληψη Χαρακτηριστικών του Προϊόντος.  
Για περισσότερες πληροφορίες απευθυνθείτε στην εταιρεία Bayer Hellas.